SGA and Turner Syndrome: the impact of growth hormone treatment on physical and mental well-being by Bannink, E.M.N. (Ellen)
SGA and Turner Syndrome
The impact of growth hormone treatment
on physical and mental well-being
Ellen Manon Noëlle Bannink
binnenwerk_banink_30aug.indd   1 30-8-2006   8:48:54
Cover design:  Gemma Jones, Melbourne, Australia
 www.gemmajones.net
Lay-out:  Legatron Electronic Publishing, Rotterdam
Printer:  PrintPartners Ipskamp, Enschede
The printing of this thesis and the studies described were fi nancially supported 
by Novo Nordisk A/S, Denmark and Novo Nordisk Farma B.V., The Netherlands.
ISBN 90-9020882-8
Copyright © 2006 E.M.N. Bannink
All rights reserved. No part of this thesis may be reproduced or transmitted in 
any form, by any means, electronic or mechanical, without the prior written 
permission of the author, or where appropriate, of the publisher of the 
articles.
binnenwerk_banink.indd   2 20-8-2006   12:53:22
SGA and Turner Syndrome
The impact of growth hormone 
treatment on physical and mental well-being
SGA en Turner Syndroom
De invloed van groeihormoon 
behandeling op fysiek en mentaal welzijn
Proefschrift
Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam 
op gezag van de Rector Magnificus Prof. dr. S.W.J. Lamberts en volgens 
besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 18 oktober 2006 om 11.45 uur
Door
Ellen Manon Noëlle Bannink
Geboren te Uden
binnenwerk_banink_30aug.indd   3 30-8-2006   8:49:32
Promotiecommissie
Promotor: Prof. Dr. S.L.S. Drop
 Prof. Dr. A.C.S. Hokken – Koelega
Co-promotor:  Dr. S.M.P.F. de Muinck Keizer - Schrama
Overige leden: Prof. Dr. W.A. Helbing
 Prof. Dr. F.H. de Jong
 Prof. Dr. A.A. Kaptein
binnenwerk_banink.indd   4 20-8-2006   12:53:22
Groeien kan op vele manieren
 
  
Aan Michael en mijn ouders
binnenwerk_banink.indd   5 20-8-2006   12:53:22
Table of Contents
Chapter 1 General introduction 9
 1 Background  10
  — Small for gestational age (SGA)  10
  — Turner syndrome  14
 2 Treatment in short SGA children and girls with Turner syndrome:  21
  Growth hormone and estrogen treatment  
  — SGA 21
  — Turner syndrome  24
 3  Aims of the study and outline of this thesis 28
Chapter 2 Free/dissociable IGF-I, not total IGF-I correlates with growth  39
 response during growth hormone treatment in children born SGA
 
Chapter 3 Free-dissociable insulin-like growth factor I (IGF-I), total IGF-I and  57
 their binding proteins in girls with Turner Syndrome during   
 long-term growth hormone treatment
 
Chapter 4 Quality of life in adolescents born small for gestational age (SGA):  77
 Does growth hormone make a difference? 
Chapter 5 Quality of life after long-term growth hormone therapy and  95
 induced puberty in women with Turner Syndrome
Chapter 6 Puberty induction in Turner Syndrome: Results of estrogen treatment  113
 on development of secondary sexual characteristics, uterine dimensions, 
 and serum hormone levels
Chapter 7 Long-term follow-up after growth hormone therapy in women  131
 with Turner Syndrome
Chapter 8 Aortic distensibility and dimensions and the effects of  149
 growth hormone treatment in the Turner Syndrome
binnenwerk_banink.indd   6 30-8-2006   7:50:17
Chapter 9 General discussion 163
Chapter 10 What have we learned from all these years of GH therapy? 193
 — SGA  195
 — Turner syndrome 198
 — Recommendation for future research 203
Chapter 11 Summary, Samenvatting 209
 — English 210
 — Nederlands 216
Dankwoord    225
Curriculum Vitae    231
List of abbreviations
binnenwerk_banink.indd   7 30-8-2006   7:50:18
Chapter 
1
binnenwerk_banink.indd   8 20-8-2006   12:53:22
General introduction
binnenwerk_banink.indd   9 30-8-2006   7:50:49
10
C
ha
pt
er
 1
G
en
er
al
 i
nt
ro
du
ct
io
n Introduction 
Growth hormone is available in unlimited volumes since 1986, when growth hormone 
(GH) could be manufactured. Since then, multiple studies investigated the effect 
of GH-therapy in children with short stature, either with or without disturbances in 
the GH-IGF-I axis. In this thesis, two populations of children with short stature are 
presented: short children being born small for gestational age (SGA) and girls with 
Turner syndrome (TS). In both populations, GH has proven to be effective, resulting in 
normalisation of height during childhood, adolescence and adulthood [1-9]. Although 
several studies have investigated safety aspects and adverse effects of long-term GH 
therapy, up to today still many questions remain unanswered regarding long-term 
effects and side effects during and after discontinuation of GH treatment. 
This chapter describes definitions and presents background of SGA and Turner 
syndrome, their prevalence and etiology, and clinical characteristics. It provides the 
previously reported growth promoting results of GH-therapy and shows safety aspects 
of growth hormone therapy. Finally, the aims of the study and the outline of the 
thesis will be presented.
1 Background 
— Small for gestational age (SGA)— 
Definition
Small for gestational age, or SGA, refers to the size at birth of the newborn adjusted 
for the gestational age. Both, children born full-term and premature can be born 
SGA. In literature, different definitions have been used classifying SGA, such as birth 
weight and/or length below the 3rd or 10th percentile (or below −1.88 or −1.29 SDS). 
Some investigators use birth weight, others birth length or both birth weight and 
length. In all Dutch multicenter studies, SGA was defined as a birth length below the 
−2 SDS using the data of Usher and McLean [10].
Intra uterine growth retardation, or IUGR, refers to a deceleration of fetal growth, 
which slows down from a preceding growth pattern. To diagnose IUGR, antenatal fetal 
auxology is required, to demonstrate subnormal prenatal growth velocity. Thus, IUGR 
does not necessarily result in SGA. SGA and IUGR are not synonyms, although SGA is 
often a result of growth retardation in utero.
binnenwerk_banink.indd   10 20-8-2006   12:53:24
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SGA comprises a variety of underlying causes. In 40% of the infants born SGA, the 
underlying mechanism remains unclear. However, the cause of SGA should be 
identified where possible, as it may have consequences for prognosis and treatment 
effects. Impaired fetal growth can originate from a number of fetal, maternal, 
placental, and environmental factors.
Fetal factors include chromosomal disorders (e.g. Down syndrome, Turner 
syndrome), congenital defects (e.g. cardiac abnormalities), metabolic diseases, and 
genetic disorders (e.g. achondroplasia).
Maternal factors include age, tobacco smoking, alcohol abuse, and maternal 
medical conditions, such as infections (e.g. Toxoplasmose, Rubella, Cytomegalovirus, 
Herpesvirus, Malaria), hypertension, renal disease, diabetes mellitus, collagen 
vascular diseases (e.g systemic lupus erythematosis), and heart disease.
Placental factors are factors jeopardizing placental function, which is supplying 
essential nutrients and oxygen from the mother to the fetus. Thus, placental factors 
include all factors jeopardizing placental perfusion, such as placental hemangiomas, 
infarcts, and placenta previa.
Environmental factors include infections and exposure to toxins.
Hypotheses regarding the association of SGA with pathology in adult life
SGA is associated with an increased risk of the development of cardiovascular diseases, 
and metabolic syndrome, or one of its components: hypertension, dyslipidemia, 
impaired glucose tolerance, or diabetes mellitus [11-13]. 
‘The fetal origin hypothesis’, also called ‘fetal programming hypothesis’, or ‘fetal 
undernutrition hypothesis’, was postulated by Barker [14], and suggests that the SGA 
associated adult diseases are programmed by undernutrition in utero. Impaired fetal 
growth, especially when timed during mid- to late gestation, would lead to permanent 
changes in organ-structure and physiology.
‘The fetal insulin hypothesis’, postulated by Hattersley [15], suggests that 
genes involving insulin resistance could affect both birth weight and disease in 
later life. Insulin resistance appears as a key component underlying the metabolic 
complications. Insulin also plays a crucial role in fetal growth.
The insulin-like-growth factor (IGF) system is involved in pre and postnatal 
growth and development. Additionally, IGF-I has been suggested to be involved in 
degenerative common diseases such as atherosclerosis and diabetes [16,17]. Low 
IGF-I levels have a positive association with cardiovascular diseases, atherosclerosis 
and diabetes, all associated with short children born SGA. IGF-I levels in short 
SGA children are reported to be reduced, but within the normal range [2,18,19]. 
Therefore, a disturbance in the GH-IGF-axis also may play a role in the etiology.
binnenwerk_banink.indd   11 20-8-2006   12:53:24
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By definition, approximately 3% of the newborns are SGA. As mentioned earlier, SGA 
newborns may be born full-term or premature. If catch-up growth occurs, it is more 
or less finalized before 1 year of age [20]. Therefore, the presence of catch up at 2 
years of age seems to be relevant for predicting final height outcome. Ten to 15% of 
the children born SGA do not show a catch-up growth within 2 years, indicating a 7−10 
fold increased risk for being short as adult [20,21]. This means that 1:350 to 1:400 
live births remain short after being born SGA.
Clinical aspects
Short stature remains in app. 10%−15% of the children born SGA. Children born SGA 
have a 5 to 7 times higher risk of short stature in adulthood, defined as a height 
below −2 SDS, than children born appropriate for gestational age [20]. Approximately 
22% of the short adults are born SGA [22]. Children born SGA without catch-up growth 
show primary growth failure, meaning that they have a normal growth velocity. The 
underlying mechanisms for lacking catch-up growth are still poorly understood. 
Growth hormone secretion, measured over 24 hours, was subnormal in 60% of the 
SGA children without catch-up growth, whereas 25% showed low GH peaks during 
GH provocation tests [23,24]. IGF-I levels are in the lower half of the normal range 
[2,18]. These findings suggest that disturbances in the GH/ IGF-I axis may play a role.
Chromosomal abnormalities, genetic disorders, or congenital anomalies may 
cause SGA. For that reason, it is important to search for dysmorphic features and 
signs of congenital malformations. In the Dutch multicenter studies, children with 
multiple dysmorphic features were excluded, except for Silver Russell Syndrome 
(SRS). Typical features of SRS are severely reduced birth weight and length, short 
stature during childhood and adulthood, typical craniofacial abnormalities with a 
large, prominent forehead (frontal bossing), a small triangular face, asymmetry of 
the limbs, clinodactyly of the fifth finger and some other minor features [25]. It is 
sometimes difficult to diagnose SRS, as only minor features may be present. As the 
growth pattern of children with SRS do not differ from short SGA children, most trials 
investigating SGA included SRS children.
Body composition and diminished appetite. Short SGA children appear small, 
lean and fragile. They show a significantly reduced lean body mass, fat mass, skin 
fold measurement and body mass index [26-28]. Parents report often that their 
child has lack of appetite and low food intake. Short SGA children show a decreased 
caloric, fat and carbohydrate intake, at a mean age of nearly 6 years, compared to 
the Recommended Daily Food intake for age-matched controls [28]. The explaining 
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Behavioral causes are, for example, cultural expectations of food intake and body 
figure, parental anxiety for (over)weight, children not fed orally for a long period at 
a critical age (more common in SGA than in AGA children). These factors may cause 
feeding problems. Organic causes include swallowing problems, respiratory distress, 
and lack of appetite due to various systemic diseases. SGA children may have a lower 
metabolic rate, or a disturbed appetite due to hormonal disturbances influencing the 
appetite.
Age at start of puberty in short children born SGA is comparable to normal [29]. 
A large Swedish study concluded that in SGA boys, the mean age at puberty onset 
did not differ between normal boys and those with perinatal factors. Girls born SGA 
were 5 months younger than normal girls at the onset of puberty and menarche, 
however within the normal range [30]. Associations between intrauterine exposures 
and disease risk in later life may be confounded by, or mediated through, effects on 
adolescence.
Intelligence and psychological performance. Short children, born SGA, have a 
lower self-concept than their Dutch peers [31]. They also showed deficits in divided, 
focused, and sustained attention. They were less accurate, exhibited more variability 
in reaction time, and performed more slowly and more impulsively than did the age-
matched controls [32]. This indicates that short children born SGA and attention 
deficits are related [32].
Furthermore, short children born SGA showed a lower estimated total IQ, 
performal IQ, and verbal IQ compared to their peers [33]. Also in a large Swedish study 
among 248,051 adult men, being born SGA showed an association with increased risk 
of subnormal intelligence and psychological performance. Among the SGA males, the 
most important predictor for subnormal intelligence and psychological performance 
was the absence of catch-up growth, suggesting that being born SGA without catch-up 
growth is of disadvantage [34]. Being born SGA, with or without catch-up growth, has 
also been associated with poor academic performance, poorer mental and emotional 
well-being, low social competence, and behavioral problems [35-37].
Cardiovascular and insulin-resistance risk factors. Epidemiological studies 
have found a predisposition for diseases such as diabetes mellitus type 2 and 
cardiovascular diseases in adults born with a low birth weight [38-40]. In SGA children 
and adolescents, decreased insulin sensitivity is found [41-44]. In 8% of the children 
presented in this thesis, impaired glucose tolerance was present before start of 
GH therapy [42]. Furthermore, SGA children had a significantly higher systolic 
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peers [45]. 
— Turner syndrome —
History
In 1938, the American physician Henry Turner described 7 women who were 
characterized by short stature, absence of pubertal development, and deformity of 
the elbow (cubitus valgus) [46]. In 1929, Ullrich, a pediatrician from Munich already 
described the same characteristics in some of his female patients [47]. The term 
Turner syndrome is used in the Anglo-Saxon literature, but in most German literature 
Ullrich-Turner syndrome is used. Henry Turner’s description has had a significant 
influence on further research into the disease. In 1959, Ford et al reported a missing 
chromosome in patients with Turner syndrome [48].
Etiology
Turner syndrome is caused by the total or partial absence of one of the X-
chromosomes in all or part of the body cells. Genomic imprinting has been implicated 
in the pathogenesis of TS. Imprinting occurs when allelic genes or chromosomes are 
expressed differently depending on the parent of origin. In 70−75% of the patients 
with 45,X karyotype, the retained X-chromosome was maternal [49]. Conversely, a 
higher incidence of the paternal X retention has been noted in spontaneously aborted 
fetuses [49]. Studies continue to establish an association between the retained 
parental X-chromosome and phenotypic features in TS. 
There is a wide variety of the genotype. The phenotype/genotype correlation in 
TS is generally poor. In general, TS patients with 45,X genotype show the highest 
incidence of cardiac and renal malformations, and congenital lymphedema [50]. The 
different karyotypes present in TS are listed in Table 1. Y-chromosomal material is 
present in 5−10% of patients with TS (like 45,X/46,XY; 45,X/46,X,idic(Y); 45X/46XX/
47XXY etc). 
Testing for ‘hidden’ Y chromosomal material should be performed in any TS patient 
with evidence of virilization or when a marker chromosome (a sex chromosomal 
fragment of unknown origin, i.e. X vs. Y) is found. This can be achieved by DNA studies 
or fluorescent in situ hybridization (FISH). The prevalence and clinical significance of 
‘hidden’ Y material detected only by FISH or DNA analysis needs further investigation. 
The presence of Y-chromosome material is associated with a 7−10% prevalence of 
a gonadoblastoma, a benign tumour that may become malignant [51]. Therefore, a 
gonadectomy is recommended.
binnenwerk_banink.indd   14 20-8-2006   12:53:24
15
C
ha
pt
er
 1
G
en
er
al
 i
nt
ro
du
ct
io
nTable 1: The different karyotypes present in TS.
Genotype Percentage Phenotype
45,X 50—60% The most severe type with the highest incidence 
of structural abnormalities.
Mosaic forms 
(eg 45,X/46XX; 45,X/47XXX etc)
20% A higher mean height, and spontaneous puberty 
and menses in up to 40% of the cases.
Isoforms (e.g. 46 X,i(Xq), and 
ring-chromosomes 
(e.g. 46,Xr(X)), and deletions 
(e.g. 46,X,Xp-; 46,X,Xq-),
30% In TS with isochromosome 46X,i(Xq), common 
in 6−18% of all TS, structural abnormalities 
are uncommon, however increased risk of 
auto-immunity, particularly thyroiditis and 
infl ammatory bowel disease (IBD) exist [52,53].
Mental retardation is associated with the presence 
of ring chromosomes (r(X)) [54].
Prevalence
Turner syndrome is relatively common, 1:2000−1:2500 female births, and 
approximately as many as 15% of spontaneous abortions have a 45,X karyotype. About 
90% of 45,X pregnancies result in spontaneous abortion. There are no known ethnic or 
racial factors influencing the incidence. TS is not associated with advanced maternal 
age [55,56].
Clinical features
The phenotype of Turner syndrome is always female. Short stature and gonadal 
dysgenesis are the main characteristics in Turner syndrome (TS), present in 80−100%. 
The features, as described below, can be present in a patient with Turner syndrome, 
although there is remarkable phenotype variability between individuals. This can 
partly be explained by the phenomena of X-inactivation and genotype variability. 
The phenotype/genotype correlation in TS is generally poor. Genes involved with 
stature, such as the SHOX-gene, lymphatic development, naevus formation, ovarian 
development, and the cognitive phenotype in TS are expressed on the X-chromosome 
[57-60]. Variability of inactivation of these genes leading to varying degrees of 
haploinsufficiency, especially in the pseudoautosomal regions, partly explains the 
considerable phenotype variation seen in TS.
Short stature (80−100%) is due to a moderate intrauterine growth retardation, 
a lower growth velocity during childhood and the absence of the pubertal growth 
spurt. A low birthweight has been associated with a breakpoint between Xq13.3−q22, 
whereas cases with a breakpoint between Xq22−q27 had a normal birthweight [61]. 
The mean final height of untreated Caucasian females with TS is between 143−147 cm 
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45,X differ from those with another chromosomal pattern. The underlying mechanisms 
leading to the stunted growth in girls/women with Turner syndrome are poorly 
understood. Physiological and stimulated growth hormone levels are normal [64]. IGF-
I levels are subnormal, but within the normal range. Furthermore, the short stature is 
very unlikely due to a form of skeletal dysplasia, since the structure and biochemical 
composition of the epiphysial cartilage are normal [65]. 
Short stature and skeletal abnormalities (see below) in Turner syndrome are related 
to the SHOX gene (short stature homeobox containing gene on the X chromosome) 
[57,66]. The SHOX gene is part of the pseudo-autosomal region located at the terminal 
ends of both sex chromosomes (on Xp22). The phenotypes associated with SHOX gene 
deficiency vary widely, and are dependent on the dose of the deficient gene. 
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Figure 1: Reference curve for healthy girls (straight line) [67] and for untreated girls with 
Turner syndrome (North European references, dashed line) [62]. (Figure adapted from the 
Growth Analyser, www.growthanalyser.org).
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Turner patients. During the first 3 months in utero, the ovaries develop normally 
[68]. Thereafter, a rapid loss of the oocytes occurs, leading to insufficient estrogen 
production, which is responsible for the absence of normal development of the 
breasts, uterus, and female body shapes [69]. Most girls with TS don’t enter puberty 
spontaneously. Between 5 and 10% of the women with TS retain sufficient ovarian 
function to commence puberty spontaneously [70]. The frequency of spontaneous 
puberty in mosaicism was significantly higher compared to the 45,X karyotype. 
However, very few women will maintain ovarian function (app. 2−5%), in rare 
occasions resulting in spontaneous pregnancy [71-73]. There is evidence that a locus 
(or loci) for ovarian failure maps to one region of the X chromosome, Xp11.21-p22.1 
[59]. 
Structural cardiovascular malformations (CVM) occur in 45−75% of patients 
with Turner syndrome (TS) [74-79]. Imprinting may play a role in its origin [80]. 
Congenital bicuspid aortic valve (25−55%) and coarctation of the aorta (30%) (see 
Figure 2a) are the most common of the cardiovascular malformations. Hypertension 
is also frequently seen in TS, even without cardiac or renal malformations [81]. These 
are risk factors for aorta dilatation and aneurysm. In 3−8% of the TS women, aortic 
dilatation, mainly of the aortic root (see Figure 2b), is present. Aortic root dilatation 
in TS is even described in children and adolescents with TS [82,83]. In recent studies, 
however, aortic dilatation was even present in up to 25−50% of patients with TS and 
CVM [76,79,84]. Aortic dilatation is also frequently seen in TS without other cardiac 
abnormalities. A rare, but potentially devastating result of aortic dilatation can be 
aortic dissection. Several reports have been published on aortic dissection in women 
with TS [77,83]. Especially the number of case-reports on dissection during pregnancy 
continues to rise [85,86], as oocyte donation is becoming more accessible for TS 
women. An obvious reason for this finding is that known predisposing factors for aortic 
dissection such as hypertension and cardiac malformations are seen more frequently 
in TS than in normal women [75]. Another suggestion to explain the increased risk 
for arterial dilation and dissection in women with TS is a connective tissue defect 
[77,87]. 
Also development of cardiovascular disease (CVD) is more frequently present in 
patients with TS. Patients with TS are more prone to develop risk factors for CVD, such 
as hypertension, dyslipidemia, diabetes mellitus, obesity, and hyperinsulinemia. It 
has even been reported that CVD is the main cause of their decreased life span [88].
binnenwerk_banink.indd   17 20-8-2006   12:53:25
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2a: coarctation aortae 2b: aortic root dilatation
Figure 2: Cardiovascular malformations occurring in Turner syndrome.
Visible features of neck, mouth and jaw, chest and skin are present in 60−79% 
of the Turner patients. An obvious and typical feature is a short thick (‘webbed’) 
neck, and a low hairline. A cervical vertebral hypoplasia contributes to the short neck 
appearance [89]. Abnormalities of mouth and jaw are: high arched palatum, small 
and backward rotated lower jaw, and defective dental development. The thorax 
can be scutiform, with apparent wide nipples, and nipples are often inverted. Skin 
features are lymph edema of hands and feet, especially in the neonatal period, 
increased number of pigmented naevi, dysplasia of finger and toenails, vitiligo, and 
after surgical operations keloid scarring is more often present [70].
Skeleton abnormalities (40−59%) described in Turner syndrome that are SHOX 
related are: cubitus valgus (wide angle of arm), Madelungs deformity (present in 
app. 7%), and short metacarpal bones (e.g. 4th). Possibly the high arched palatum 
and micrognathia (smaller lower jaw) are also SHOX related [66]. Other skeleton 
abnormalities often present in Turner patients are: square-shaped “shield” chest, 
spongiose bone structure, and scoliosis. Osteoporosis is common in the adult patient.
Renal abnormalities are present in 40−59% of the Turner patients, and can exist 
of structural malformations, such as ‘horseshoe kidney’, renal aplasia, duplication of 
the renal pelvis and ureters, unilateral and bilateral malpositioning of the kidneys, 
and ureters with an abnormal course. Most of these abnormalities do not have serious 
consequences and do not cause diminished functioning [70].
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rotated ear implant, ptosis of the eyes, strabismus, color-vision impairment, and 
myopia are common in patients with TS [70,90]. Anatomic distortion of Eustachian 
tubes and impaired middle-ear ventilation predispose patients with TS to otitis media 
that can lead to permanent hearing loss.
Increased risk for developing auto-immune diseases, such as, thyroid disorders 
(hypothyroidism, Hashimoto’s thyroiditis), celiac disease, and diabetes mellitus 
exists in the patient with TS [53,91,92]. The prevalence of autoimmune thyroid 
disease doubles from the 1st to the 3rd decade in life. There is a discrepancy between 
the high frequency of abnormal laboratory findings and the frequency of clinical 
illness. Thyroid antibodies can occur in up to 60% of the females with TS, while only 
between 20−30% of the adult women with TS have hypothyroidism (compared to 1.5% 
of adult women in the general population). The prevalence of celiac disease in TS is 
reported to be 6.4% in TS women aged between 8 and 36 years old, compared to < 1% 
in the general population [92]. The subclinical picture occurs in 60% of the patients. 
The exact pathogenesis of thyroid and other autoimmune diseases in women with TS is 
unknown. The isochromosome Xq is associated with a higher risk for the development 
of autoimmune disorders [50].
Body shape in girls and women with TS is more stocky compared to normal female 
body shape. Their trunk is relatively large, so are their hands and feet. The shoulders 
and pelvis are broad compared to height [93,94]. As a group, females with TS have 
a predisposition to become overweight compared to normal women, with a higher 
body mass index (BMI) [93,95]. 
There is a wide variety of skin manifestations in TS, such as pigmented naevi, 
naildysplasia, alopecia areata, keloid tendency, premature skin aging, psoriasis, and 
vitiligo [96].
Although intelligence is usually normal in TS, girls and women with TS reported 
to have more often psychosocial problems, such as impaired social relationships, 
a lower self-esteem, and less sexual activity. Furthermore, they were more likely 
to meet criteria for attention-deficit hyperactivity disorder than controls and were 
often employed in jobs for which they were overqualified. One study in untreated 
women with Turner syndrome assessed the quality of life in terms of working status, 
daily routine and love and marriage [97]. This study reported that most of the 
unmarried women lived with their parents, were well-educated and worked as normal 
women. However, they appear to be anxious about their body and marriage. Mental 
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abnormality [98].
Furthermore, Turner patients have more difficulties with mathematics and visual-
spatial tasks compared to their peers [99]. In general, females with TS experience 
motor impairment [100]. A small, nonmosaic deletion of the distal short arm of the 
X-chromosome in adult women is associated with the same cognitive profile seen in 
women with TS [60], suggesting that haploinsufficiency for genes in the short arm of 
the X-chromosome(Xp) are responsible for the cognitive features in TS.
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 syndrome: Growth hormone and estrogen treatment 
— Small for gestational age (SGA) —
Several studies have shown the beneficial effects of growth hormone (GH) treatment 
on linear growth, and subsequently on adult height in short children born SGA, 
including the study presented in this thesis [3,5,6,101,102]. In addition, it has been 
reported that ending GH after a GH-induced catch-up growth and before reaching 
final height, resulted in a reduced height velocity, returning to pretreatment 
values [103]. A distinct catch-down growth was observed after discontinuation of 
the GH treatment. This indicates that GH treatment has to be continued until adult 
height for an optimal effect.
Results of the first Dutch GH-trial in short SGA children
Efficacy 
The GH-trial presented in this thesis is the first Dutch GH trial treating short SGA 
children. It is a randomized, double blind, dose-response multicenter study, which 
started in 1991. Seventy-nine short SGA children were enrolled (age: 3−9 yrs for girls, 
3−11 yrs for boys), and were treated with either 1 mg GH/m2/day or 2 mg GH/m2/day 
until adult height. All were pre-pubertal at start of GH. Height normalized in the 
majority of the children within 2 years after start of GH therapy [2], and was continued 
until start of puberty. GH had no influence on the age at onset and progression of 
puberty compared to appropriate-for-gestational age controls (AGA), regardless the 
GH-dosage [104]. Duration of puberty and pubertal height gain were not significantly 
different between both GH-dosage groups. In this respect there were no significant 
differences between GH treated SGA girls and untreated SGA girls, as published in the 
literature [30]. GH treated SGA boys receiving the lower GH dose of 1 mg/m2/day, 
were 0.5 years older at pubertal onset than untreated SGA boys, as published in the 
literature [30]. 
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Figure 3: Height SDS of GH-treated short SGA children of the first Dutch GH-trial in 
short SGA children (adapted from Y. van Pareren [3]). Group A: 1 mg GH/m2/d, group B: 
2 mg GH/m2/d. 98% Of the GH treated SGA children had an adult height within their Target 
height range (TH-SDS, based on parental height). 85% Of the GH treated SGA children had 
an adult height within the normal range. Controls: Parallel group of short SGA children 
who did not receive GH treatment. AH = Adult height.
Ninety-eight percent of the children reached an adult height within the target-
height range, and 85% within the normal range (above −2 SDS) (Figure 3) [3]. The 
mean gain in height SDS from start of GH treatment until adult height was 1.8 (0.7) 
SDS for the GH-dose of 1 mg/m2/d, and 2.1 (0.8) SDS for a GH-dose of 2 mg/m2/d, 
which was not significanlty different. The adult height improvement was 11−13 cm in 
girls and 12−14 cm in boys.
Safety
GH treatment is known to decrease insulin sensitivity [105,106]. A low birth weight has 
been associated with increased risk of developing diabetes type 2 in adult life [13]. 
Therefore, extra care has been provided for evaluation of glucose intolerance and 
signs of insulin resistance. During GH treatment, fasting and stimulated insulin 
levels increased significantly [42], indicating a relative insulin resistance, which 
was accompanied by increased insulin release to maintain normoglycaemia. Values 
of glycosylated hemoglobulin (HbA1c) remained normal. Six months after end of GH 
treatment, the GH-induced insulin resistance disappeared, and fasting and stimulated 
insulin levels returned to normal [107]. 
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dyslipidemia. During GH treatment, the significantly increased systolic blood pressure 
(0.7 SDS), which was present at start of GH therapy, decreased to a normal systolic 
blood pressure [45]. Diastolic blood pressure was normal at start of GH-treatment, 
and also decreased significantly during GH treatment. Serum lipids were normal, and 
remained stable during GH treatment. Six months after end of GH treatment, these 
beneficial effects of GH on blood pressure and serum lipids had not changed [107].
A reduced sensitivity to insulin-like growth factor I (IGF-I) may play a role 
in the poly-endocrinopathy which is associated with short SGA [108]. The IGF-I 
system plays an important role in growth and development, and IGF-I mediates the 
growth promoting effects of growth hormone (GH). The IGF-I system has also been 
suggested to be involved in common diseases such as atherosclerosis, diabetes and 
neoplasias [16,17,109-112]. Free IGF-I is believed to represent the bioactivity of the 
IGF-I system. GH therapy increases total and free levels in healthy subjects [113]. 
During growth hormone (GH) treatment in SGA children, total IGF-I levels increased 
up to the upper normal range [2]. The effect of GH-therapy on free IGF-I levels in GH-
treated short SGA children is not yet known.
Other possible GH effects in SGA
As mentioned earlier, short stature during childhood and adolescence, resulting in a 
short adult height occurs in 10−15% of the individual born small for gestational age 
(SGA). Short children can suffer from physical, social and psychological problems. 
Being born SGA has also been associated with lower intelligence, impaired school 
performance, low social competence and behavioral problems. After 8 years of GH 
treatment, performal and total IQ-scores, behavior, and self-perception had improved 
significantly over time from a significantly lower value to values comparable to Dutch 
peers [33]. In addition, the taller the child became, the less problem behavior it 
showed. The effect of GH treatment on quality of life (QoL) is still not known.
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I GH treatment
Efficacy
Several studies have proven the beneficial effects of GH therapy on growth velocity, 
and subsequently on adult height in girls with Turner syndrome, including the study 
presented in this thesis [4,7-9,114]. Previously, it has been shown that the parental 
origin of the retained X-chromosome was of no influence on the response to GH 
treatment [115].
The GH-trial presented in this thesis is the Dutch GH dose-response study, 
treating girls with Turner syndrome. It was a randomized, multicenter dose-response 
study, which started in 1989. Sixty-eight untreated girls with TS (age: 2−11 yrs) 
commenced in this study. The diagnosis was confirmed by lymphocyte chromosomal 
analysis. The patients were randomly assigned to group A, B or C, receiving different 
GH-dosages. Group A (n = 23) received 1.3 mg/m2 body surface/day (equivalent 
to 0.045 mg/kg), group B (n = 23) 1.3 mg/m2/d during the 1st year, followed by 
2 mg/m2/d (≈ 0.0675 mg/kg/d) and group C (n = 22) 1.3 mg/m2/d during the 1st year, 
2 mg/m2/d during the 2nd year, and thereafter 2.7 mg/m2/d (≈ 0.090 mg/kg/d). 
In most of the TS girls, the GH therapy resulted in normalization of height during 
childhood and adulthood, with puberty induction at a normal age of 12.7 (0.7 SDS) 
yrs old. A GH-dosage of 1.3 mg GH/m2/d (group A) leaded to an average height of 
157.6 cm, which is equal to an SD-score of –1.6 when using references for normal 
Dutch girls [4]. A higher GH-dose resulted in a significantly higher adult height, group 
B: 162.9 cm (equal to SD-score of −0.7), and group C: 163.6 cm (equal to SD-score of 
−0.6). The adult height between group B and group C was not significantly different. 
Treatment resulted in a mean height improvement of 11.9−16.9 cm (Figure 4).
Safety
GH treatment is known to decrease insulin sensitivity in normal adults [105,106]. 
In untreated girls and women with Turner syndrome glucose intolerance, insulin 
resistance and non-insulin and insulin-dependent diabetes mellitus are more common 
than in healthy girls and women [88,116-118]. Therefore, concern has been expressed 
regarding possible effects of supra-physiolocial GH-dosages in girls with TS. During 
GH treatment, fasting and stimulated insulin levels increased significantly [119]. 
Fasting glucose levels increased also significantly, but stayed within the normal 
range, stimulated glucose levels showed no change. Individual values of glycosylated 
hemoglobulin (HbA1c) remained normal. Six months after GH discontinuation, fasting 
and stimulated insulin levels decreased to normal levels, however they remained 
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Figure 4: Height gain (difference in cm between adult height and modified projected 
adult height) of GH treated girls with TS in the Dutch GH dose-response trial (adapted 
from Y. van Pareren [4]). Group A: 1.3 mg GH/m2/d, group B: 2 mg GH/m2/d, group C: 2.7 
mg GH/m2/d. Mean (SD) height gain is given (cm).
above pre-treatment levels [120]. Fasting glucose levels also decreased after GH 
discontinuation. 
Hypertension and dyslipidemia are also more common in patients with TS. During 
GH treatment the SD-scores of the systolic blood pressure did not change significantly, 
while the diastolic blood pressure SD-scores decreased [121]. Six months after GH 
discontinuation, there was a decrease in blood pressure compared to pre-treatment, 
but it remained slightly higher than in girls matched for age [120]. During the first 4 
years of GH-therapy, total cholesterol, low-density lipoprotein (LDL) and atherogenic 
index (AI) decreased, high-density lipoprotein (HDL) and triglycerides increased 
[120]. Six months after GH discontinuation compared with 4 yrs lipid levels, total 
cholesterol and LDL had increased, and triglyceride levels had decreased. Possible 
explanations for the changes in lipid levels may be the effect of increasing age, or a 
GH effect.
Patients with TS have a higher risk of congenital or developed cardiovascular 
malformations and abnormalities. TS patients were treated with supra-physiological 
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GH hypersecretion is associated with an increased morbidity and mortality from 
cardiovascular disease. An increased left ventricular mass has been reported in 
acromegalic patients. GH treatment in TS patients, even at the highest dosage of 
2.7 mg GH/m2/d, did not result in left ventricular hypertrophy [121].
IGF-I mediates the growth promoting effects of growth hormone (GH). The 
IGF-I system has also been suggested to be involved in common diseases such as 
atherosclerosis, diabetes and neoplasias [16,17,109-112]. Free IGF-I is believed to 
represent the bioactivity of the IGF-I system. GH therapy increases total and free 
levels in healthy subjects [113]. During growth hormone (GH) treatment in girls with 
TS, total IGF-I levels increased, with mean around the upper normal range [4]. Six 
months after GH discontinuation, total IGF-I levels had fallen to levels comparable to 
normal age matched girls, but remained higher than pre-treatment levels. The effect 
of GH-therapy on free IGF-I levels in GH-treated patients with TS is not yet known.
II Estrogen treatment
In order to induce puberty, synthetic or natural estrogens have to be given to girls 
with Turner syndrome. Route and timing of the start of estrogen therapy, as well as 
the dose and form, are still a point of discussion. Estrogens have a biphasic effect 
on growth: stimulatory at low doses and inhibitory at higher doses [122]. Thereby, 
estrogens cause an acceleration of bone maturation, which subsequently reduces the 
growth phase and therefore may result in decreased adult height [123]. However, a 
delay in pubertal development may have serious psychosocial consequences, as the 
maturation of female identity is also essential at this age in girls. Progestagens should 
be added for at least 10 days/month, to prevent the development of endometrial 
carcinoma. Another option is to use both, estrogens and prostagens at the same time 
continuously. The advantage of the latter therapy is no menstrual bleedings after 
the use of this therapy for one year. However long term outcome of this therapy is 
unknown.
Additional effects of estrogens are their positive effects on bone mineral 
density, lipid profile, liver enzymes, physical fitness [124], cardiovascular system 
and neurocognitive development [125,126]. Theoretically, starting a low dose of 
oestrogen therapy before the planned induction of puberty could be favourable for 
these additional effects, particularly the neurocognitive development. However, 
starting estrogens before the age-appropriate time is not advantageously for adult 
height [127,128].
In the Dutch GH dose-response trial, as presented in this thesis, micronized 
17β-estradiol was given to the girls of 12 yrs and older, after at least 4 years of GH 
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ntreatment, in order to induce puberty. During GH treatment, in the first 2 years, 
5 µg/ kg body weight/ day was given orally, following by a dose of 7.5 µg/kg/d in the 
3rd year, and 10 µg/kg/d thereafter. Cyclic progesterone therapy 5 mg/d in the first 
14 days of the month was added after 2 years of estrogen therapy. At discontinuation 
of GH therapy, estrogen treatment was increased to an adult dose of 1 mg/day, and 
later on to 2 mg/day. Progesterone dosage was increased to 10 mg/d. 
Recently, from ours and other studies it appeared that, when GH treatment has 
been optimized, it is not necessary to delay the induction of puberty [4,129], and in a 
low dose, estrogens do not negatively influenced height velocity or adult height. 
Other possible effects of the GH and/or estrogen treatment in TS
Women with TS have a different body shape, their figure appears more stocky than 
that of normal women, with relatively short lower extremities, relatively large 
hands and feet, and relatively broad shoulders and pelvis [93,94,130]. During GH 
treatment, the pre-existing disproportion between height and sitting height in TS 
improved moderately, however the disproportionate growth of the feet, partly due to 
the natural development in TS, may be also influenced by higher GH dosage [94]. 
Short children can suffer from physical, social and psychological problems. After 
long-term GH therapy, behaviour of the TS women was comparable to normal Dutch 
peers [131]. In contrast, their self-perception and their attitude towards their body 
where slightly less positive, and they had a slightly different coping pattern than 
their normal Dutch peers. There was no evidence of depression. Thus, some women 
with TS still experience psychosocial problems, also after reaching a height within 
the normal range.
The effect of GH treatment or the accompanying gained height on quality of life 
(QoL) is still not clear.
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n 3  Aims of the study and outline of this thesis
The studies presented in this doctoral dissertation were part of two long-term GH-
trials in: 
Short children born Small for Gestational Age (SGA), started in 1991. 
Girls with Turner Syndrome (TS), started in 1989. 
A time frame of both studies is shown in Figure 5. 
‘89 ‘90 ‘91 ‘93 ‘96 ‘99 ‘03 ‘06 ‘06
Inclusion
period
Turner study
Inclusion
period
SGA study
Thesis:
W de Waal (SGA)
A van Teunenbroek (TS)
Thesis:
T Sas
(SGA & TS)
Long-term 
follow-up:
Turner Syndrome
Thesis:
YK van Pareren
(SGA & TS)
Present thesis by EMN Bannink:
SGA and Turner syndrome, 
The impact of GH treatment on physical and metal well-being
Figure 5: Time frame. 
Previous results of both studies were presented in the following theses:
1996: “Influencing extremes of growth. Too tall – too small”, by W. de Waal. 
In this thesis preliminary results of the first years of the GH-trial in short SGA children 
were reported.
1996: “Growth hormone treatment modalities in girls with Turner Syndrome”, by 
A. van Teunenbroek. 
In this thesis the four-year results of the GH-trial in TS girls were reported
1999: “Long-term growth hormone treatment in two growth disorders”, by T.C.J. 
Sas. 
Part: Children with short stature born SGA: reported the five-year results of the 
GH-trial in short SGA children. 
Part: Girls with Turner Syndrome: reported the seven-year results of the GH-trial in 
TS girls.
2006: “Added Centimeters and Their Repercussions. How effective and safe is 
growth hormone in the treatment of short stature in girls with Turner syndrome 
and in children born small for gestational age?”, by Y.K. van Pareren. 
In this thesis adult height, psychosocial consequences and 6 month (short-term) 
follow-up results of both studied populations were reported.
This doctoral dissertation gives a detailed report of various studies performed on 
the effects of long-term growth hormone treatment during GH therapy and after end 
1)
2)
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studies performed are not necessarily in the sequence in which they were carried 
out.
Serum IGF-I levels (Chapter 2 and 3)
Most of the GH effects are due to GH stimulated production of insulin-like-growth-
factors (IGF). The IGFs are tightly bound, both in the circulation and in tissues, to 
a family of 6 proteins, known as the IGFBPs. IGFBP-3 is the major binding-protein 
of IGF-I. Therefore the molar ratio of total IGF-I/IGFBP-3 is assumed to correspond 
to free IGF-I levels. Free IGF-I is believed to represent the bioactivity of IGF-I. GH 
stimulates the production of total IGF-I and IGFBP-3. The total IGF-I levels rise above 
the normal range in GH-treated short SGA children, as well as in GH treated TS girls. 
Whether free IGF-I levels are also increased during GH treatment, which may have 
long-term consequences, remains to be investigated. Furthermore, the value of free 
IGF-I measurement in addition to total IGF-I and IGFBP-3 is of interest. Both short and 
long term effects of the exposure of SGA children and TS girls to high circulating IGF-I 
levels during childhood are not well documented.
The aim of this part of the study was to assess free-dissociable IGF-I levels 
in short SGA children and TS girls before, during and after long-term GH therapy. 
Additionally, to analyze whether free IGF-I, total IGF-I, IGFBP-3, or the molar ratio 
of total IGF-I/ IGFBP-3 during GH therapy were related to various IGF-I bioactivity 
outcome parameters, such as adult height, growth response, glucose and insulin 
levels. In addition, it was infestigated whether free IGF-I measurements are of value 
in evaluating the GH treatment.
Quality of life (Chapter 4 and 5)
Quality of life is increasingly recognized as an important measure of the impact of a 
special disorder, disease or therapeutic outcome. 
The aim in this part of the study was to evaluate the quality of life after long-
term GH treatment in the two studied populations presented in this thesis, short SGA 
children and TS girls. 
Puberty induction (Chapter 6)
Most girls with TS do not start puberty spontaneously due to ovarian failure. 
Therefore, puberty has to be induced with exogenous estrogen therapy in most of 
the TS girls. Route and timing of the of start of estrogen therapy as well as the dose 
and form are still a point of discussion. Estrogens have a biphasic effect on growth: 
stimulatory at low doses and inhibitory at higher doses. Thereby, estrogens cause 
an acceleration of bone maturation, which subsequently reduces the growth phase 
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development may have serious psychosocial consequences. Previously, a puberty 
induction starting at an appropriate age, as described in this study, has been proven 
not to influence height velocity or adult height.
The aim of this part of the study was to describe the effects on breast development 
and uterine dimensions, when puberty induction was started at an appropriate 
age, using a low dose of 17β-estradiol, and to compare the pubertal development 
with normal Dutch girls. Additionally, to discuss whether serum levels of estradiol, 
gonadotropins, and sex hormone binding globulin are useful in evaluating induced 
pubertal development.
Long-term effects after end of GH treatment (Chapter 7 and 8)
TS is associated with a number of diseases and conditions, besides short stature and 
hypogonadism, such as congenital cardiovascular malformations, and risk factors for 
cardiovascular disease (CVD). Furthermore, untreated TS women show a different, 
more stocky body than normal women, with relatively short lower extremities, 
relatively large hands and feet, and relatively broad shoulders and pelvis. The effect 
of GH on these conditions, during GH therapy and short term after GH discontinuation, 
has been described previously in the TS population presented in this thesis.
The aim of this part of the study was to investigate the risks for cardiovascular 
disease, carbohydrate metabolism, and the body proportions, in young women with 
Turner syndrome, nearly 5 years after end of long-term GH treatment, and compare 
them with normal and, if possible, with untreated women with Turner syndrome 
(Chapter 7).
Furthermore, to assess biophysical properties and dimensions of the aorta in TS, 
and to evaluate a possible relation to the long-term GH therapy or GH-dosage applied 
(Chapter 8).
Chapter 9 discusses the significance of this study, and brings data in perspective. 
Chapter 10 summarizes the results of the complete study, dated from 1991 for 
the SGA population, and 1989 for the Turner population, and provides an answer 
to the question: “Was it − and is it − all worthwhile?”. Chapter 10 also includes 
recommendations for future research. Finally, Chapter 11 summarizes the findings 
of this thesis in English, as well as in Dutch.
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Free/dissociable IGF-I, not 
total IGF-I correlates with 
growth response during 
growth hormone treatment 
in children born small for 
gestational age
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A Abstract 
Context: IGF-I plays an important role in pre- and postnatal growth. Its serum levels 
are regulated by metabolic and genetic factors. Mean total IGF-I in short SGA children 
is reduced, but within the normal range. Free/dissociable IGF-I is the bioactive form 
of IGF-I. 
Objective: Investigating changes in free IGF-I during GH-treatment in short SGA 
children. Evaluating if free IGF-I levels contribute to predicting first year growth 
response and/or adult height. 
Design, setting & intervention: Randomized double-blind GH dose-response study 
with either a GH-dose of 1 mg/m2/d (group A) or 2 mg/kg/d (group B). Free IGF-I, 
total IGF-I, IGFBP-3 were determined at baseline, after 1 and 5 years, at stop, and 6 
months after GH discontinuation. 
Patients: 73 (46 male) short SGA children (36 group A), baseline mean age 7.7 (2.2) 
years, mean GH-duration 8.2 (2.1) years. 
Main outcome: Untreated SGA children showed mean free IGF-I SDS of −0.2 (1.2), 
not related to total IGF-I. During GH-therapy, free IGF-I significantly increased to 
1.6 (0.7) SDS, as did total IGF-I and IGFBP-3 (2.0 (0.8), 1.3 (0.9) SDS, resp.). Multiple 
regression analysis showed a negative correlation between baseline free IGF-I SDS 
and one-yr growth response and adult height, independently of baseline total IGF-I 
SDS. Total IGF-I, IGFBP-3, or their ratio showed no correlations with growth response.
 
Conclusions: Circulating baseline free IGF-I was a better predictor for short-term 
growth response as well as for adult height in GH-treated SGA children than were total 
IGF-I, IGFBP-3, or their ratio. Suggesting a possible role for free IGF-I measurement in 
predicting the effect of GH therapy in short SGA children. 
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About 10−15% of the infants born small for gestational age (SGA) fail to show 
spontaneous catch-up growth during the first 2 years of life, and have an increased 
risk of being short as adults [1-3]. Various factors have been mentioned with respect 
to the stunted postnatal growth, such as intrauterine reprogramming, genetic 
variations, reduced growth hormone (GH)-secretion, and reduced sensitivity for IGF-I 
[4-6]. 
IGF-I plays an important role in both pre- and postnatal growth and its serum levels 
are regulated by GH and by metabolic and genetic factors. In neonates born SGA, low 
circulating IGF-I levels have been observed [7-10]. Short SGA children exhibit plasma 
IGF-I levels that are in the lower-normal range, approximately between −1 to −1.5 
standard deviation score (SDS) [11-13].
Several studies demonstrated that GH treatment in short SGA children results in 
normalization of height during childhood and adulthood [14-18]. During GH treatment 
in SGA children, a rapid increase in total IGF-I levels and a slower increase in IGFBP-
3 levels occurs [19]. Controversies exist on the role of total IGF-I and/or IGFBP-3 
levels in the growth response. It has been reported that the growth response showed 
a positive association with the short-term increase in total IGF-I [19], and an inverse 
relation to baseline IGF-I levels [19,20]. Other authors reported a positive correlation 
between the growth response and the change in both total IGF-I and IGFBP-3 in SGA 
children [21]. However, in another study on short SGA children one could not confirm 
these results [22]. This apparent discrepancy may be due to the use of different 
definitions for SGA, leading to differences in inclusion criteria and study groups. 
In the circulation, IGF-I is mainly bound to IGF binding proteins (IGFBPs), of which 
six classes have been identified (IGFBP- 1 to − 6) [23]. The GH-dependent IGFBP-3 is 
the major carrier protein of IGF-I in the circulation, normally accounting for more 
than 90% of the IGF-binding [24]. Under normal circumstances, less than 1% of the 
total plasma IGF-I pool is in the unbound free biologically active form [25,26], which 
exchanges rapidly with the tissue compartments [23]. To our knowledge, free IGF-I 
levels have not been studied in SGA children before and during GH treatment. The 
first aim of our study was to evaluate free IGF-I levels at start and during GH therapy 
until adult height. Secondly, we wanted to determine if free IGF-I levels would 
contribute in predicting the first year growth response and adult height. 
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GH trial
Ninety short children born SGA participated in a multi-center GH trial in the 
Netherlands, which started in 1991. Inclusion criteria for the dose-response trial 
were: birth length SDS below −2, chronological age (CA) between 3 and 11 years in 
boys and 3 and 9 years in girls, height SD-score for CA below −2, no spontaneous 
catch-up growth during last year, pre-pubertal stage, and uncomplicated neonatal 
period without severe asphyxia, sepsis, or lung problems [12,15]. 
The GH trial evaluated the effect of GH on long-term growth and adult height. 
In brief: to stratify for spontaneous GH secretion during a 24-hour GH profile, a 
group of 79 children was divided into three groups: ‘normal profile’, ‘GH insufficient 
profile’, and ‘no profile performed’. Twenty-four-hour GH profiles were performed at 
baseline in 39 of the children, as previously described [27], an arginine stimulation 
test was performed in all 79 children. After stratification for age and spontaneous GH 
secretion during a 24-h GH profile, all children were randomly and blindly assigned 
to one of 2 GH-dosage groups: group A receiving 1 mg/m2/d (~33 μg/kg/d), or group 
B receiving 2 mg/m2/d (~67 μg/kg/d) [15]. GH was given double blindly. In addition, 
the remaining 11 short SGA children were treated parallel to the trial with a known 
dose of 2 mg/m2/d, because they were older than the maximum age according to the 
inclusion criteria. Three-monthly, the total GH-dose was adjusted to the calculated 
body surface. Biosynthetic GH (r-hGH Norditropin®, Novo Nordisk A/S, Denmark) 
was given subcutaneous once daily until adult height, defined as height velocity 
below 0.5 cm during the previous 6 months. Every 3 months height and weight were 
measured. Height was expressed as SD-score for chronological age and gender, using 
the references for healthy Dutch children (28). Adult height was expressed as SD-
score for gender and an adult age of 20 years. 
Study subjects and design
For the present study we only investigated patients who received GH-therapy for ≥ 5 
years. Seven of the 11 older subjects were excluded, because they were treated less 
than 5 years until adult height, whereas 3 other subjects were still being treated with 
GH at time of analysis, and could therefore not be included. At start of the present 
study, seven had dropped out of the GH trial, and were lost to follow-up due to the 
following reasons: lack of motivation (n = 3), moving abroad (n = 2), treatment for 
precocious puberty (n = 1), and biochemical signs of GH insensitivity (n = 1). Thus, 73 
subjects remained eligible for the present study. 
Five of them were GH-deficient (GHD), defined as having IGF-1 and IGFBP-3 below 
−2 SD and peak GH-levels below 20 mU/l after stimulation with arginine. Seven had a 
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at start and after 1 year of GH therapy. 
Both EDTA-plasma and serum samples were taken between 09.00 and 12.00 hours 
at baseline, 1 year and 5 years after start of GH-therapy, before discontinuation of 
GH-therapy (final year), and 6 months after ending GH-therapy (post GH). Thus, a 
maximum of 5 samples per subject was analyzed. The baseline, 1st year and post 
GH samples were collected after an overnight fasting. All samples were stored 
appropriately at −80°C until assayed. 
Levels of free IGF-I, total IGF-I, and IGFBP-3 
Free IGF-I levels were measured in serum with a commercial two-site 
immunoradiometric assay (IRMA) using a commercial kit (Diagnostic System 
Laboratories, Inc., Webster, Texas, USA). This IRMA detects both the unbound IGF-I 
and the easily dissociable IGF-I [29]. The inter-assay CV was 9.7%, calculated from 
data produced by the investigators, measured at serum levels of 0.26 and 3.41 ng/ml. 
There was no difference in CV between the low and high level. In order to establish 
normative range values for circulating free IGF-I, serum samples were collected 
from healthy children (116 girls and 211 boys, aged between 0 and 17 years) who 
underwent minor surgical procedures. Serum samples were obtained and stored at 
−80°C in well-capped tubes until analysis. Smoothed references for free IGF-I were 
constructed using the LMS method, designed for constructing normalized standards of 
nonparametric data, described by Cole [30].
The free IGF-I assays were performed by the same investigator (EB), in the same 
laboratory, under standardized circumstances, i.e. the assays were performed at 5oC, 
serum samples were kept at 5oC, and incubated for exactly 2 hours. The various serum 
samples investigated in the present study had not been thawed previously. However, 
we did investigate the effect of repeated freezing and thawing (3 times) of several 
(n = 13) serum samples on the free-IGF-I levels, but could not find a significant effect 
(i.e. not larger than the inter-assay variation). Moreover, samples tested again after 
a year of storage showed the same results. Using 13 healthy adult volunteers working 
in our department, we compared free IGF-I levels in sera obtained after an overnight 
fast with those in the non-fasting state. No significant differences were found. This 
finding is in agreement with a previous report on this subject, showing that, despite a 
marked elevation in IGFBP-1, overnight fasting did not influence circulating free IGF-I 
levels [31]. 
Total IGF-I plasma levels were measured by a semi-automated chemiluminescence 
technique (Advantage, Nichols Institute Diagnostics, San Juan Capistrano, USA). 
Plasma IGFBP-3 levels were measured by specific RIA, as described previously [32]. 
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ratio between total IGF-I andIGFBP-3 have been previously determined in the same 
laboratory [32,33]. 
Statistical methods
Unless indicated otherwise, results are expressed as mean (SD). Differences over 
time and between the GH-dosage groups were analyzed using repeated measurement 
analyses. Spearman’s rho correlations were used to assess correlations between SD-
scores of free IGF-I, total IGF-I, IGFBP-3 and total IGF-I/IGFBP3 molar ratio, and 24- 
hour GH-profiles outcome measures. The outcome measures for the 24-h GH profiles 
were the number of peaks, mean pulse amplitude, and the area under the curve 
above zero-level (AUC0).
Multiple regression analyses were used to assess the relationships between either 
free IGF-I, total IGF-I, IGFBP-3 or total IGF-I/IGFBP3 ratio, and first year change in 
height SDS and final height SDS outcome, respectively. Each laboratory parameter was 
entered separately in the model, along with age at start of GH therapy, target height 
(TH) SDS, and GH-dose. In the model for adult height SDS we also included height SDS 
at start of GH treatment. These multiple regression analyses were repeated for the 
subgroup of patients who underwent a 24-hour GH profile. The 24-hour GH profiles 
outcome measures were included into the models separately. The percentages of 
variance explained by the model (R2 in %) and the adjusted R2 (%) are given. A P-value 
of < 0.05 was considered statistically significant. All calculations were performed 
with SPSS 11.5.
Ethical considerations
The Medical Ethics Committee of each participating center approved the trial 
protocol. The Medical Ethics Committee of the Erasmus Medical Center approved the 
collection of reference serum samples in healthy children. Written informed consent 
was obtained from each participant older than 12 years, and parents.   
Results 
Study subjects
The clinical characteristics of the 73 children participating in this study are shown in 
Table 1. There were no significant differences between the two GH-dosage groups. 
The difference in target height between the two GH-dosage groups nearly reached 
significance (P = 0.06).
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ATable 1:  Clinical characteristics of the two GH groups.
Group A
1 mg GH/m2/d
n = 36
Group B
2 mg GH/m2/d
n = 37
Total group
n = 73
Male (%) 26 (72%) 20 (54%) 46 (63%)
Gestational age (weeks) 37.2 (3.3) 36.3 (4.2) 36.7 (3.8)
Birth length SDS −3.5 (1.4) −3.6 (1.6) -3.5 (1.5)
Birth weight SDS −2.6 (1.2) −2.5 (1.0) -2.5 (1.1)
Age (years): Baseline 7.5 (2.0) 7.9 (2.5) 7.7 (2.2)
At stop GH 16.0 (1.2) 15.8 (1.5) 15.9 (1.4)
Height SDS:  Baseline −3.1 (0.7) −3.1 (0.7) −3.1 (0.7)
Adult height −1.5 (0.9) −1.2 (1.0) −1.4 (0.9)
Target height −0.9 (0.9) −0.5 (0.9) −0.7 (0.9)
Height SDS gaina 1.6 (0.7) 1.9 (0.7) 1.7 (0.8)
BMI SDS:       Baseline −1.2 (1.3) −1.2 (1.1) −1.2 (1.2)
Post GH 0.0 (1.2) 0.1 (0.9) 0.1 (1.1)
Duration of GH therapy (years) 8.5 (1.9) 7.9 (2.2) 8.2 (2.1)
Data expressed as mean (SD) or number (n). Post GH = 6 months after end of GH.
a: Adult height SDS − height SDS at start GH therapy
THboys = ½ * (Heightfather + Heightmother + 12) +3 
THgirls = ½ * (Heightfather + Heightmother − 12) + 3
Free IGF-I levels
The serum free IGF-I levels in the reference group showed an age-dependent increase 
(Figure 1). Pre-pubertal girls had higher free IGF-I levels than boys, but during puberty 
boys had higher free IGF-I levels than girls. 
At baseline, for both groups of short SGA children, serum levels of free IGF-I SD-
scores were not different from 0 SDS (mean SDS(SD) group A: -0.3(1.3), group B: −0.2 
(1.2)) (Figure 2). There were also no significant differences between the two GH 
dosage groups during GH treatment and thereafter. During GH therapy, the mean(SD) 
values of free IGF-I SDS in the total group of SGA subjects increased significantly from 
-0.2 (1.2) to 1.6 (0.7). After the first year, the free IGF-I SDS did not further increase. 
After 5 years of GH-treatment, 34.7% of the study subjects had free IGF-I SDS above 
the +2 SDS. Six months after the end of GH therapy, the mean free IGF-I SD-score had 
decreased to 0.5(1.0), which was significantly higher than baseline SDS. During GH 
therapy, 27.5% of all free IGF-I measurements were > + 2 SDS, 0.5% > + 3SDS, and 32 of 
the 73 patients (44%) never exceeded the +2SDS. 
There were no significant differences in free IGF-I levels between SGA patients 
with or without GHD, neither between SGA patients with or without SRS, at any point 
in time [34].
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Figure 1: The mean of the Dutch reference population is represented by a solid line (―—), 
the −/+1 SDS by a dotted line (….), and the −/+2 SDS by a broken line (----). Serum levels 
of free IGF-I in short boys (1a) and girls (1b) born SGA, before start of GH treatment (open 
boxes) and after 1 year of GH treatment (closed boxes).
Total IGF-I and IGFBP-3 levels
At baseline, mean total IGF-I SDS and IGFBP-3 SDS were significantly lower than 0 
SDS (−0.9 (0.9) and −1.2 (1.2) resp.) (Figure 2), whereas mean SDS for the total IGF-
I/IGFBP-3 molar ratio did not significantly differ from zero (−0.1 (0.2)) (Figure 2). 
Also, for these parameters no significant differences were noted between the two GH 
dosage groups, at any point in time.
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IGF-1 SDS had increased to 1.4 (1.0) and 1.95 (0.8) SDS, mean IGFBP-3 SDS to 0.5 (1.1) 
and 1.2 (0.9), and the molar ratio SDS to 1.3 (1.6) and 1.3 (1.0), respectively.
Mean IGFBP-3 SDS after 5 years of GH therapy of 1.2 (0.9) declined to 0.2 (1.0) SDS 
at GH-discontinuation, which is in absolute values a decline from 139 (31) to 108 (40) 
nmol/l. Mean IGFBP-3 SDS at GH-discontinuation was significantly lower compared to 
the value found after 5 years of GH-therapy, but did not significantly differ from that 
after 1 year of GH-therapy. 
Six months after GH discontinuation, SDS for total IGF-I, IGFBP-3, and total IGF-
I/IGFBP-3 molar ratio had decreased, but the values of these parameters were still 
higher than those found at baseline.
Relationships between free IGF-I, total IGF-I, IGFBP-3, and total IGF-I/
IGFBP-3 molar ratio and height 
Pre-treatment: At baseline, there was a weak, but significant correlation 
between free IGF-I SDS and height SDS (r = 0.25, P < 0.05). Baseline free IGF-I SDS was 
also positively correlated with baseline IGFBP-3 SDS (r = 0.41, P < 0.001), but not with 
baseline total IGF-I and the total IGF-I/IGFBP-3 molar ratio SD-scores (r = 0.08, P = 
0.49 and r = −0.17, P = 0.15, respectively). Baseline total IGF-I SDS, IGBP-3 SDS, and 
total IGF-I/ IGFBP-3 molar ratio SDS did not show any correlation with baseline height 
SDS. At baseline there were no correlations between any of the 24-hour GH profile 
characteristics or the stimulated GH peak and height SDS, free IGF-1, total IGF-1, 
IGFBP-3, or total IGF-1/IGFBP-3 ratio. 
During GH treatment: After 1 and 5 years of GH treatment, free IGF-I SDS showed 
a positive relationship with total IGF-I SDS (r = 0.46 (P < 0.001) and r = 0.32 (P < 
0.01) respectively), and after 1 year of GH with the SDS value of total IGF-I/IGFBP-3 
molar ratio (r = 0.45, P < 0.001). There was no correlation between free IGF-I SDS and 
IGFBP-3 SDS after 1 and 5 years of GH-treatment. 
First year growth response: For the change in height SDS during the first year, 
the multiple regression model including the independent variables: age at start of GH 
therapy, TH SDS, and GH-dose, explained 38.8% (R2) of the variance (Table 2). Adding 
baseline free IGF-I SDS significantly increased the R2 to 48.3% (P < 0.01), contributing 
nearly 10% to the prediction of the first year change in height SDS. When, instead of 
or in addition to free IGF-I, baseline total IGF-I SDS or IGFBP-3 SDS were added, this 
did not improve the model significantly (P = 0.4). First year’s change in free IGF-I SDS 
was not related to first year change in height SDS. 
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Figure 2: SD-scores of free IGF-I (2A), total IGF-I (2B), IGFBP-3 (2C), and the ratio total 
IGF-I/IGFBP-3 (2D) for group A (light grey) and group B (dark grey) are shown before, 
during and after GH-treatment. Normal range (−/+2 SDS) is shown (dotted lines). 
*: Significantly different from 0 SDS. 
#: Significantly different from group A. (If GH discontinuation was at 5 years, patient was 
only included in ‘at stop’ sample, not in both ‘after 5 years’ and ‘at stop’)
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In the subgroup of 39 SGA patients of whom 24-hour GH profiles were available, 
the model including baseline free IGF-I SDS along with the independent variables, age 
at start of GH therapy, TH SDS, and GH-dose, showed an R2 of 44.6%, and an adjusted 
R2 of 37.4%. Adding either the AUC0 or mean peak amplitude to the model, improved 
the model significantly, explaining the variance of the first year growth response for 
56.4% and 54.2%, respectively (adjusted R2: 49.1% and 46.6%, respectively), whereas 
adding the number of peaks was of no influence.
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independent variables age at start of GH therapy, TH SDS, height SDS at start of 
GH, and GH-dose explained 40.0% (R2) of the variance in adult height SDS (adjusted 
R2: 36.4%). Adding baseline free IGF-I SDS, the R2 significantly increased to 46.8% 
(P < 0.01, adjusted R2 42.6%). Subsequent addition of baseline IGFBP-3 SDS, improved 
the model even further (P = 0.01, R2 52.7%, adjusted R2 48.2%). The addition of 
baseline total IGF-I SDS did not improve the model further (P = 0.5). The optimal 
multiple regression models for first year response and adult height are shown in Table 
2.
When free IGF-I was not included in the model, baseline total IGF-I together with 
the independent variables in a multiple regression model also improved the model 
significantly, but less pronounced (maximum R2 was 44%). 
None of the 24-h GH-profile characteristics were of significant influence on adult 
height outcome.
Table 2: Multiple regression models for first year change in height SDS and adult height 
SDS. 
Dependent variable Independent variables B se β P
Change in height SDS after 1 year Age at start (years) − 0.048 0.014 − 0.348 0.001
TH SDS − 0.055 0.031 − 0.164 0.082
GH dose (mg/m2/d) 0.295 0.056 0.487 < 0.001
Free IGF-I SDS at start − 0.079 0.028 − 0.293 0.006
R2 (Adjusted R2) 48.3% (45.0%)
SD of the residual 0.226
Adult height SDS Age at start (years) 0.034 0.046 0.079 0.467
TH SDS 0.184 0.114 0.176 0.111
Height SDS at start 0.715 0.149 0.525 < 0.001
GH dose (mg/m2/d) 0.486 0.174 0.258 0.007
Free IGF-I SDS at start − 0.193 0.089 − 0.232 0.033
IGFBP-3 SDS at start − 0.224 0.080 − 0.287 0.007
R2 (Adjusted R2) 52.7% (48.2%)
SD of the residual 0.683
B: Unstandardized coefficients, β: standardized coefficients, P: P value.
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Our study describes free IGF-I levels in short children born SGA, before, during and 
after GH treatment. Mean free IGF-I SD-values were normal in short SGA children, 
in contrast to the total IGF-1 and IGFBP-3, which were significantly lower than 0 
SDS. During GH-treatment, free IGF-I increased, but stayed largely within the normal 
range, whereas total IGF-I increased to a greater extent than free IGF-1, reaching 
the +2 SDS. After ending GH-treatment, free IGF-I declined to similar levels as total 
IGF-1 did, whereas IGFBP-3 declined further. However, all remained slightly higher 
than baseline levels. The SD-scores are not influenced by differences in pubertal 
onset with the normal population, as puberty in GH treated short SGA children was 
comparable to normal children, and started at the same age [34].
Baseline free IGF-I was inversely related to the first year growth response and 
adult height in contrast to baseline levels of total IGF-I. Also IGFBP-3 SDS was inversely 
related to adult height SDS. All of the characteristics of the 24-hour GH profiles were 
inversely related to first year growth response, but not to adult height or any of the 
baseline IGF-I parameters. 
For the present study we used, under strictly controlled conditions, the DSL IRMA 
for the measurement of free IGF-I levels in serum. In fact, this assay determines 
the sum of truly free IGF-I and readily IGFBP-dissociable IGF-I which is thought to 
represents a more biologically relevant pool than free IGF-I alone [25]. There was no 
difference between fasting and non-fasting state. Serum free IGF-I levels in healthy 
boys and girls appeared to increase with age and are higher in prepubertal girls than 
in boys, which is in agreement with earlier reports [25,26,35].
Most samples were analyzed at the end of the study, several years after collecting 
them. According to our experience total IGF-I and IGFBP-3 in EDTA plasma or serum is 
very stable, i.e. after more then 10 years of storage at −80°C the values do not change 
significantly. However, we did not have the opportunity to examine the stability of 
free-IGF-I upon long-term storage. The samples showed the same results after testing 
again after up to three years of storage. The samples used had not previously been 
thawed, and were stored in well-capped tubes at −80°C.
At baseline mean, serum free IGF-I SDS in short SGA children was not significantly 
different from zero SDS, either with or without GHD. Serum levels of total IGF-I and 
IGFBP-3 were, however, significantly lower than normal, which has previously been 
reported [13,19,22,36]. In our study, there were also no differences in free IGF-1 
levels between SGA children with and without GHD during GH therapy and thereafter. 
Since free IGF-I levels are reported to be decreased in untreated GH-deficient 
children and adults [25,35,37], our results suggests that these children with GHD have 
a different pathophysiology of short stature than SGA subjects with GHD. 
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adult height SDS, also after adjusting for baseline levels of total IGF-I and IGFBP-3. 
This suggests that at baseline the free fraction of the total IGF-I level in the circulation 
has a predictive value not only for first year growth response to GH-therapy, but also 
for adult height SDS in short SGA children, irrespective of baseline total IGF-I levels.
We did not find a correlation between baseline free IGF-I SDS and baseline total 
IGF-I SDS. This finding is in contrast with observations under conditions of primary 
abnormalities in the GH secretion, such as GHD and acromegaly, where usually a close 
relationship is found between serum free IGF-I levels and total IGF-I levels and total 
IGF-I/IGFBP-3 molar ratios [38]. One explanation might be that short stature in SGA is 
due to genetic variations in the IGF-I gene, resulting in altered IGF-I binding to their 
various binding proteins [39,40]. 
There was no correlation between the change in free IGF-I and first year growth 
response. Apparently, the relationship between the concentration of free-IGF-I in the 
circulation and growth (tissue) response is different before and during GH treatment. 
As total IGF-I increases more than free IGF-I during GH treatment, it might be that 
there is an increased clearance of free IGF-I from the circulation to the tissues, due 
to a very short half life of free IGF-I in the circulation compared with that of total 
IGF-I [38]. However, the nearly equal SDS levels of total IGF-I and free IGF-I during GH 
treatment does not support this theory. 
One has to consider, however, that the levels of IGF-I or IGFBP-3 measured were 
circulating levels. Unfortunately, we could not measure locally produced IGF-I 
levels. In this respect it must be emphasized that circulating concentrations of IGF-
I (and IGFBP-3) may not necessarily reflect those occurring at the various tissue 
compartments, since there is also an (unknown) contribution of locally produced 
growth factor. 
In conclusion, our study showed that untreated short children born SGA have 
normal free IGF-1 levels, whereas total IGF-I and IGFBP-3 were decreased. Baseline 
serum free IGF-I was a better predictor for short term growth response as well as 
for adult height in GH-treated SGA children than were total IGF-I, IGFBP-3, or total 
IGF-I/IGFBP-3 ratio. This finding suggests a role for free IGF-I measurement in the 
prediction of growth response of short SGA children at start of GH therapy. 
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Free-dissociable insulin-like 
growth factor I (IGF-I), total 
IGF-I and their binding proteins 
in girls with Turner Syndrome 
during long-term growth 
hormone treatment
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S Abstract 
Objective: To investigate the effect of GH-treatment on free IGF-I levels in TS girls, 
and to verify relationships between free IGF-I levels and total IGF-I, IGFBP-1, 2 and 
3. Additionally, to analyse whether free IGF-I, total IGF-I, IGFBP-3, or its ratio, were 
related to IGF-I bioactivity outcome parameters. 
Design: Sixty-five TS girls were randomly assigned to 3 different GH-dosage groups 
(1.3, 2.0, and 2.7 mg/m2/d). Mean duration of GH therapy was 8.7(2.0) years. Free 
IGF-I, total IGF-I, IGFBP-1,-2,-3 were determined at baseline, first, second, third, 
and fifth yr of GH therapy, before start of estrogen therapy, final yr of GH treatment, 
6 months after GH, and 4.8(2.0) years after GH discontinuation. 
Main outcome: During GH treatment, mean free IGF-I levels stayed < +2 SDS, while 
mean total IGF-I and IGF-I/IGFBP-3 ratio were > +2 SDS. There were no differences in 
free IGF-I levels between the 3 GH-groups, whereas total IGF-I and ratio levels were 
significantly higher in the highest GH-group. The following variables contributed 
significantly to predicting the square-root of free IGF-I levels: age, GH dose, estrogen 
dose, IGFBP-1, IGFBP-3, BMI, and total IGF-I or total IGF-I/IGFBP-3 ratio. However, the 
explaining variance did not exceed 55%. Several IGF-I bioactivity outcome parameters 
positively correlated with total IGF-I and IGF-I/IGFBP-3 ratio, whereas free IGF-I did 
not. 
Conclusions: During long-term GH therapy in TS girls, mean free IGF-I levels stayed 
within the normal range, while mean total IGF-I and total IGF-I/IGFBP-3 ratio 
exceeded the upper normal range. Although total IGF-I and the total IGF-I/IGFBP-
3 ratio did not accurately represent free IGF-I levels, they seemed to be better 
representing the IGF-I bioactivity than measured free IGF-I.  
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SIntroduction
The insulin-like growth factor (IGF) system plays an important role in growth and 
development. IGF-I mediates the growth-promoting effects of growth hormone (GH), 
and exerts negative feedback on pituitary GH secretion. In the circulation, it is bound 
mainly to IGF binding proteins (IGFBPs), six classes of which have been identified 
(IGFBP- 1 to − 6) [1]. 
Under normal circumstances, less than 1% of the total plasma IGF-I pool is 
considered to be present in the unbound free biologically active form [2,3], which 
exchanges rapidly with the tissue compartments [1]. The GH-dependent IGFBP-
3 is the major carrier protein of IGF-I in the circulation, normally accounting for 
more than 90% of the IGF-binding [4]. Hence, the total IGF-I/IGFBP-3 ratio has been 
proposed to be a surrogate measure of biologically available free IGF-I 
Since recombinant human GH became available in 1985, increasing numbers of 
children with short stature have been treated, including those with Turner Syndrome 
(TS). On average, untreated TS patients reach an adult height that is 20 cm shorter 
than their healthy peers. The exact cause of the stunted growth is still unknown. 
Despite normal GH secretion and normal to subnormal IGF-I levels, GH treatment 
can normalize height during childhood [5,6], and also provide an adult height gain of 
12−17 cm [7,8]. Additional estrogen therapy is necessary in most TS patients as, due 
to ovarian failure, there is no spontaneous puberty. 
When TS girls are receiving GH treatment, the total IGF-I levels in their circulation 
may rise to high-normal or supra-physiological values [5]. Besides increasing total 
IGF-I levels, GH therapy also causes an increase in plasma IGFBP-3 levels, which may 
affect the levels of the biologically active free-IGF-I. However, data on free-IGF-I 
levels are lacking. Neither is there enough documentation on the adverse short-term 
and long-term effects of exposing TS patients to high circulating IGF-I levels during 
childhood. In a previous study on girls with TS, we encountered increased fasting and 
stimulated plasma insulin during GH therapy [9]. After GH discontinuation, there was 
also a relationship between GH dosage and aortic wall distensibility, the higher GH 
dose having a beneficial effect [10]. We did not investigate, however, whether these 
effects are related to plasma levels of total IGF-I and/or free IGF-I. 
Therefore, our main objectives were to investigate the effect of long-term GH-
treatment, GH dosage, and simultaneously administrated 17-β estradiol on free IGF-I 
levels, and to establish the relationship between the latter parameter and circulating 
levels of total IGF-I, IGFBP-1, 2 and 3. We also explored whether free IGF-I, total IGF-
I, IGFBP-3, and/or the total IGF-I/IGFBP-3 molar ratio were related to various IGF-I 
bioactivity outcome parameters, such as adult height, height SDS gain, glucose and 
insulin levels, and aortic wall distensibility.
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Study subjects
Sixty-eight previously untreated girls with Turner Syndrome (TS) participated in an 
open-randomized multi-center growth-hormone (GH) dose-response study in the 
Netherlands [7]. 
Diagnosis of TS was confirmed by lymphocyte chromosomal analysis. Subjects were 
included if their chronological age was between 2−11 years and their height lay below 
the fiftieth percentile according to normal Dutch references. The exclusion criteria 
were abnormal thyroid function, associated endocrine and or metabolic disorders, 
growth failure due to other causes (e.g. emotional deprivation), hydrocephalus, 
previous use of drugs which could interfere with the GH treatment, and spontaneous 
puberty. Three girls dropped out of the study due to lack of motivation. 
Study design
After stratification for chronological age and height standard deviation scores 
(SDS), the patients were randomly assigned to group A, B or C, receiving different 
GH dosages. Group A (n = 23) received 1.3 mg/m2 body surface/day (equivalent to 
0.045 mg/kg); group B (n = 23) received 1.3 mg/m2/d during the first year, followed 
by 2 mg/m2/d (≈ 0.0675 mg/kg/d); and group C (n = 22) received 1.3 mg/m2/d during 
the first year, 2 mg/m2/d during the second year, with 2.7 mg/m2/d (≈ 0.090 mg/kg/d) 
thereafter.
Biosynthetic human GH (Norditropin, Norditropin Simplexx, Novo Nordisk A/S, 
Denmark) was given subcutaneously once daily between 20.00 and 22.00 hours, using 
a pen-injection system. Every 3 months the dose was adjusted to the calculated body 
surface. In accordance with the study protocol, the GH treatment was discontinued 
either when height velocity (HV) was less than 1 cm over 6 months, or when the 
patient decided she was satisfied with the height she had achieved. 
In order to induce puberty, a daily oral dose of micronized 17β-estradiol was 
administered to girls of 12 years and older, after at least 4 years of GH treatment. 
In the first 2 years, a dose of 5 µg/kg body weight/day (~0.05 µg ethinyl estradiol/
kg/d) was given; in the third year the dose was 7.5 µg/kg/d, and thereafter it was 
10 µg/kg/d. After GH discontinuation, the estrogen dosage was increased to 1 or 
2 mg/day, i.e. the level usually provided to adults. In addition, cyclic progestagen 
therapy (Duphaston 5 mg/d, 14 days of the month) was initiated after 2 years of 
estrogen therapy. If puberty had developed spontaneously (Tanner breast stage ≥ B3) 
during the GH-therapy, no estrogens were given during GH-therapy.
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SDetermination of circulating levels of free IGF-I, total IGF-I, IGFBP-3, 
IGFBP-2, and IGFBP-1
Blood samples were taken, between 09.00 and 12.00 hours, at baseline and 
subsequently every year. Both serum and EDTA plasma were obtained and all samples 
were stored at −80 °C in well-capped tubes until assayed. Free IGF-I, total IGF-I, 
IGFBP-1, IGFBP-2, and IGFBP-3 were determined at baseline, 1 year, 2 years, 3 years, 
and 5 years after the start of GH therapy, at the yearly visit before start estrogen 
therapy, in the final years of GH treatment, and 6 months after GH discontinuation. 
At a follow-up visit of 4.8 (2.0) years after GH discontinuation, a blood sample could 
be obtained from 39 out of 65 patients. A maximum of 9 samples per subject were 
available for analysis. All free IGF-I, IGFBP-1, IGFBP-2 measurements, most of the 
IGFBP-3, and some of the total IGF-I measurements were analyzed at the end of the 
study, i.e. between 2002 and 2003. 
Free IGF-I levels were measured in serum with a two-site immunoradiometric 
assay (IRMA) using a commercial kit (Diagnostic System Laboratories, Inc., Webster, 
Texas, USA). The IRMA assay measures the unbound IGF-I and the easily dissociable 
IGF-I [11]. The inter-assay CV was 9.7%. In order to establish normative range values 
for circulating free IGF-I, serum samples were collected from healthy children who 
underwent minor surgery. Serum samples from 116 girls (age: 0−17 years) were 
obtained and stored at −80 °C until analysis. Smoothed references for free IGF-I were 
constructed using the LMS method, a method for constructing normalized standards 
of nonparametric data, described by Cole [12]. 
The various free IGF-I assays were performed by the same analyst (EB), under 
the same circumstances in the same laboratory. They were performed at 5oC. Serum 
samples were kept at 5oC and incubated for exactly 2 hours. Using 13 healthy adult 
volunteers working in our department, we compared free IGF-I levels in sera obtained 
after an overnight fast with those derived in the non-fasting state. No significant 
differences were found. This finding is in agreement with a previous report on this 
subject, showing that, despite a marked elevation in IGFBP-1, overnight fasting did 
not alter circulating free IGF-I levels [13]. 
Total IGF-I plasma levels were measured using an immunometric technique on 
an Advantage Chemiluminescense System (Nichols Institute Diagnostics, San Juan 
Capistrano, USA). Serum levels of IGFBP-1, IGFBP-2 and IGFBP-3 were measured using 
specific RIAs, as described previously [14-16]. All assays were performed in the same 
laboratory. 
Since the levels of total IGF-I, IGFBP-3, IGFBP-2, total IGF-I/IGFBP-3 molar ratio, 
and free IGF-I all depend on age and sex, all values were transformed to SD-scores 
using the LMS method [12], using reference values for healthy children determined 
in the same laboratory [15,16]. As no extended reference values of IGFBP-1 were 
available, plasma IGFBP-1 concentrations could not be transformed to SDS.
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Height and weight were measured at baseline and subsequently every 3 months in 
the same department. Height, weight, and body mass index (BMI) were expressed as 
SD-score using the references for healthy Dutch girls [17] or the references for North 
European untreated girls with TS [18]. Final height (FH) was defined as the height (in 
cm) most recently available after discontinuation of GH therapy. Final height SDS gain 
was defined as [adult height SDS − height SDS at start], according to the references 
for untreated girls with TS [18]. 
Oral glucose tolerance tests (OGTT) were performed at baseline, after 4 years of 
GH therapy and 6 months after GH, as described by Van Pareren et al [9]. Outcome 
measures for OGTT were fasting glucose and insulin levels, the 120-minute area under 
the curve (AUC) for glucose and insulin, and glucose/insulin ratio at baseline, after 
30 and 120 minutes.
Aortic wall distensibilities were determined at 4 levels (ascending aorta and 
descending aorta at level of the pulmonary artery bifurcation, diaphragm level, 
abdominal aorta) according to procedures described previously [10]. Distensibilities 
(10ˉ³ mmHgˉ¹) were calculated as follows: D = (Amax–Amin)/[Amin*(Pmax − Pmin)]. 
D = distensibility, A = aortic area (mm²), P = blood pressure, max = systolic phase, min 
= diastolic phase.
Statistical methods 
Unless indicated otherwise, results were expressed as mean (SD). Spearman’s 
correlation was used to assess the relationship between free IGF-I and age before GH 
treatment. Differences between the dosage groups were tested with one-way ANOVA 
analyses, using the Bonferroni method to adjust for multiple comparison analysis. 
Differences over time were tested using paired t-tests. To assess relationships 
between free IGF-I and other measurable variables, a stepwise forward regression 
was used to construct a model for free IGF-I. Data on absolute free IGF-I level were 
square root transformed to achieve a normal distribution. The following variables 
were used: age, estrogen dose, GH dose, total IGF-I, IGFBP-3, total IGF-I/IGFBP-
3 molar ratio, IGFBP-2, IGFBP-1, BMI, and karyotype (45,X yes/no). Interaction 
variables of GH-dose with the variables total IGF-I, total IGF-I/IGFBP-3 ratio, and 
IGFBP-3, were added to the model to establish whether the effect of GH on square 
root of free IGF-I depends on these various variables. Only variables with a P < 0.05 
were kept in the model. Pearson’s correlations were used to assess the relationship 
of free IGF-I, total IGF-I, IGFBP-3, and its ratio on the four IGF-I bioactivity outcome 
parameters, which were adult height (cm), height SDS gain, OGTT measurements, and 
aortic wall distensibilities. Three-year and 5-year delta SDS values were correlated to 
3 and 5-year delta height SDS. To characterize the levels of free IGF-I, total IGF-I, 
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SIGFBP-3, and total IGF-I/IGFBP-3 ratio over time, the area under the curve (AUC) 
from start until discontinuation of GH-therapy was calculated. The calculated AUC 
was correlated to adult height, height SDS gain, post GH OGTT measurements, and 
aortic wall distensibilities. The AUC after 4 years of GH therapy was calculated and 
correlated to the 4-year delta scores of the OGTT measurements. P-values of < 0.05 
were considered to be statistically significant. All calculations were performed with 
SPSS 11.5.
Ethical considerations
The medical ethics committee of each participating center approved the trial 
protocol. The Erasmus Medical Center medical ethics committee approved the 
collection of reference serum samples. Written informed consent was obtained from 
each participant in this study and/or from their parents.
Results 
Study subjects 
The clinical characteristics of the 65 girls participating in this study (22 in group A 
and B, and 21 in group C) are shown in Table 1. Fifty-one patients of the 65 (78.5%) 
received GH for more than 7 yr. There were no significant differences between the 
groups, except for final height and height gain. Patients in group B and C had all 
reached a greater adult height than those in group A, whereas group C patients also 
showed a greater height gain than group A patients. 
Circulating levels of free IGF-I, total IGF-I, IGFBP-3, IGFBP-2, and IGFBP-1
In normal healthy girls, the serum free IGF-I levels showed a gradual age-dependent 
increase (Figure 1). The same phenomenon was found for TS patients before GH 
treatment (r = 0.32, p = 0.01), although at that time most of them had lower values. 
Free IGF-I: During GH treatment, free IGF-I levels increased (up to 7-fold) (Figure 
1), but the mean free IGF-I SDS did not exceed the normal range (Figure 2a). Twenty-
four and a half percent of the measurements during GH therapy were above the +2 
SDS, whereas 19 of the 65 girls never exceeded the +2 SDS. Mean free IGF-I SDS did 
not differ significantly among the three GH dosage groups. In all cases, mean free 
IGF-I SDS six months after GH therapy were still significantly higher than the values 
encountered at baseline, being comparable to those observed after the first year of 
GH-therapy. However, at the follow-up visit, several years after GH discontinuation, 
mean free IGF-I levels had decreased to subnormal levels.
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Figure 1: The mean of the Dutch female pupulation is represented by a solid line (—), the 
−/+ SDS by a dotted line (......), and the −/+2 SDS by a broken line (− − −). Serum levels of 
free IGF-I in Turner girls before start of GH treatment (open boxes) and 3 years after start 
of GH treatment (closed boxes).
Total IGF-I and total IGF-I/IGFBP-3 molar ratio: During GH treatment, the 
mean SD-scores both of total IGF-I and of total IGF-I/IGFBP-3 molar ratio were supra-
physiological in group B and group C, exceeding +2 SD (Figure 2b, 2c). During GH 
therapy, 62.7% of all total IGF-I measurements and 56.4% of all ratio measurements 
were above the +2 SDS. Three of the 65 girls never exceeded the +2 SDS for total 
IGF-I, and 4 never exceeded the +2 SDS for the ratio. 
After 3 years of GH therapy, there were no differences with respect to these 
parameters between the three GH dosage groups. In contrast, after 5 years of GH 
therapy, and also one year before initiation of estrogen treatment, total IGF-I SDS 
and ratio SDS were significantly higher in patients of group C than the values found 
for subjects of group A. In the final year of GH therapy, group C exhibited higher 
total IGF-I SDS values compared to patients in group A. However, 6 months after GH 
discontinuation and during the follow-up visit, the various differences between the 
patients of the different GH dosage groups were no longer present. 
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STable 1: Clinical characteristics at start of the GH-therapy (baseline) and at final year of 
GH therapy, including other variables of the study participants. 
Group A
n = 22
Group B
n = 22
Group C
n = 21
Total group 
n = 65
Age (yrs):  Baseline 6.1 (2.1) 6.7 (2.4) 6.5 (2.4) 6.4 (2.3)
Final year of GH 14.8 (0.9) 14.6 (1.4) 14.7 (0.9) 14.7 (1.1)
Height (cm): Baseline 104.6 (12.0) 108.6 (11.7) 106.8 (12.6) 106.7 (12.0)
Adult height 158.3 (6.4) 163.3 (5.6)* 163.8 (6.1)* 161.9 (6.4)
Height SDSa: Baseline −2.7 (0.9) −2.4 (1.0) − 2.6 (1.0) −2.6 (1.0)
Adult height −1.6 (1.0) −0.8 (0.9)* −0.7 (1.0)* −1.0 (1.0)
Height SDS gainb 1.7 (1.0) 2.1 (0.7) 2.5 (0.9)* 2.1 (0.8)
BMI sds:     Baseline 0.2 (1.0) 0.2 (1.1) 0.1 (1.0) 0.2 (1.0)
Final year of GH 0.9 (1.1) 1.2 (0.9) 0.9 (0.8) 1.0 (0.9)
Duration of GH therapy before start E2 (years) 6.5 (1.9) 6.3 (2.2) 6.3 (2.1) 6.3 (2.0)
GH duration (years) 9.0 (1.5) 8.3 (2.4) 8.7 (2.0) 8.7 (2.0)
Karyotype:   45,X 19 (86%) 21 (95%) 16 (76%) 56 (86%)
Other 3 (14%) 1 (5%) 5 (24%) 9 (14%)
Data represent the mean (SD). GH-dosage: Group A: 1.3 mg/m2/day, group B: 1.3 mg/m2/d 
during the 1st year, followed by 2 mg/m2/d, and group C: 1.3 mg/m2/d during the 1st year, 
2 mg/m2/d during the 2nd year, and thereafter 2.7 mg/m2/d. 
a: Height for age (references according to healthy Dutch girls [18]). 
b: Final height sds – height sds at start GH therapy (references untreated Turner girls [19]) 
Differences between groups: * = P < 0.05 if compared to group A (lowest GH-dose). There were 
no significant differences between group B and C.
Six months after GH therapy and at the follow-up visit, total IGF-I SDS and ratio 
SDS had returned to baseline SDS levels, with the exception of the ratio SDS for 
group C patients that had remained higher than they had been before GH treatment. 
Several years after GH discontinuation, at the follow-up visit, mean IGF-I values had 
decreased to subnormal levels, whereas total IGF-I/IGFBP-3 molar ratios were not 
significantly different from normal.
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Figure 2: SD scores (SDS) of circulating levels of free IFG-I (2a), total IGF-I (2b), and 
total IGF-I/IGFBP-3 molar ratio SDS (2c) before, during, and after discontinuation of 
GH treatment for group A (white), group B (grey), and group C (black), respectively. 
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increase in IGFBP-3 SDS, although less pronounced than the increase in total IGF-I SDS. 
For most patients, the IGFBP-3 SDS values were around the +1 SD (Figure 3). During GH 
therapy, only 2.6% of the IGFBP-3 measurements were above the +2 SDS, whereas 56 
of the 65 girls never exceeded the +2 SDS. Within all groups, IGFBP-2 SDS and IGFBP-
1 levels showed a significant decrease during GH treatment. Six months after GH 
therapy and at the follow-up visit, SDS values of IGFBP-3 and IGFBP-2 were the same 
as those measured before the start of GH therapy, whereas IGFBP-1 concentrations 
remained low. IGFBP-2 and IGFBP-3 levels showed an inverse relationship (r = −0.50, 
p < 0.001). 
Explaining variables for free IGF-I levels
We investigated which variables showed the closest relationship with free IGF-I 
levels (Table 2). A stepwise forward regression analysis performed on all free IGF-
I measurements resulted in a model using the following variables: age, estrogen 
dose, GH-dose, BMI, circulating levels of total IGF-I, IGFBP-3, IGFBP-1. This model 
accounted for 52.4% of the variation in square root of the free IGF-I levels (model 
1). Since total IGF-I levels and the molar ratio between total IGF-I and IGFBP-3 were 
closely related (r > 0.9, p < 0.001), these parameters were evaluated in separate 
models to prevent multicolinearity. When the total IGF-I/ IGFBP-3 molar ratio was 
used instead of total IGF-I, this explained 53.1% of the variation in the square root of 
free IGF-I levels (model 2). In neither model did IGFBP-2 or the karyotype influence 
the square root of free IGF-I levels. 
As shown in Table 2, the total IGF-I level and the total IGF-I/IGFBP-3 molar ratio 
predicted free IGF-I levels similarly. In both models, age appeared to be the strongest 
predictor of free IGF-I levels (β = 0.319 and β = 0.297, respectively). Free IGF-I levels 
were positively related to age, GH dose, IGFBP-3 levels, total IGF-I levels and total 
IGF-I/IGFBP-3 molar ratio. On the other hand, free IGF-I levels were decreased 
significantly by estrogen treatment and were inversely related to IGFBP-1 levels and 
BMI. After adding the interaction variable (GH dose X total IGF-I) and (GH dose X total 
IGF-I/ IGFBP-3 molar ratio) respectively to both models, the explained variation of 
the square root of free IGF-I levels increased significantly to 54.0% in model 1 and 
54.2% in model 2 (data not shown). In both models, these interaction variables were 
of significant influence (both p < 0.001). This indicates that the square root of free 
IGF-I depends on the effect of the GH-dose on the total IGF-I levels and total IGF-I/
IGFBP-3 molar ratio.
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STable 2: Variables in two linear regression models, with the square root of the serum free 
IGF-I concentration as dependent variable, either including IGF-I (model 1), or including 
ratio IGF-I/IGFBP-3 (model 2). R2: explaining % of variance.
Model 1 Model 2
Independent variable Standardized
coeffi cient (β)
P Standardized 
coeffi cient (β)
P
Age (years) 0.319 < 0.001 0.297 < 0.001
E2 dose per kg −0.221 < 0.001 −0.218 < 0.001
GH dose (mg/m2/d) 0.154 0.007 0.116 0.046
IGFBP-3 (mg/l) 0.189 < 0.001 0.263 < 0.001
IGFBP-1 (ug/l) −0.168 < 0.001 −0.145 0.002
BMI (kg/m2) −0.102 0.041 −0.112 0.023
Total IGF-I (ng/ml) 0.167 0.013
Ratio total IGF-I/IGFBP-3 0.190 < 0.001
R2 52.4% 53.1%
SD of the residual 0.356 0.354
Relationships between circulating levels of free IGF-I, total IGF-I, IGFBP-
3, and total IGF-I/IGFBP-3 molar ratio, and IGF-I bioactivity outcome 
parameters 
Changes in free IGF-I SD-scores as encountered after 3 and 5 years of GH treatment 
did not correlate with the gain in height SDS at these intervals. In contrast, the 
alterations in the SD-scores of total IGF-I, IGFBP-3, and their ratio in the circulation 
after both 3 and 5 years of GH therapy, were significantly related to the respective 
gain in height SDS, with similar correlation coefficients (Figure 4). In addition, the 
AUC of free IGF-I levels during GH therapy did not correlate with any of the IGF-I 
bioactivity outcome parameters, while AUCs of the total IGF-I and total IGF-I/IGFBP-3 
ratio levels appeared to influence several of these parameters significantly, including 
adult height gain and fasting insulin levels after 4 years of GH therapy (Table 3).
As determined 4.8(2.0) years after GH therapy, the AUC during GH therapy of the 
various variables did not correlate with 6-month after GH OGTT outcome, or with 
aortic distensibilities. 
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Figure 4: Relationship between five year changes in SDS values of free IFG-I, total IGF-
I, IGFBP-3, and total IGF-I/IGFBP-3 molar ratio, and the five year change in height SDS. 
Correlation r is given.
Table 3: Relationships between various clinical variables and circulating levels of free 
IGF-I, total IGF-I, IGFBP-3, and the total IGF-I/IGFBP-3 molar ratio. Only the significant 
correlation coefficients (r) are given.
 
Free IGF-I 
total AUC
Total IGF-I
total AUC
IGFBP-3
total AUC
Total IGF-I/IGFBP-3
total AUC
Final height (cm) NS 0.260 NS 0.328
Final height SDS gaina NS 0.376  0.341 0.311
OGTT after 4 years of 
GH therapy 
free IGF-I
4 years AUC
total IGF-I
4 years AUC
IGFBP-3
4 years AUC
total IGF-I/IGFBP-3
4 years AUC
Ins at t = 0 NS 0.284 NS 0.248
AUC ins at t = 120 min. NS 0.280 NS 0.232
Ins/ glc at t = 0 NS  0.258 NS 0.242
Ins/ glc at t = 30 min. NS 0.353 0.360 0.235
a: Final height SDS − height SDS at start GH therapy (references are to untreated Turner girls 
[18]). AUC = area under the curve from start of GH therapy until end of GH therapy (total AUC) 
or 4 years of GH therapy (4 yrs AUC). Glc = glucose, Ins = insulin.
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Absolute serum free IGF-I levels in healthy girls appeared to increase with age, which 
is in agreement with previous reports on this subject [2,19]. For our measurements, as 
performed under strictly controlled conditions, we used the DSL IRMA, which employs 
solid phase antibodies directed against unbound IGF-I. It has been suggested that this 
assay in fact determines the sum of truly free IGF-I and readily IGFBP-dissociable IGF-
I, which has been hypothesized to represent a more biologically relevant pool than 
free IGF-I alone [2]. 
To our knowledge, this is the first report on free IGF-I levels in GH-treated TS 
girls. We found subnormal levels of free IGF-I in TS girls both before and after GH 
treatment. These results complement data reported previously by Gravholt et al., 
who found lowered free IGF-I levels in untreated adult TS women [20]. GH treatment 
in our patients increased the absolute levels of free IGF-I up to 7-fold, although the 
relative increase from baseline could be explained partly by age, and appeared to be 
independent of the GH dosage employed. In contrast, total IGF-I levels increased in a 
GH-dose-dependent manner and at least once in 62 out of the 65 TS girls, it reached 
levels that were above the normal range. Similar observations have been reported 
for GH treated children and adults with GHD, although there are also conflicting 
reports [2,21-23]. 
At present, it is difficult to explain the apparent discrepancy with respect to the 
GH-induced longitudinal changes in circulating levels of free IGF-I and total IGF-I. 
Under several conditions, especially those with primary abnormalities in GH secretion 
(e.g. acromegaly and GHD), there is usually a close relationship between free IGF-I 
levels, total IGF-I levels and the total IGF-I/IGFBP-3 molar ratios [21]. For this reason, 
it has repeatedly been suggested that the total IGF-I/IGFBP-3 molar ratio should 
reflect changes in free IGF-I levels. Although in our TS girls the levels of total IGF-I 
and the total IGF-I/IGFBP-3 molar ratio in the circulation were significantly related 
to free IGF-I levels, the best fitting model only explains less than 55% of the variation 
in free IGF-I levels. 
In this respect it is important to emphasize that the kinetics of free IGF-I in the 
circulation differs strikingly from those of total IGF-I. Under normal circumstances, 
free IGF-I has a very short half-life (about 14 min) compared to the much larger pools 
of binary and ternary complex IGFBP-bound IGF-I. GH-induced changes in plasma 
levels of IGFBP-1, −2, −3, and −5 may thus have different affects on steady-state 
concentrations of free-IGF-I and total IGF-I levels. 
Interestingly, free IGF-I levels in sera of adult TS patients appeared to correlate 
inversely with the degree of IGFBP-3 proteolysis [20]. Since enzymatic proteolysis of 
this IGFBP is considered to reduce its affinity for IGF-I, it was hypothesized that this 
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the circulation, a result of the very short half life of free IGF-I. It may well be that, in 
our TS girls, an initial GH-dose-dependent rise in free IGF-I levels was compensated 
by an increased clearance of free-IGF-I from the circulation. 
This hypothesis is supported by the findings that, despite GH-dose dependent total 
IGF-I levels, there were no differences in free IGF-I levels between the different GH 
dosage groups. It is also supported by the finding that, after adding the interaction 
variables (GH dose X total IGF-I) and (GH dose X total IGF-I/IGFBP-3 molar ratio), 
the square root of free IGF-I depends on the effect of the GH-dose on the total IGF-I 
levels and on the ratio. 
As a consequence, we conclude that, although the total IGF-I and the ratio change 
in the same direction as free IGF-I, and show a relevant correlation, they cannot serve 
as reliable surrogate markers for free dissociable IGF-I levels during GH treatment in 
girls with TS
An inverse relationship was found between IGFBP-2 and IGFBP-3. This is a well-
known phenomenon that has also been reported for various other states such as 
increasing age, GH deficiency, acromegaly, fasting, and moderate impairment of 
liver function [24]. It has been proposed that circulating IGFBP-2 levels are regulated 
primarily by changes in free IGF-II levels (not determined in the present study). 
During GH treatment, estrogen therapy reduced free IGF-I levels. One of the few 
studies to have evaluated the effect of estrogens on free IGF-I found that high-dose 
estrogen treatment in constitutionally tall girls leads to a considerable decrease in 
free IGF-I [25]. On the other hand, an ultrafitration based assay established that, 
despite an increase in IGFBP-3 proteolysis, adult TS patients undergoing estrogen 
therapy did not show significant changes in circulating free IGF-I levels [20). However, 
our own assessment of the influence of estrogen therapy was made in a model along 
with other variables.
Most samples were analyzed at the end of the study, several years after collecting 
them. According to our experience IGF-I and IGFBP-3 in EDTA plasma or serum is very 
stable, i.e. after more than 10 years of storage at −80°C the values do not change 
significantly. However, we did not have the opportunity to examine the stability of 
free-IGF-I upon long-term storage. The samples showed the same results after testing 
them again after a year of storage.
In general, although free dissociable IGF-I is believed to represent the major 
bioactive form of IGF-I [2,26], one may question whether, from pathophysiological 
and diagnostic perspectives, it is relevant to assess the concentration of free IGF-I in 
patients with TS. In the present study, free IGF-I levels showed no clear correlations 
either with gained height, final height, and height changes after 3 or 5 years of 
GH therapy, or with changes in insulin sensitivity during GH therapy. In contrast, 
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Scirculating levels of total IGF-I and the total IGF-I/ IGFBP-3 molar ratios correlated 
considerably with the various variables. Thus, with respect to the biological endpoints 
named above, the determination of free dissociable IGF-I is of no predictive value in 
the evaluation of GH-treated TS girls. 
In conclusion, during GH-therapy in TS girls, mean free IGF-I levels stayed within 
the normal range, whereas mean total IGF-I levels and ratio levels exceeded the upper 
normal range. Levels of total IGF-I and the ratio are not good representatives of free 
IGF-I levels, and the former parameters seem to have a much higher predictive value 
for several biological endpoints – and hence IGF-I bioactivity. Obviously, this needs to 
be explored further in vivo and in vitro studies. 
The recently developed sensitive IGF-I kinase receptor activation assay (KIRA)[27], 
which enables the determination of IGF-I-receptor activating IGF-I concentrations, 
may be helpful in clarifying the bioactive capabilities of circulating IGF-I levels. The 
very long-term safety of supra-physiological growth factor levels during childhood 
also remains to be investigated. 
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Quality of life in adolescents 
born small for gestational age 
(SGA): Does growth hormone 
make a difference?
binnenwerk_banink.indd   77 20-8-2006   12:53:33
78
C
ha
pt
er
 4
Q
oL
 i
n 
G
H
-t
re
at
ed
 S
G
A Abstract
Background/Aims: To evaluate quality of life (QoL) in adolescents born SGA without 
spontaneous catch-up growth, treated with and without long-term growth hormone 
(GH) therapy. Additionally, to assess whether GH treatment has a positive effect on 
QoL, besides improving adult height and height SDS during childhood. 
Methods: Two groups of adolescents born SGA without spontaneous catch-up growth 
participated in the QoL evaluation; a GH-treated group (n = 44, mean GH duration: 
8.8 (1.7) years) and an untreated group (n = 28), both mean age 15.8 (2.1) years. QoL 
was measured by self-reports of the TACQOL-S, a disorder-specific questionnaire, and 
the CHQ, a generic questionnaire. 
Results: The GH group scored significantly better health status and health-related 
QoL on several scales of the TACQOL-S. On all TACQOL-S scales the GH group scored 
better QoL than the untreated group, with effect sizes of moderate to large, not 
all differences reaching statistical significance. The generic CHQ did not reveal 
significant differences in QoL between the GH group and the untreated group. 
Conclusions: Firstly, adolescents born SGA, with a GH-induced improved height, had 
in many aspects a better QoL than untreated adolescents born SGA, according to the 
disorder-specific questionnaire. Secondly, we advise to use, in addition to a generic 
questionnaire, a disorder-specific questionnaire for measuring QoL in children treated 
for short stature, as the generic CHQ did not reveal such differences.
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Quality of life (QoL) is increasingly recognized as an important measure of the impact 
of a special disorder, disease or therapeutic outcome. Over the past decades health 
status (HS) and QoL have been studied in a variety of diseases and disorders, including 
short stature [1-3]. Short stature during childhood and adolescence, resulting in a 
short adult height occurs regularly after being born small for gestational age (SGA). 
It is widely held that short children can suffer from physical, social and psychological 
problems [4]. The physical limitations of short stature and their often younger 
appearance may result in being treated differently by peers, and they may receive 
unintentional discrimination from adults. Social interaction, in particular during 
sports and games with peers, subjects them to taunts and bullying [5]. Adult short 
stature is often perceived to be a disadvantage. It can be a major physical disability 
in terms of not being able to drive a car, reach for objects and perform ordinary daily 
tasks that a person of average height takes for granted. It can also cause difficulties, 
or even discrimination, in getting the preferred job or career. 
There are, however, some inconsistencies in the literature. It is reported that the 
psychosocial difficulties, associated with being short, seems to be less severe than 
assumed [1,6]. However, hard data on QoL in short stature SGA children or adults are 
lacking.
About 10% of the SGA children will not catch-up to a height above −2 SDS and will 
reach an adult height below −2 SDS [7]. GH-treatment has been proven to be effective 
for obtaining a normal height during childhood, adolescence and adult height, after 
being born SGA [8-10], regardless of the serum growth hormone (GH) levels [11,12]. 
With GH treatment during childhood, short SGA children will reach a normal height 
within 2 years after start of GH [9], and will acquire an adult height which is in 98% 
positioned within the target height range, and in 85% within the normal range of the 
population when treated with long-term continuous GH [10].
Some QoL questionnaires, such as the ‘Health Utility Index’, focus on the quantity 
and severity of limitations in executing ordinary daily tasks and psychosocial 
functioning due to a health problem, handicap, or disorder, the so-called ‘health 
status’. Persons with short stature might not just experience physical limitations, 
but the accompanying social problems of short stature can overrule the physical 
limitations. For example, the problem is not that the adolescent can’t go to a pub or 
club, but the problem is that he/she will not be asked by friends or is not permitted to 
enter due to younger appearance. Therefore, it is important to include the emotional 
impact of the HS on a person’s life. The HS in combination with the emotional 
impact is called the health-related QoL (HRQoL). It’s rating how the adolescent or 
child feels about their functioning, rather than functioning alone. Recently, a Dutch 
binnenwerk_banink.indd   79 20-8-2006   12:53:34
80
C
ha
pt
er
 4
Q
oL
 i
n 
G
H
-t
re
at
ed
 S
G
A questionnaire for short stature was constructed as a disorder specific module of 
the generic TNO-AZL Children’s Quality of life (TACQOL), called the TACQOL-short 
stature (TACQOL-S). This questionnaire explicitly offers respondents the possibility 
of differentiating between their ability to function and their associated feelings. The 
quantity of problems is known as the HS. The HRQOL, qualifies the emotional impact 
of the problem.
The study aims were to compare QoL scores between 2 groups of adolescents born 
SGA, a GH-treated group and an untreated group, who all had attained adult or near 
adult height. This was measured with a disorder specific health-related QoL, the 
TACQOL-S, specially developed for children with short stature. Additionally, a generic 
questionnaire, the Child Health Questionnaire (CHQ) was applied. The adolescent 
completed both, the TACQOL-S and the CHQ. 
Patients and Methods
GH-Treated SGA Group (GH Group) 
All children with a height < −2SDS were referred to a pediatric endocrinologist, 
according to the national guidelines for short stature. Seventy-nine short children 
born SGA were enrolled in a multi-center, double-blind, randomized dose-response GH 
trial, which started in 1991. The inclusion criteria for participation in the GH-treated 
SGA group of the QoL evaluation were: completion of the GH trial until final height 
or satisfied height, age ≤ 18 years, be able to fill in the questionnaire, no growth 
interfering treatment other than GH therapy. Seventeen adolescents did not meet 
the inclusion criteria due to: > 18 years old (n = 11), treatment for precocious puberty 
(n = 1), dropped out of the GH-trial within 4 years after start of GH therapy due to GH 
insensitivity (n = 1), due to moving abroad (n = 2), due to lack of motivation (n = 2). 
This leaves 62 of the 79 adolescents eligible for participation in the QoL evaluation. 
Forty-four adolescents out of the 62 (71%) agreed to participate, mean (SD) age 
15.7 (2.1) years. No differences in clinical characteristics were found between the 
adolescents who participated and the adolescents who did not participate. 
The GH trial evaluated the effect of GH on long-term growth and ultimately on 
adult height, as well as psychosocial development, cognition and QoL. Inclusion 
criteria for the dose-response trial were: birth length SDS below −2, chronological 
age (CA) between 3 and 11 years in boys and 3 and 9 years in girls, height SD-score 
for CA below −2, no spontaneous catch-up growth, prepubertal stage, uncomplicated 
neonatal period without severe asphyxia. Biosynthetic GH (r-hGH Norditropin®, Novo 
Nordisk A/S, Denmark) was given subcutaneous once daily. GH was given double 
blindly in a dosage of 1 (group A) or 2 (group B) mg GH/m2 body surface/day (~ 33 
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their GH dosage. GH treatment was discontinued after reaching adult height (height 
velocity < 0.5 cm in 6 months) or on patient’s decision after reaching satisfactory 
height (near adult height). Twenty-three of the 44 participants (52%) had reached 
adult height or near adult height and had discontinued GH treatment.
For analysis of the QoL questionnaires we combined the 2 randomized GH dosage 
groups (GH group), as they were samples from the same underlying population 
at baseline because of the randomization. As a result there were no significant 
differences in height SDS at time of QoL evaluation, nor was there a difference in 
height SDS gain between the two dosage groups.
Untreated SGA Group (Untreated Group) 
In 1990, 107 children, born in three academic hospitals in the Netherlands during the 
same time period as the GH group (1980 until 1989) with a birth length below −2 SDS, 
were included in a cohort study to evaluate natural growth in SGA children with short 
stature in parallel to the GH-trial [7]. The inclusion criteria for participation in the 
untreated SGA group of the QoL evaluation were: age ≤ 18 years, be able to fill in the 
questionnaire, no growth interfering treatment. Fifty adolescents did not meet the 
inclusion criteria due to: > 18 years old (n = 28), GH therapy (n = 19), treatment for 
precocious puberty (n = 1), not being able to fill in the questionnaire due to moving 
abroad (n = 2). This leaves 57 of the 107 adolescents eligible for participation in the 
QoL evaluation. Twenty-eight out of 57 (49%) adolescents agreed to participate (mean 
age (SD) 15.8 (2.1)).
Design and Clinical Evaluation Dose-Response GH Trial 
Children of the study group were assigned to either group A, with a GH dose of 
1 mg/m2/day (33 μg/m2/day), or group B with a GH dose of 2 mg/m2/day (67 μg/m2/
day) [9,10,13]. A daily subcutaneous injection of biosynthetic GH (r-hGH Norditropin, 
Novo Nordisk A/S, Copenhagen, Denmark) was given at bedtime. Three-monthly, the 
total GH dose was adjusted to the calculated body surface.
Every 3 months height was measured using a Harpenden stadiometer [14]. Four 
measurements per visit were taken and the mean was used for analysis. Target height 
(TH) was calculated with Dutch reference data with addition of 3 cm for secular trend: 
½ x (Heightfather + Heightmother + 12) + 3 for boys and ½ x (Heightfather + Heightmother 
− 12) + 3 for girls [15]. Height and TH were expressed as an SD score for chronological 
age (CA) and gender [15].
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All QoL data were collected in the year 2001. For measuring the QoL, the child form 
(CF87) of the Child Health Questionnaire (CHQ) was used for adolescents ≤ 18 years. 
Participants ≤ 15 years had in addition to the CHQ, the TNO-AZL Children’s Quality of 
Life Short stature module (TACQOL-S), a questionnaire developed by The Netherlands 
Organisation for Applied Scientific Research (TNO) in conjunction with the Academic 
Hospital in Leiden (AZL).
 TACQOL-S: The TACQOL-S is a disorder specific questionnaire and was specially 
designed in the Netherlands to measure the impact of short stature on QoL for children 
aged 5−15 years [16]. The questionnaire was constructed as a disorder-specific module 
of the generic TNO-AZL Children’s Quality of Life questionnaire (TACQOL) [17-19]. The 
items were based on years of clinical and research experience and interviews with 
children with short stature. As such, it explicitly offers respondents the possibility of 
differentiating between their functioning; the quantity of problems, called the HS 
and their associated feelings with it, the emotional impact, called the HRQOL. We 
used the TACQOL-S child form (CF), a self-report questionnaire consisting of 37 items 
(all referring to the last few weeks) divided in 5 scales: Physical abilities (e.g. Did 
you experience the tables at school as being too high?), Vitality (e.g. Have you been 
getting tired quickly?), Contact with peers (e.g. Have other children been bullying 
you?), Contact with adults (e.g. Were adults surprised after they heard your age?), 
Body image (e.g. Would you like to look different?). A higher test score indicates a 
better QoL on that specific scale. The TACQOL-S was performed in a subgroup of the 
total group, in participants ≤ 15 years of age (n = 39). Internal consistency of the 
scales of the TACQOL-S, the Cronbach’s alpha [20] was studied in a larger group of 
short children (n = 63). The Cronbach’s alphas were all above 0.70, except for vitality 
HS (0.57). In general, a Cronbach’s alpha ranging from 0.70 to 0.84 is regarded as 
satisfactory for comparing different groups [21]. If a scale has a Cronbach’s alpha 
< 0.70 and significance occurs, conclusions should be drawn carefully.
In the last month, did it happen that ......
People think you were younger
than you acutally are?
never sometimes often always
(very) good not so well rather bad bad
During this I felt .......
Figure 1: Example of the format of the TACQOL-S.
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in the USA [22,23] and since then widely used in the US, Australia, Slavic countries, 
Germany, Denmark, France, Belgian, China and the Netherlands. The child form 
(CF87) of the CHQ is a self-report form and is designed to measure generic HS covering 
physical and psychosocial domains in children and adolescents ≤ 18 years of age. A 
Dutch version [12], consisting of 87 items divided into 12 scales, was used. A higher 
test score indicates a better quality for that specific scale, with a maximum score 
of 100. The reference population consisted of 444 children of four representative 
schools in Rotterdam, the Netherlands, as prescribed previously by Raat et al. [12]
Socioeconomic Status: Data on occupational level were provided by the parents. 
Parental occupational level (SES) ranged from 1 (lower occupation) to 3 (higher 
occupation). When both parents were employed the highest of the two SES levels was 
used. For unemployment the lowest SES was used [24]. 
Statistical Analysis
All data are expressed as mean (SD) unless otherwise specified. Independent t-tests 
were used to test for differences between participants and non-participants to the 
QoL study, analyzed per GH dosage group. Only in participants to the QoL study were 
independent t-tests used to test for differences in clinical data between the two 
dosage groups (A and B) and compared to untreated group, and independent t-tests 
were used to test for differences between the group ≤ 18 yrs and ≤ 15 yrs. Mann-
Whitney U tests were used to test for differences in TACQOL-S and CHQ outcome 
between GH group, untreated group and references. 
The magnitude and meaning of the differences in QoL outcome between groups 
can be calculated as Cohen’s effect size (d) [25,26]. The effect size d is calculated 
as follows: [mean(a) − mean(b) / largest standard deviation score (SDS)]; this means 
that differences between groups are expressed in units of the largest within-group 
standard deviation. According to Cohen, effect sizes between 0.2 and 0.5 indicate a 
small effect, an effect size between 0.5 and 0.8 indicates a moderate effect, whereas 
effect sizes of 0.8 or larger indicate a large effect [25,26].
Multiple linear regression analyses were performed to assess possible factors 
influencing the QoL outcome. Each questionnaire scale was tested separately. For 
this purpose, the variables sex (M = 1, F = 2), age at time of QoL evaluation (in yrs), 
and height SDS or height SDS corrected for target height SDS (Ht SDS − TH SDS) at time 
of start GH treatment and at time of QoL evaluation, with and without SES (range 
1−3), were tested. The percentages of variance explained by the model (R2 in %) are 
given. P < 0.05 was considered significant. All calculations were performed with SPSS 
10.1. 
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A Ethical Considerations 
The Medical Ethics Committees approved the evaluation of QoL. Due to ethical 
considerations the Medical Ethics Committees did not allow a randomized control 
group the long-term dose response GH trial. Written informed consent was obtained 
from the parents or custodians and from each adolescent. 
Results
Clinical Data 
Table 1 shows the clinical characteristics of all participating adolescents at baseline 
and at time of the QoL evaluation. The mean (SD) height SDS gain was significantly 
higher in the GH-treated group (2.4 (1.1)) versus the untreated group (0.5 (0.6)). 
Mean (SD) height SDS was in 2001 significantly higher in the GH-treated group (−0.6 
(1.2)), than in the untreated group (−1.8 (0.8)). This difference was larger in the 
subpopulation ≤15 years, who participated in the TACQOL-S. The GH group showed 
significantly better growth than the untreated group, resulting into better height 
SDS, height SDS gain and target height corrected height SDS (P < 0.01). 
There were no significant differences in clinical characteristics between the 
complete group ≤ 18 years (CHQ group) and the subgroup ≤ 15 years (TACQOL-S 
group), apart from age. The TACQOL-S group was 1.6 year younger than the CHQ 
group, due to a younger age at start of the GH dose-response trial. Regarding parental 
occupational levels, the GH group was not significantly different compared to the 
untreated group. 
TACQOL-Short Stature
Table 2 shows HS and HRQOL scores of the self-report TACQOL-S, measured in 2001. 
For ‘physical abilities’ and ‘contact with adults’, HRQOL and HS were significantly 
higher in the GH group compared to the untreated group. HS of ‘body image’ was 
significantly higher in the GH group compared to the untreated group, whereas 
HRQOL scored also higher but this difference was not significant. 
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ATable 1: Mean (SDS) clinical data of all the adolescents who participated in the evaluation 
of the quality of life evaluation, at baseline (1991) and at time of QoL evaluation (2001). 
Whole group, CHQ 
participants all ≤ 18 years
Subgroup, TACQOL-S 
participants all ≤ 15 years
GH-treated SGA
(n = 44)
Untreated SGA
(n = 28)
GH-treated SGA 
(n = 24)
Untreated SGA
(n = 15)
Male : Female (% male) 28 : 16 (64) 12 : 16 (43) 14 : 10 (58) 6 : 9 (40)
Gestational age 36.8 (4.0)b 34.3 (3.6) 36.4 (4.0)a 33.5 (3.0)
Birth length SDS −3.4 (1.3) −3.8 (1.3) −3.4 (1.5) −3.9 (1.5)
Birth weight SDS −2.5 (1.1)a −3.0 (0.8) −2.5 (1.2)a −3.1 (0.8)
Target height SDS −0.7 (0.9) −0.5 (1.0) −0.7 (0.8) −0.5 (0.9)
Age
At time of start study 6.6 (2.0)c 5.9 (2.3)c 5.0 (1.1) 4.4 (1.4)
At QoL evaluation 15.8 (2.1)c 15.8 (2.1)c 14.2 (1.2) 14.2 (1.1)
Height SDS
At time of start study −3.1 (0.7)b −2.3 (0.7) −3.1 (0.7)a −2.5 (0.7)
At QoL evaluation −0.6 (1.2)b −1.8 (0.8) −0.1 (1.1)b −1.7 (0.8)
Height SDS gain 2.4 (1.1)b 0.5 (0.6) 2.9 (1.1)b 0.8 (0.5)
Corrected height SDS (Hsds-THsds):
At time of start study −2.4 (0.8)a −1.8 (0.9) −2.3 (0.7) −2.0 (0.8)
At QoL evaluation −0.1 (1.2)b −1.3 (0.7) 0.6 (1.1)b −1.3 (0.7)
Duration of GHRx at 
QoL evaluation
8.8 (1.7)b − 10.1 (1.2)b −
Data are expressed as the mean (±SD). 
Independent t-test: a P < 0.05; b P < 0.01; GH-treated compared to untreated group; c P < 0.01, 
CHQ participants compared to TACQOL-S participants.
In Table 2, the effect sizes of the differences in HS and HRQOL between the GH 
group and the untreated group, as reported by the children, are shown. A positive 
effect size indicates better QoL scores in the GH group, whereas a negative effect 
size, which did not occur, indicates better QoL scores in the untreated group. The 
effect size of the difference between the GH-treated group and the untreated group 
regarding ‘physical abilities’ was 0.83 (P = 0.004) for HS and 0.9 (P = 0.002) for 
HRQOL, which indicates a large effect. The effect size of the difference between 
the GH-treated group and the untreated group regarding ‘contact with adults’ was 
0.76 (P = 0.02) for HS and 0.85 (P=0.002) for HRQOL. This indicates a large effect 
in quantity of problems (HS), and an even larger effect on the emotional impact 
(HRQOL). The effect size of HS on ‘body image’ was 0.59 (P = 0.04) and the effect size 
of HRQOL of ‘body image’ was 0.47 (P = 0.2). 
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GH-treated
SGA group 
(n = 24)
Untreated 
SGA group
(n = 15)
Effect 
size1
(d)
P value
Physical abilities
HS 90.8 (9.8)b 74.3 (19.8) 0.83 0.004
HRQoL 93.6 (7.4)b 78.6 (16.6) 0.90 0.002
Vitality2
HS 75.0 (18.4) 65.8 (21.9) 0.42 0.234
HRQoL 79.2 (16.5) 69.6 (23.8) 0.40 0.283
Contact with peers
HS 81.0 (18.5) 73.8 (21.9) 0.33 0.296
HRQoL 85.7 (16.4) 76.3 (19.9) 0.47 0.110
Contact with adults
HS 85.2 (10.6)a 70.9 (18.8) 0.76 0.017
HRQoL 92.9 (4.4)b 80.0 (15.1) 0.85 0.002
Body image
HS 88.4 (8.0)a 74.1 (24.1) 0.59 0.038
HRQoL 91.2 (6.9) 81.8 (20.1) 0.47 0.191
Data are expressed as the mean (±SD). 
There were no differences between the 2 dosage groups. a P < 0.05; b P < 0.01, compared to 
the untreated group (0 mg/m2/d). Higher scores = Better health related QoL (HRQoL)/ Health 
status (HS). 1 Effect size = positive effect size indicate better QoL in GH-treated SGA group; 0.2 
≤ d < 0.5 = small effect; 0.5 ≤ d < 0.8 = moderate effect; d ≥ 0.8 = large effect. Negative effect 
size (not present) indicates better QoL in untreated SGA group. 2 Cronbach’s alpha was 0.57.
CHQ Data 
As shown in Table 3, the children of the untreated group scored significantly lower 
on ‘family cohesion’ than their normal peers, 64.6 (26.9) vs. 75.7 (23.2) respectively, 
whereas those of the GH group were not significantly different from their normal 
peers. The children of both SGA groups (GH-treated and untreated) scored 
significantly lower than their normal peers on ‘role social-emotional’, 88.4 (16.2) 
and 82.7 (17.5) respectively, vs. 92.3 (16.8). There were no significant differences 
between the GH group and the untreated group.
As shown in Figure 2, the GH group showed on all the scales of the CHQ higher 
scores than the untreated group; however, these differences between the GH-treated 
and untreated groups did not reach statistical significance. 
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GH treated SGA
(1 or 2 mg/m2/d)
(n = 44)
Untreated SGA
(0 mg/m2/d)
(n = 28)
Reference Population1
(n = 441)
Physical Functioning 95.5 (6.4) 93.0 (12.2) 96.8 (5.4)
Role Social − Physical 96.0 (9.6) 90.5 (18.6) 96.5 (11.6)
Role Social − Emotional 88.4 (16.2)a 82.7 (17.5)b 92.3 (16.8)
Role Social − Behavior 93.4 (14.8) 88.9 (15.7) 91.4 (13.7)
Bodily pain 75.0 (20.9) 74.6 (23.0) 78.2 (19.5)
Behavior 84.8 (9.4) 82.8 (12.4) 83.6 (10.2)
Mental Health 79.2 (11.3) 75.1 (15.1) 78.2 (13.0)
Self Esteem 77.6 (11.3) 74.0 (12.9) 75.4 (12.5)
General Health 73.2 (11.9) 72.2 (16.4) 74.6 (15.9)
Family Activities 80.0 (15.0) 77.1 (19.7) ND
Family Cohesion 72.4 (20.4) 64.6 (26.9)a 75.7(23.1)
Data are expressed as mean (SD). 
No significant differences between GH-treated and the untreated group;
a P < 0.05, b P < 0.01, compared to reference values. 
ND = Not Done, this scale was not fielded in this study. 
1’Reliability and validity of the CHQ-CF87 in a Dutch population’, by Raat et al. [12]
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Figure 2: Effect sizes of the differences on the QoL scales between the GH-treated 
SGA group  and the untreated SGA group as measured with the CHQ and reported by the 
children. Higher score indicates better QoL in the GH-group. Effect size (d): 0.2 ≤ d < 0.5 = 
small effect; 0.5 ≤ d < 0.8 = moderate effect; d ≥ 0.8 = large effect.
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TACQOL-S. Using multiple regression, the HRQoL score in the GH group for the 
scale ‘contact with adults’ increased with 3.0 units per 1 SDS of the current height, 
adjusted for sex, age and height SDS at start GH treatment (R2 = 43.5%). This means 
the taller they were, the more they felt age-appropriately treated by adults. In the 
same GH group, the HRQoL score of ‘body image’ increased with 5.3 units per 1 height 
SDS corrected for target height (Ht SDS − TH SDS), after adjustment for sex, age and 
height SDS corrected for TH SDS at start (R2 29.4%). This indicates the taller they were 
compared to their parents, the more they felt satisfied and happy with their own 
body. Lastly, in the GH group the HS score of ‘vitality’ decreased with 14.7 units per 1 
height SDS corrected for TH SDS at start of the GH-therapy, adjusted for sex, age and 
current height SDS corrected for TH SDS (R2 44.3%). This indicates that the smaller 
they were at start of the GH therapy compared to their parents, the more vital they 
currently felt. In the untreated adolescents, height SDS or height SDS corrected for 
TH SDS were not associated with QoL, measured with the TACQOL-S. Socio-economic 
status was not of significant influence.
CHQ. In the adolescent reports of the CHQ-CF87, the QoL score on the scale ‘role 
social behavior’ increased with 6.8 units and 12.6 units per 1 SDS of the current height 
in the GH group and untreated group, respectively (R2 18.1% and R2 29.8%). This 
means the taller the adolescents were, the less problems they experienced in daily 
life (like doing schoolwork or sports with friends) with their behavior. In addition, the 
QoL score of ‘family cohesion’ in the GH group increased with 11 units per 1 height 
SDS at the start, adjusted for sex, age and current height SDS (R2 14.5%). None of the 
CHQ scales were affected by height SDS corrected for TH SDS.
 
Discussion
This study delineates various aspects of QoL in short children born SGA after long 
term GH treatment. Although generic instruments are widely used, they may include 
irrelevant aspects or miss certain aspects of importance for specific groups of 
patients, here with short stature, and therefore being insensitive when measuring the 
effect of short stature on QoL. We therefore included a QoL questionnaire specially 
developed for children and adolescents with short stature, the TACQOL-S.  
Before reviewing these results one has to consider the following issues to 
appreciate the outcome. As we do not have baseline data, QoL was not evaluated 
longitudinally. The GH trial started in 1991, when QoL was not as much recognized 
as an important measure outcome as it is today. Moreover, the QoL questionnaires 
were developed in the early and mid-1990s, after the start of this GH trial. Due to 
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on QoL outcome were analyzed. Second, subjects were not randomized, but from 
2 separate studies, with similar inclusion criteria and age. It appeared that the 
untreated group had a higher height SDS than the GH group at the start of the GH 
study. This might have positively influenced their QoL during childhood, as their 
height was always nearer to the normal range. Despite a shorter height at start of 
study, the GH-treated group reported a better QoL, after 10 years of GH treatment, 
on several domains of the disorder-specific questionnaire compared to the untreated 
group. Third, there is a limited experience with the disorder specific questionnaire 
the TACQOL-S. However, the TACQOL-S is constructed from the generic TACQOL, 
which is broadly validated and used. The items were based on years of clinical and 
research experience and interviews with children with short stature. Fourth, a 
placebo effect could be argued. It is well known that a placebo effect on growth 
in GH-controlled trials only lasts for 3 months after start of GH treatment [27,28]. 
As our study analyzed the long-term effect, after nearly 9 years of GH treatment, 
we do not expect any placebo effect. Finally, in the GH-treated SGA group, 62 of 79 
enrolled in the early 1990s, were eligible for the health-related QoL evaluation, of 
which 44 (71%) completed the questionnaires. While clinical characteristics of the 44 
responders did not differ significantly from nonresponders, we are unaware of other 
potential sources of selection bias. In the untreated SGA group 57 of 107 enrolled in 
the early 1990s, were eligible for health-related QoL evaluation, of which 28 (49%) 
completed the questionnaires. GH therapy that was applied outside the context of 
clinical studies (n = 19) was a source of not being eligible for QoL evaluation; although 
to our knowledge (psychological) problems did not correlate to GH therapy in that 
subgroup, drop-out as well as nonresponders may have introduced bias of which we 
are unaware.
The specific self-report questionnaire, the TACQOL-S, showed that the GH-
treated SGA adolescents had a significantly better HS and HRQOL regarding ‘physical 
abilities’ and ‘contact with adults’ and ‘body image’ HS compared to untreated SGA 
adolescents. The better QoL in ‘physical abilities’ means that the adolescents in 
the GH group had experienced an improvement in sports, in reaching things which 
are high up, were able to sit comfortable at tables and in chairs at school without 
experiencing them too high. The ‘contact with adults’ was better in the GH group. 
The GH group reported a positive influence of height on the ‘contact with adults’, 
indicating that the taller they were, the better they felt age-appropriately treated 
by adults. The effect size of the quantity of problems in contact with adults was 
moderate, but the emotional impact was large. This means that the adolescents 
in the GH group were more age-appropriately treated than the adolescents in the 
untreated group, and the adolescents experienced this respect for age by the adults 
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was positively influenced by their height corrected for target height, meaning the 
closer the height was to that of their parents, the more happy they were with their 
bodies. The influences of height were not found in the untreated group. This might be 
related to the smaller variation in height SDS and smaller group size of the untreated 
group.
Our study shows effect sizes which were moderately to markedly better in the 
GH group compared to the untreated group on all scales of the TACQOL-S, both 
with respect to HS as well as the HRQOL, although some did not reach a significant 
difference. This might be due to the limited size of our study population. However, 
Kazis et al [26] reported that not only statistical outcome, but also the effect size 
contribute to an understanding of the differences between groups. The authors 
demonstrated that statistically significant differences might not be synonymous with 
what is clinically important. 
The generic self-report questionnaire, the CHQ, showed a near-normal QoL in SGA 
adolescents after long-term GH treatment. The GH group was extremely short at the 
start with a height SDS far below the normal range and had normalized its height 
at the time of QoL evaluation. For the CHQ results, no significant differences were 
shown between the GH group and the untreated group. We have to realize, however, 
that the untreated group had never been as extremely short as the GH group, and 
always had a height SDS just below the normal range for many years and at time 
of QoL evaluation just within the normal range. In both groups, GH and untreated, 
height influenced their ‘role social − behavior’ positively, meaning they experienced 
less social problems related to behavior when they were taller. These findings are 
in line with a recent paper by our group, revealing a significant decline in problem 
behavior in SGA children during GH-treatment [29]. 
Several studies have previously shown that using a generic questionnaire for a 
special disorder or disease, one might miss relevant QoL issues [16,30-33]. Not only 
the most obvious daily life issues, like walking up the stairs, closing the buttons on 
your shirt, are relevant for an optimal QoL, less obvious daily life issues, like reaching 
up for kitchen cupboards, going shopping for clothes or hanging out with friends, 
are important. These issues might seem less obvious to someone who has a chronic 
disease or handicap, but their contribution to a persons QoL can be of great merit. 
A generic questionnaire focuses mainly on daily life issues, which are limited in case 
of a chronic disease or handicap. The items of the TACQOL-S are more sensitive for 
effects of stature on QoL outcome. So, in addition to generic QoL measurements, 
height-specific QoL measurements should be applied in growth studies.
It has been suggested that psychological training in coping with the psychosocial 
problems related to short stature would be a less-invasive alternative for GH 
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QoL outcome in a prospective randomized study model. Unfortunately, to date no 
structural psychological program has been evaluated to be effective and of practical 
use. Recently, it has been shown that GH-treated children had significantly reduced 
total problem behavior, externalizing behavior and a better self-perception after 10 
years of GH treatment compared to pretreatment [34,35]. Taller children had less 
problem behavior over time. These findings were parallel to their height improvement 
[34]. This indicates that GH treatment is capable of improving several aspects of 
short SGA children, not only height.
In conclusion, our study shows that children born SGA, when treated with long-
term GH therapy, show significantly better QoL on physical abilities and contact with 
adults than untreated children born SGA, when measured with the disorder-specific 
TACQOL-S. Additionally, also fewer problems with body image were reported in the 
GH group. Furthermore, our study shows a larger effect size of QoL in the GH-treated 
versus the untreated group when tested with the disorder-specific TACQOL-S. The 
generic CHQ did not reveal such significant differences. Our results are, however, 
preliminary and need to be verified in a larger randomized, placebo-controlled study 
design. Furthermore, we advise to use, in addition to a generic questionnaire, a 
height-specific questionnaire for measuring the influence of GH treatment on QoL.
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Quality of life after long-term 
growth hormone therapy and 
induced puberty in women 
with Turner syndrome
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S Abstract 
Objective: To evaluate health-related quality of life (HRQOL) in young women with 
Turner syndrome (TS) after long-term growth hormone (GH) therapy and induced 
puberty and to analyze whether HRQoL was influenced by auxologic parameters, 
pubertal development or subjective parameters.
Study design: The study group comprised 49 women with TS, mean (standard 
deviation) age 19.6 (± 3.0) years, all former participants of 2 GH studies, ≥ 6 
months after GH discontinuation. Puberty was induced by estrogen treatment, at 
mean age 12.9 (± 1.1) years. HRQoL was measured by self-reports of the 2 generic 
questionnaires, SF36 and TAAQOL. As an additional source of information on HRQoL, 
we applied parental proxy-reports.
Results: HRQoL of the women with TS was normal. Remarkably, the women with TS 
had higher HRQoL scores on some of the scales, including ‘social functioning’ and 
‘role–emotional’. Satisfaction with height and breast development had a positive 
influence on several HRQoL scales.
Conclusions: The young women with TS who reached normal height and had age-
appropriate pubertal development reported normal HRQoL. The relatively high 
scores on some of the HRQoL scales can be explained by an estrogen effect or by a 
possible response shift, indicating a different internal reference in women with TS. 
We hypothesize that GH and estrogen treatment positively influenced HRQoL in young 
women with TS.
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SIntroduction
It is generally accepted that a main goal of any medical treatment, therapy or 
intervention is improving quality of life. The 2 major characteristics of Turner 
syndrome (TS) are short stature and absence of pubertal development because of 
gonadal dysgenesis. It is widely held that short children can suffer from physical, 
social and psychological problems [1]. Currently, growth hormone (GH) treatment 
for short stature in children with TS is now an accepted indication in many parts 
of the world. GH treatment in TS increases growth velocity and normalizes height 
during childhood and adolescence. This treatment results in a height gain to an 
adult height within the normal range [2-5]. Another feature of TS is an absence or 
delay in development of bodily feminization, which can cause psychosocial problems 
in affected teenage girls [6]. Age-appropriate induction of puberty with estrogens, 
which mimics normal pubertal development without compromising adult height, is 
possible [3,7]. 
Several studies have reported psychosocial problems in girls and women with 
TS, including impaired social relationships, poor self-esteem, and decreased sexual 
activity [8-12]. Furthermore, these patients are more likely to meet criteria for 
attention-deficit hyperactivity disorder than controls and are often employed in jobs 
for which they are overqualified. One study in untreated women with TS assessed 
their quality of life in terms of working status, daily routine, and love and marriage 
and reported that most of the unmarried women lived with their parents, that 
many were well educated and worked as normal woman, and that they appeared 
anxious about their bodies and marriage [13]. Carel et al reported normal HRQoL 
in GH-treated women with TS, without any influences of height or other variables 
associated with GH-treatment [14]. This study did not include subjective measures in 
terms of height, pubertal development, and visible TS features, however.
In the present study we evaluated the HRQoL in young women with TS after 
long-term GH treatment and puberty induction at an age-appropriate time. We 
compared HRQoL scores of the young women with TS to scores in samples from the 
general population. We also analyzed whether HRQoL outcome was influenced by 
anthropometric parameters, pubertal development and subjective parameters, such 
as satisfaction with height and breast development.
binnenwerk_banink.indd   97 20-8-2006   12:53:37
98
C
ha
pt
er
 5
H
RQ
oL
 i
n 
G
H
-t
re
at
ed
 y
ou
ng
 w
om
en
 w
it
h 
T
S Methods
Subjects
All young women with TS who had participated in 2 earlier GH trials were invited to 
participate in an HRQoL evaluation. The 2 earlier trials were a dose-response GH trial 
(DRS) and a frequent-response GH trial (FRS) to investigate the effects of long-term 
GH therapy, given in different dosages and at varying frequencies (see below). To 
be eligible, a woman had to have discontinued GH treatment for at least 6 months 
and to be able to fill in the questionnaires. Forty-nine women agreed to participate 
(response rate 49/69: 71%), with 20 women not participating either for practical 
reasons or because they had lost interest in participating in such studies.
GH-trials
The study designs of the DRS and the FRS have been described by Sas et al [2,15]. 
Both of these studies started in 1989. Sixty-nine cases were eligible for participation 
in the HRQoL evaluation, including 52 of the DRS and 17 from the FRS.
Dose-response study: Sixty-eight Dutch girls with TS, age 2 to 11 years, were 
enrolled in the open randomized multi-center GH DRS. Biosynthetic GH (r-hGH 
Norditropin®, Novo Nordisk A/S Denmark) was given subcutaneously once daily at 
bedtime at a dose of 1.3, 2, or 2.7 mg GH/m2 body surface area/ day (~ 0.045, 0.067, 
or 0.09 mg/kg/day). To induce puberty, micronized 17β-estradiol was given to the 
girls age 12 years and older after at least 4 years of GH treatment. During the first 2 
years 5 µg/ kg body weight/ day was given orally, following by a dose of 7.5 µg/kg/d 
in the third year, and 10 µg/kg/d thereafter. Cyclic progestagen therapy (Duphaston, 
5 mg/d for the first 14 days of each month) was added after 2 years of estrogen 
therapy. If puberty had developed spontaneously (as marked by Tanner breast stage 
≥ 2) during the study period and before start of estrogen therapy, then no estrogen 
was given during GH-therapy. Of the 68 subjects, 6 girls dropped out of the study and 
were lost to follow-up, 6 girls were still receiving GH treatment, and 4 girls were 
unable to complete the questionnaires because of mental retardation. This left 52 
girls eligible for participation in the HRQoL evaluation; 34 agreed to participate.
Frequency-response study: Nineteen Dutch girls with TS, age 11 years and 
older, were enrolled in an open randomized multicenter FRS. Biosynthetic GH 
(r-hGH Norditropin®, Novo Nordisk A/S Denmark) was given subcutaneously once 
or twice daily in a dosage of 2 mg GH/m2 body surface area/ day (~ 0.067 mg/kg/
day). To induce puberty, ethinyl estradiol was given orally at a dose of 0.05 µg/ kg 
body weight/ day at start of the trial. After the first 2.25 years of GH treatment, 
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therapy was added. Two girls were unable to fill in questionnaires because of mental 
retardation, leaving 17 girls eligible for participation in the HRQoL evaluation; 15 
agreed to participate.
Health-Related Quality of Life Evaluation
The HRQoL evaluation was performed after GH treatment had been discontinued 
for at least 6 months and final height had been reached. The HRQoL evaluation 
consisted of 2 generic self-report questionnaires, the Medical Outcome Study Short 
Form-36 Health Survey (SF36) and the TNO/AZL Adult Quality Of Life (TAAQOL). As an 
additional source of information on QoL of the study population, we applied proxy-
reports. The parents were used as proxies because women with Turner syndrome are 
considered more immature than their peers [10].
SF36: We used the validated Dutch translation of the SF36 [16]. Developed by 
Ware and Sherbourne in 1992 [17], the SF36 measures physical and mental health and 
social functioning. It is a self-report questionnaire consisting of 35 items divided into 
the following 8 domains (with the number of items in each domain in parenthesis): 
Physical functioning (10), Role limitations due to physical health problems (4), 
Bodily pain (2), General health perceptions (5), Vitality (4), Social functioning (2), 
Role limitations due to emotional health problems (3), and Mental health (5). For 
each domain, the results were scored from 0 to 100, with a higher score indicating a 
better subjective quality of life.
TAAQOL: The TAAQOL explicitly offers respondents the ability to differentiate 
their ability to function and their associated feelings. This concept, known as HRQoL, 
qualifies the quantity of the problem with its emotional impact. The TAAQOL was 
designed in the Netherlands and validated in the general population [18,19]. It is 
a self-report questionnaire consisting of 45 items which refers to the preceding 
few weeks, divided into the following 12 domains (with the number of items in 
parenthesis): Gross motor skills (4), Fine motor skills (4), Cognition (4), Sleep (4), 
Bodily Pain (4), Social functioning (4), Daily activities (4), Sexual functioning (2), 
Vitality (4), Positive emotions (4), Negative passive emotions (eg depression)(4), 
Negative active emotions (eg aggression)(3). For each domain, the results are scored 
from 0 to100, with a higher score indicating a better subjective quality of life. An 
example of the format of the questionnaire is shown in Figure 1.
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In the last month, did it happen that ......
You had difficulty 
remembering things?
no a little some a lot
not at all a little quite a lot very
How much did that bother you?
Figure 1: Example of the format of the health related questionnaire: TNO/AZL Adult 
Quality of Life (TAAQOL).
Reference population 
SF36 and TAAQOL data of the Dutch general female population are available and were 
used for comparison. The population for the female reference data for the SF36 had 
an age range of 16 to 25 years (n = 121) [16], and that for female reference data for 
the TAAQOL had a mean age of 19.7 (2.0) and a range of 16 to 22 years (n = 116) [18]. 
Additional measurements
The mailed questionnaires contained additional items on subjective parameters of 
nationality and socio-economic status (SES). Information provided by the parents 
included parent’s occupation, parent’s educational level, daughter’s nationality, and 
daughter’s current and past health problems. The SES scores ranged from 1 (low) to 
3 (high). When both parents were employed, the highest of both SES levels was used. 
For unemployment, the lowest SES score was used [20]. Reported health problems 
during life were counted.
Both the women with TS and their parents answered the following questions about 
the women with TS: 
Are you satisfied with your (your daughter’s) adult height? 
Are you satisfied with your (your daughter’s) breast development?
Do you think that other people can see that you (your daughter) have (has) Turner 
syndrome? 
If answered yes to the previous question, how do you think people can see that 
you (your daughter) have (has) Turner syndrome? 
Do you think your (your daughter’s) appearance will cause limitations? If “yes”, 
which limitations? 
Furthermore, they were asked where the woman with TS was living, with their 
parents or elsewhere. 
•
•
•
•
•
binnenwerk_banink.indd   100 20-8-2006   12:53:37
101
C
ha
pt
er
 5
H
RQ
oL
 i
n 
G
H
-t
re
at
ed
 y
ou
ng
 w
om
en
 w
it
h 
T
SThe following variables were scored dichotomously (0 = no, 1 = yes): being satisfied 
with height and breast development, having visible features of TS, and having self 
reported limitations due to their physical appearance. In addition, the following 
spontaneously reported limitations due to physical appearance were also scored 
dichotomously (0 = no, 1 = yes): having limitations in relationships, having limitations 
in job perspectives, having feelings of insecurity, lacking charisma, and difficulties 
buying shoes or clothes. To determine whether the quantity of self-reported features 
of TS had a linear effect or a dichotomous effect, the self-reported visible features of 
TS were counted and scored from 0 to 3, with 0 representing no visible features and 3 
representing 3 or more visible features.
Statistical analysis
All data are expressed as mean (standard deviation) unless otherwise specified. 
Independent t-tests were used to test for differences between self-reports or 
parent reports and the normal references based on a review of HRQoL measures 
of the TAAQoL and the SF36 scales. Independent t-tests were also used to test for 
differences between participants and non-participants of the HRQoL study. A paired 
t-test was used to test for differences between self-reports and parent-reports. The 
McNemar test and the Wilcoxon signed-rank test were used to test for differences in 
reported subjective data on features of TS and limitations between the women with 
TS and their parents.
The effect of physical features of TS and limitations on HRQoL outcome, reported 
by the patients with TS was analyzed per HRQoL scale in a regression model. Each of 
the following explanatory variables was entered separately in the model, along with 
age and SES: satisfaction with height, satisfaction with breast development, visible 
features of TS, self-reported limitations (ie, limitations in relationships, limitations 
in job perspectives and, feelings of insecurity), number of health problems, age at 
start of puberty, height standard deviation score (SDS) gain, and adult height. Age at 
start of puberty was defined as age (years) at first visit with Tanner breast stage B2 
[21], spontaneous or induced. Height was scored in cm.
Results from the regression analyses are given as unstandardized coefficients (B) 
along with their 95% confidence interval and their 2-tailed P-value. The estimated B-
coefficient is the relevant effects adjusted for age and SES. Only B-coefficients with 
a P-value < 0.15, and only variables with a significant influence on at least one of the 
HRQoL scales are reported. The effects of age and SES are not presented. P-values 
< 0.05 were considered significant. All calculations were performed with SPSS 11.5 
software.
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The institution’s Medical Ethics Committee (MEC) of each participating center 
approved earlier GH trials and the MEC of our institution the subsequent HRQoL 
evaluation. Written informed consent was obtained from the parent or custodian of 
each child for the GH study and from each participant for the HRQoL evaluation.
Results
Clinical data
Table 1 presents the clinical characteristics of the 49 women with TS who participated 
in the HRQoL evaluation. The average height of 160.7 (±6.5) cm is −1.2 (±1.1) SDS 
lower than the normal Dutch references [22] and 2.2 (±1.0) SDS higher than the 
North European untreated women with TS [23]. The mean age at onset of puberty, 
defined as first visit with breast stage B2, was 12.9 years compared to 10.8 years in 
the normal population [7,24]. The progression through puberty, defined as the time 
intervals from breast stage B2 to B3, B2 to B4, and B2 to B5, was comparable to that of 
normal references (data not shown)[7]. Three of the 49 participating women with TS 
(6%) experienced a spontaneous start of puberty. All of the 49 women were receiving 
hormone replacement therapy in adult dosages. The duration of GH treatment was 
7.1 (±2.7) year. At the time of the HRQoL evaluation, the mean (SD) time after GH-
discontinuation was 2.9 (±1.6) years. No significant differences in breast development 
or other clinical characteristics as listed in Table 1 were found between the women 
who participated in the HRQoL evaluation and the women who did not participate.
HRQoL evaluation
SF36: Table 2 gives the HRQoL results of the SF36 of young women with TS. The 
women with TS reported a significantly better HRQoL in the ‘Social functioning’, 
‘Role limitations − Emotional’ and ‘Bodily pain’ domains compared with the normal 
population. For the remaining domains, the HRQoL scores were equal to those of the 
normal population.
TAAQOL: The TAAQOL (Table 3) revealed significantly better HRQoL scores for 
‘Pain’, ‘Daily activities’, ‘Sexuality’ and ‘Aggressive emotions’ in the women with TS 
compared with normal references. For the remaining domains, the HRQoL scores were 
comparable between with the 2 populations. For the ‘social functioning’ domain, the 
self-reports and the parent-reports were significantly different in terms of HRQOL.
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STable 1: Clinical data of young women with Turner syndrome, who participated in the 
evaluation of the quality of life. 
Turner population (n = 49)
Age (yrs) at QoL evaluation 19.6 (3.0)
Range (years) 14.8−25.8
Adult height (cm) 160.7 (6.5)
Adult height SDSa −1.2 (1.1)
Height SDS gainb 1.7 (1.0)
Age start puberty (years) 12.9 (1.1)
Karyotype 45,X 39 (80%)
‘Other’ 10 (20%)
Living situation:
With parents 39 (85%)
With partner 2 (4%)
On their own 5 (11%)
Data are expressed as the mean (± SD) or n (%). 
a: Height for age: references healthy Dutch girls [22] 
b: Final height SDS − height SDS at start GH therapy (references for untreated Turner girls [23]) 
Table 2: Health related QoL (HRQoL) results of the SF36, expressed as the mean (± SD). 
Self-report
n = 48
Parent-report
n = 35
References1
n = 121
P value¶
Physical Functioning 91.3 (12.4) 90.0 (17.8) 92.2 (11.0) 0.630
Role − Physical 91.1 (20.3) 92.1 (22.5) 86.8 (28.3) 0.145
Bodily Pain 86.4 (16.3)** 91.1 (20.0)** 79.0 (20.0) 0.003
Vitality 68.0 (18.0) 71.7 (13.5) 68.0 (16.2) 0.994
General Health 79.0 (16.3) 74.3 (19.9) 76.3 (16.6) 0.253
Social Functioning 92.4 (15.2)* 90.4 (17.4) 86.7 (16.9) 0.012
Role − Emotional 90.3 (24.8)** 91.4 (26.0)* 79.2 (33.5) 0.003
Mental Health 77.2 (17.0 ) 79.0 (12.8) 75.8 (14.4) 0.580
1: Aaronson NK, et al J Clin Epidemiol 1998;51(11):1055-68.[16] 
Higher scores = better HRQoL. 
* P < 0.05, ** P < 0.01 compared with reference values. 
¶ P value of the difference between the self-report and the references.
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Self-report
n = 49
Parent-report
n = 36
References1
n = 116
P value¶
Gross motor function 92.6 (15.0) 90.3 (21.0) 89.3 (19.6) 0.299
Fine motor function 98.5 (5.3) 96.0 (8.9) 95.7 (13.1) 0.054
Cognitive functioning 79.7 (23.7) 84.2 (19.2) 83.2 (21.2) 0.356
Sleep 78.2 (23.2) 75.5 (26.9) 71.7 (25.7) 0.129
Pain 86.6 (16.7)** 85.9 (18.7)* 76.7 (21.7) 0.005
Social functioning 90.3 (17.6) 85.1 (15.9)§ 89.3 (17.4) 0.731
Daily activities 91.1 (16.4)** 85.8 (23.2) 82.6 (22.8) 0.008
Sexuality 98.9 (5.3)** 92.1 (21.9) 89.8 (21.7) < 0.001
Vitality 63.9 (20.4) 68.6 (20.0) 62.1 (22.6) 0.630
Positive emotions 69.6 (17.9) 69.4 (15.9) 73.3 (20.7) 0.275
Depressive emotions 78.1 (18.1) 78.7 (16.5) 75.1 (19.0) 0.351
Aggressive emotions 90.9 (13.5)** 89.8 (9.0)** 82.7 (17.8) 0.002
1: Manual TAAQOL, Leiden: TNO & LUMC [18]. Higher scores = better HRQoL. 
* P < 0.05, ** P < 0.01 compared with reference values. § P = 0.01, self-reports compared to the 
parent-reports. ¶ P value of the difference between the self-report and the references.
Table 4: Additional data reported by Turner women and their parents.  
Turner women 
(n = 45)
Parents 
(n = 47)
P value 
Satisfi ed with height:
yes 42 (93%) 44 (94%) 1.00
no  3 (7%)  3 (6%)
Satisfi ed with breasts:
yes 26 (58%) 27 (57%) 0.77
no 17 (38%) 18 (38%)
no opinion  2 (4%)  2 (4%)  
Self-reported visible Turner features: 0.007
None 12 (26%)* 28 (61%)
Yes: n = 1 21 (46%) 11 (24%)
n = 2 11 (24%)  6 (13%)
n ≥ 3   2 (4%)  1 (2%)
Self-reported limitations due 
to physical appearance: 
None 35 (78%) 30 (67%)b
Yes: 10 (22%) 15 (33%) 0.66
Relationships 3a * 1 0.024
Work 4 3 0.36
Feelings of insecurity 4a 3 0.32
Lack of charisma − 6 0.16
Buying clothes/ shoes − 2 1.00
Data expressed as n (%). a: 2 Limitations reported by 1 patient. b: 2 Parent reports were missing. 
*: Significant difference between the Turner women and their parents. 
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Of the women with TS, 26% had a low SES level, 34% had an intermediate level and 
40% had a high SES level, not significantly different from the SES levels in the normal 
population (ie, 33% low, 34% intermediate, and 33% high). 
Table 4 gives data for subjective measures reported by the TS patients and 
their parents. Four of the women with TS and 2 of the parents did not return the 
questionnaire. The 3 patients who were not happy with their height would have liked 
to be taller. Of the 17 patients who were not happy with their breast development, 
3 (18%) judged their breasts of uneven in size, 5 (29%) judged them too small, and 
9 (53%) judged them too big. The parents scored significantly fewer features of TS 
than their daughters. The most common features of TS reported by the women with 
TS were short stature (n = 12), neck webbing (n = 8), and pigmented nevi (n = 4). Also 
reported were abnormal nails, characteristic facial expression, and slower motor 
performance. 
The frequency of medical problems reported by the parents of the women with TS 
is 0 in 3 cases (7%), 1 in 12 cases (27%), 2 in 15 cases (33%), 3 in 10 cases (22%), 4 in 5 
cases (11%). Two respondents did not answer this question. 
Factors influencing HRQoL outcome
The explanatory variables that were evaluated separately are listed in Table 5. 
The estimated B coefficients, the relevant effects adjusted for age and SES, are 
also given. The table shows that the women who where satisfied with their height 
had a significantly better HRQoL (approximately 25 on a scale of 0 to 100) on the 
physical performance scales of both SF36 and TAAQOL. The height SDS gain had a 
significant positive effect on the HRQoL outcome of ‘Role limitations due to physical 
health problems’, with an 8.3-point higher HRQoL score per unit SDS height gain. 
SDS height gain also positively influenced daily activities. The absolute height only 
significantly influenced the HRQoL-outcome of ‘vitality’ of the TAAQOL. The women 
who had feelings of insecurity due to their physical appearance had a lower HRQoL 
in the ‘Social functioning’ domain. The difference was 18.5 points (95% confidence 
interval [CI] = 2.2 to 34.8) according to the SF36 and 30.6 points (95% CI = 13.5 to 
47.7) according to the TAAQOL. Remarkably, the age at onset of puberty did not 
significantly influence any of the HRQoL outcomes. However, the satisfaction with 
breast development at time of the HRQoL evaluation did influence several of the 
HRQoL scales.
Having visible Turner features had a significant positive effect on scores for the 
‘Pain’ domain of the TAAQOL (Table 5). This indicates that having reported visible 
features of TS is associated with a higher HRQoL with respect to ‘pain’, but the 
quantity of the reported visible Turner features was of no affect (data not shown).
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development, visible Turner features, limitations, final height, and height sds gain on 
HRQoL-outcome of the SF36 (5a) and of the TAAQOL (5b), corrected for age and SES. 
5a: SF36 Satisfi ed 
with 
heighta
Satisfi ed 
with 
breastsa
Visible 
Turner 
featuresb
Feelings of 
insecurityc1
Final Height 
(cm)
Height 
SDS gain2 
(SDS) 
Physical
functioning
B 13.5 
(−1.8; 28.9)
8.1 
(1.0; 15.3)
p 0.082 0.026
Role − Physical B 25.2 (0.3; 50.2)
13.2 
(−0.6; 27.1)
8.3 
(1.4; 15.2)
p 0.047 0.060 0.019
Bodily pain B 10.4 (0.2; 21.1)
4.3 
(−1.4; 9.9)   
p 0.054 0.135
General health B 9.7 (−0.8; 20.2)
p 0.069
Vitality B 11.1 
(−0.3; 22.6)
−0.74 
(−1.6; 0.1)
p 0.057 0.084
Social 
functioning
B 13.1 
(3.5; 22.7)
−18.5 
(−2.2; −34.8)
p 0.009 0.027
Role − Emotional B 15.4 (−0.2; 31.1)
p 0.053
5b: TAAQOL
Gross motor 
functioning
B 24.8 
(6.8; 47.7)
9.8 
(20.6; −1.0)
p 0.008 0.074
Fine motor 
functioning
B −5.6 
(0.03; −11.2)
p 0.051
Sleep B 15.3 
(0.6; 30.1)
p 0.042
Pain B 11.7 
(0.9; 22.5)
p 0.035
Social 
functioning
B −30.6 
(−13.5; −47.7)
p 0.001
Daily activities B 4.3 (0.02; 8.5)
p 0.049
Sexuality B 1.0 (−0.3; 2.4)
p 0.135
Vitality B 10.9 
(−2.3; 24.1)
−1.1 
(−2.0; −0.2)
p 0.103 0.020
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SLegend to Table 5: Results with a P value > 0.15 are not shown. Unstandardized coefficients are 
given, B (95% Confidence Interval).
a: Positive score indicates better QoL when being satisfied; negative score indicates better QoL 
when not being satisfied. 
b: Positive score indicates better QoL when reported having TS features. 
c: Negative score indicates lower QoL when having feelings of insecurity. 
1: Feelings of insecurity due to their physical appearance. The variables of self-reported 
limitations due to physical appearance in relationships and work were of no significant influence 
on the QoL-outcome. 
2+HLJKW6'6JDLQ )LQDOKHLJKW6'6îKHLJKW6'6DWVWDUW*+WKHUDS\UHIXQWUHDWHG7XUQHU
girls [23]).
SES significantly positively influenced scores in the ‘Depressive emotions’ domain 
of the TAAQOL (data not shown). Karyotype, reported number of medical problems 
in the past, and age at onset of puberty had no significant influence in either of 
the HRQOL instruments. The SF36 HRQoL domains ‘vitality’, ‘mental health’, 
¶JHQHUDO KHDOWK· DQG ¶UROH î HPRWLRQDO· ZHUH QRW VLJQLILFDQWO\ LQIOXHQFHG E\ WKH
tested variables. Furthermore, for the TAAQOL HRQoL domains ‘cognition’, ‘positive 
emotions’, ‘depressive emotions’ and ‘aggressive emotions’ were not influenced by 
the variables evaluated.
Discussion
The women with TS reported higher HRQoL scores in the domains ‘Social functioning’ 
and ‘Role limitations due to emotional health problems’. This means that women with 
TS felt less restricted in social contact and/or daily life due to their physical health 
or emotional problems than the reference population. The reported results of better 
HRQoL in social functioning in the TS women is remarkable; earlier data indicated 
that women with TS scored significantly lower on social acceptance than the normal 
population [8,25]. But the present study indicates that HRQoL is not influenced by 
this factor, as the women with TS reported normal or even better HRQoL in terms of 
in social functioning.
A possible explanation for this finding is that the women with TS no longer feel 
different from their peers as they attain normal height and normal feminization during 
the growth phase and adulthood. Satisfaction with breast development and a lack of 
feelings of insecurity due to physical appearance have a significant positive influence 
on social functioning. These data emphasize the importance of feeling equal to normal 
peers. GH and estrogen treatment resulted in normal height and breast development 
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S in most of the girls [3,7] and diminished differences from peers. Because short stature 
and delayed pubertal development can be of significant negative influence on HRQoL 
[1,6], we hypothesize that GH treatment and appropriate induction of puberty can 
normalize HRQoL in women with TS.
Our group of women with TS showed even a better HRQoL than the reference 
population on some of the HRQoL scales. The women with TS had less aggressive 
feelings, demonstrating significantly better HRQoL for the TAAQOL domain 
‘Aggressive Emotions’. These results confirm earlier reports that girls with TS have 
less delinquent and aggressive behavioral problems [8,9]. This might be an effect 
of estrogen treatment, because estrogens significantly decrease aggressive and 
delinquent behavior in girls with TS [9], whereas GH has no influence [26]. It also may 
be influenced by the diminished androgens levels in TS [27], caused by lack of ovarian 
androgen production, because androgens increase aggressiveness [28]. However, 
the higher percentage of patients with karyotype 45,X in our study in comparison 
with other studies (approximately 80% vs. 65%) also must be taken into account. 
Spontaneous puberty, indicating (some) ovarian function, is less common in patients 
with karyotype 45,X than in patients with mosaic type
As a group, the women with TS had a normal HRQoL for motor performance. The 
women with TS who were satisfied with their height and those with a greater height 
gain had a better HRQoL in areas of physical/ motor functioning, suggesting a positive 
effect of the GH-induced height gain. The effect of estrogen treatment also may 
contribute to this finding, because estrogens also improve motor performances and 
speed in women with TS [29,30].
The possibility exists that women with TS have undergone a ‘response shift’, a 
change in internal standards or values [31]. This phenomenon has been reported 
in elderly persons who exclude some age-related problems or morbidities when 
they self-assessed their susceptibility to illness [32]. In terms of the present study, 
response shifting in our subjects may mean that the women with TS have different 
internal references than normal women. Facts supporting this hypothesis can be found 
not only in the reported relatively better HRQoL for ‘social functioning’ and ‘role − 
emotional’, but also in the better HRQoL for ‘pain’ and ‘sexuality’. Based on our 
previous research and on reports in the literature, we did not expect these results. 
Because women with TS have more medical problems than the normal population, 
they tend to experience more pain and discomfort than those other women; also, 
women with TS are reported to be less sexually active then their normal peers 
[12]. Thus we remain uncertain whether the relatively high HRQoL scores for these 
domains in our women with TS reflects actual health effect or results from response 
shifting. Future studies that include cognitive interviewing will aid investigation of 
this hypothesis.
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SIn general, the parent reports yielded similar results to those of their daughters 
with TS, except for assigning lower scores for their daughter’s social functioning on 
the TAAQOL questionnaire (see Results). This finding confirms the validity of the 
HRQoL outcomes reported by the women with TS. The parents of the daughters with 
TS can be considered as first-choice proxy raters because they typically have intensive 
contact with their daughters, a phenomenon often seen in young adults with chronic 
diseases or disabilities and their parents.
Age at onset of puberty was of no significant influence on several HRQoL outcomes. 
Absolute height negatively influenced ‘vitality’; however, the effect was small (B = 
−1.1; range −2.0 to −0.2). The normal height and pubertal development of our study 
population, as well as the small differences in final height and age range of pubertal 
onset, may explain the lack of a significant affect of these measures on HRQoL. 
These results confirm the recently published findings of Carel et al [14] that indicate 
normal HRQoL in TS with no significant influence of GH treatment-related variables, 
such as adult height or estimated height gain. However, our data reveal a significant 
influence of height gain on the ‘role limitations due to physical health problems’ and 
‘daily activities’ domains. Furthermore, in our study, satisfaction with height and/ or 
breast development had a significant positive influence on several HRQoL domains, 
and those women with TS who reported feelings of insecurity due to their physical 
appearance had lower HRQoL in the ‘social functioning’ domain.
To appreciate our results one has to consider the following. HRQoL was not 
evaluated longitudinally, because the HRQoL questionnaires were developed in 
the early and mid 1990s and the GH-studies began in 1989, when HRQoL became 
recognized as an important measure of the impact of a special disorder, disease 
or therapeutic outcome. Secondly, our study did not specifically evaluate the 
consequences of infertility on HRQoL. This might be a relevant factor with increasing 
age, because infertility is present in the majority of adults with TS and can have a 
significant influence the HRQoL [33-36]. Future studies are needed to evaluate the 
influence of infertility on HRQoL in women with TS. Thirdly, it would have been ideal 
to compare the treated TS population to an untreated TS population. However, given 
that GH treatment for girls with TS is common practice since early 1990s, no untreated 
population in the same age range was available for study. Finally the response rate was 
71%. There might have been a selection bias, but we believe that this unlikely, because 
there were no significant differences in clinical data, such as age, height, height gain, 
age at start of puberty and karyotype, between the respondents and non-respondents.
In conclusion, our study shows a normal health related quality of life in young 
women with TS after long-term GH treatment and puberty induction at an age-
appropriate time. The relative high scores on some of the HRQoL scales can be 
explained by an estrogen-effect or by a possible response shift, indicating that the 
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height and with breast development had a significant positive influence on several 
HRQoL scales, including social functioning and physical functioning. Therefore we 
hypothesize that GH and estrogen treatment positively influenced HRQoL in young 
women with TS. 
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Turner syndrome: Results 
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development of secondary 
sexual characteristics, uterine 
dimensions, and serum 
hormone levels
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Background: Besides short stature, gonadal dysgenesis leading to a lack of estrogens 
is one of the main characteristics of Turner Syndrome (TS). In most TS girls, puberty is 
induced with exogenous estrogens.
Objective: To describe the pubertal development and uterine dimensions achieved 
by low-dose 17β-estradiol orally started at an appropriate age. Additionally, to 
determine whether serum hormone levels aid evaluation of pubertal progression.
Design: In 56 TS girls, we studied pubertal stage, serum E2, LH, FSH, SHBG, and E1, 
starting estrogen treatment with a low dose 17β-estradiol (5 µg/kg/day) during GH-
treatment at age 12.7(0.7). Hormone levels were measured at start, 3 months after 
start and increasing 17β-estradiol dosage. Uterine dimensions were measured in 39 
TS women at age 19.9 (2.2).
Main outcome: Although breast and pubic-hair development were similar to that in 
normal Dutch girls, breast development was 2 years delayed. Before estrogen therapy, 
E2-levels were comparable to those in prepubertal girls. With 17β-estradiol dose of 
5 µg/kg/d, these levels increased significantly, becoming comparable to normal late 
pubertal or adult concentrations, whereas SHBG-levels were unchanged. At adult 
17β-estradiol dose, SHBG had increased significantly. Uterus shape was infantile in 4 
(10.2%), cylindrical in 4, and heart-shaped in 31 (79.5%) of TS patients.
Conclusions: During GH-treatment in TS girls, normal breast development can be 
mimicked, but with a 2-year delay. In a clinical setting, serum hormone levels provide 
no additional information for evaluating pubertal progression. After age-appropriate 
pubertal induction, uterine dimensions in women aged nearly 20 were subnormal. It 
remains unclear whether this was related to E2-dosage or duration, or factors related 
to TS. 
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Besides short stature, gonadal dysgenesis is one of the main characteristics in Turner 
Syndrome (TS). It leads to lack of estrogens, which play an essential role in changes 
occurring during female puberty, such as the development of secondary sexual 
characteristics, the establishment of fertility, and the pubertal growth spurt. 
Between 5% and 10% of women with TS start pubertal development spontaneously, 
the frequency being higher number in women with TS with mosaicism than in those 
with TS with the 45,X karyotype (40% vs. 8%). However, very few of these women 
maintain ovarian function, and spontaneous pregnancies are rare (app. 2−5%) [1-3]. 
In most of the girls with TS, puberty has to be induced with exogenous estrogens.
Uterine dimensions in untreated girls and young women with TS are small for 
age, and are described as pre-pubertal [4,5]. While some studies have reported that 
estrogen therapy in early to mid-adolescence leads to normal uterine development 
[6,7], others have reported that development of the uterus after estrogen therapy is 
suboptimal [8-10]. However, the differences between these studies − which mainly 
involved different age ranges, the route of estrogen treatment, and the form of 
estrogen therapy − mean that their results are difficult to compare. Most of these 
studies did not have a standardized puberty-induction treatment protocol. 
The debate on TS has often focused on the effect of estrogen therapy on adult 
height, and on whether estrogen therapy should be started during GH treatment or 
afterwards [11-14]. Recently, various studies (including our own) have shown that 
when GH treatment has been optimized, it was not necessary to delay the induction 
of puberty [15-17], and that estrogens in a low dose did not negatively influence 
height velocity or adult height. 
Little is known about their breast development compared to normal breast 
development, when estrogens are used in a low dose, started at an appropriate age. 
The present study therefore describes the breast development and uterine dimensions 
that followed after puberty induction, started at an appropriate age, using low doses 
of oral 17β-estradiol. We also discuss whether measurements of serum levels of 
estradiol (E2), estrone (E1), gonadotropins, and sex-hormone binding globulin (SHBG) 
are useful in evaluating induced pubertal development.
 
Patient and Methods
Study design
This study was performed in a population of patients with Turner Syndrome (TS) who 
participated both in a GH trial, and additionally in a follow-up study. 
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untreated girls with TS started in an open-randomized multi-center growth hormone 
(GH) dose-response study that began in the Netherlands in November 1989. Subjects 
were included if their chronological age was between 2 and 11 years, and their height 
below 50th percentile according to normal Dutch references [18]. Every three months 
during the GH trial, their height and weight were measured, and their pubertal stage 
according to Tanner [19] was assessed. The GH treatment was discontinued when 
final height had been attained; in the study protocol, this was defined as a height 
velocity of less than 1 cm over 6 months. Height and weight were expressed as SD-
score using the references for healthy Dutch girls [20] or the references for North 
European untreated girls with TS [21]. 
In order to induce puberty, a daily oral dose of micronized 17β-estradiol was 
given to girls aged 12 and over who had already undergone at least four years of GH 
treatment. In the first two years, a dose of 5 µg/kg body weight/day (equivalent to 
0.05 µg ethinyl estradiol/kg/d) was given; in the third year the dose was raised to 
7.5 µg/kg/d, and thereafter it was 10 µg/kg/d (tablets containing 0.1 mg micronized 
17β-estradiol being supplied for the study by Novo Nordisk A/S, Bagsvard, Denmark). 
After two years of estrogen therapy, cyclic progestagen therapy 5 mg/d was added in 
the first 14 days of the month (dydrogesterone (Duphaston®) Solvay Pharmaceuticals 
BV, Weesp, the Netherlands). If start of puberty had developed spontaneously into 
Tanner breast stage B2, the start of estrogen therapy was postponed for one year. 
If, one year later, Tanner breast stage was still B2, estrogen therapy was started 
according to the schedule as described above. If Tanner breast stage was ≥ B3, no 
estrogens were given.
Post GH trial: Six months after GH therapy ended, one more visit took place as 
part of the GH trial. Thereafter, the regular check-ups was performed by the girls’ 
pediatric endocrinologist. In 2003, a follow-up study took place, a mean of 4.8 
(2.0) years after the end of GH therapy. As well as other assessments, this involved 
assessment of the pubertal stages and pelvic ultrasound of the internal genitalia. 
After the end of GH therapy, estrogen treatment was increased to an adult dose of 
1 mg/day, and additionally to 2 mg/day. Cyclic progesterone dosage was increased to 
10 mg/d. 
At the end of GH therapy, pubertal development was re-evaluated in girls who 
had had spontaneous start of puberty and no estrogen treatment during GH therapy. 
If progression of breast development was insufficient in these girls, estrogen 
substitution therapy was initiated.
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As described above, 68 girls with TS started in the GH-trial. Four girls dropped out 
before the start of estrogen therapy, and could not be included in this evaluation. 
Fifty-five girls out of the 64 had karyotype 45,X, and eight had a variant karyotype.
Six girls entered puberty spontaneously, four with karyotype 45,X and two with 
a variant karyotype; none of these 6 girls were included in the evaluation of breast 
development and evaluation of serum hormone levels (see below). Two girls dropped 
out of the study three and six months after start of estrogen therapy, and could not 
thus be included in the evaluation of the pubertal development and hormone levels. 
This left n = 56 for analysis (Figure 1), 50 of whom had karytotype 45,X, and six a 
variant karyotype.
Dropped out before start
E2 therapy, n = 4
At start of GH trial
n = 68
At start of E2 therapy
n = 64 
Dropped out 3 and 
6 months after
start E2 therapy,  
n = 2
No spontaneous 
start of puberty
n = 58
Spontaneous 
start of puberty
n = 6
Analyzed for breast
development and
serum hormone levels
n = 56  
Not participating
in follow-up study
n = 25
Participating
in follow-up study
n = 39
Year 2003:
Figure 1: Flow diagram of the patients in the initial GH-trial and the follow-up study.
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after the end of GH treatment. Twenty-five did not participate in the follow-up 
study, due either to lack of motivation (n = 18) for reasons including psychological 
problems, practical considerations or lack of interest. One was lost to follow up 
due to emigration, and six not included due to mental retardation or autism. Of 
the remaining participants, six had undergone a spontaneous start of puberty, and 
in 33, puberty was induced according to the study protocol (Figure 1). Five of the 
six girls with spontaneous start of puberty had started estrogen treatment at GH 
discontinuation. Thirty-one girls out of the 39 had karyotype 45,X, and eight had a 
variant karyotype.
The GH trial protocol was approved by the Medical Ethics Committees of each 
participating center, and the follow-up study protocol was approved by the Medical 
Ethics Committees at Erasmus University Medical Center. Written informed consent 
was obtained from the girls and/or their parents. 
Measurements
Secondary sexual characteristics: During the GH trial, pubertal stage was 
determined every three months using the criteria and definitions described by Tanner 
[19]. After the GH trial, data was collected from the hospital information systems of 
the different hospitals, up to a mean age of 16.7 (1.2), range 14.5−19.8 years. Breast 
development was compared to that in healthy Dutch girls (n = 3562) [2].
Serum hormone levels: The serum concentrations of E2, E1, luteinizing hormone 
(LH), follicle-stimulating hormone (FSH), and SHBG were measured at start of 
estrogen therapy, three to six months after start of estrogen treatment, and after 
each increase in estrogen dosage. Estrogens were administered on the morning of 
the hospital visit. To measure the serum E2 levels at the highest expected serum 
concentration, blood samples were taken 4−6 hours after estrogen administration 
[23]. Concentrations of serum E2 and E1 were measured using radioimmuno-assay kits 
provided by Diagnostic Products Corporation (Los Angeles, CA) and Diagnostic Systems 
Laboratories (Webster, TX). LH, FSH and SHBG were estimated using luminescence-
based immunometric assays (Immulite 2000, Diagnostic Products Corporation). 
Serum E2 levels were compared to normal levels as described by Sehested et al 
[24], who described a normal female population (n = 403) without oral contraceptives 
during pubertal development. Serum E2, LH and FSH were reported according to 
breast-stage, median age and range. 
Pelvic ultrasound: Pelvic ultrasound was part of a follow-up study performed 
4.8 (2.0) years after the end of GH therapy, when the girls were aged 19.9 (2.2). 
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The ultrasonographic examination was performed transabdominally according to 
the conventional full-bladder technique. The ovaries were measured when visible, 
and their volume was calculated. The fundo-cervical (FC) ratio was calculated as: 
(anterior-posterior (AP) diameter of the fundus) / (AP diameter of the cervix). Uterine 
shape was designed as infantile (cervix larger than fundus), cylindrical (mid-childhood 
with cervix and fundus approximately the same), and heart-shaped (mature-adult 
shape with fundus larger than cervix) [25]. Uterine volume was calculated according 
to the formula for a prolate ellipsoid: maximal depth X maximum width X maximum 
length X 0.523 [25]. Girls who had entered puberty spontaneously were included in 
the analysis of the pelvic ultrasound.  
Statistical methods 
Unless indicated otherwise, results were expressed as mean ± SD. Repeated 
measurement models were used to compare serum hormone levels with the different 
oral estradiol dosages over time. As oral estrogen dose was increased more rapidly 
to an adult dose after discontinuation of GH, not all girls had an estrogen dose of 
7.5 µg/kg/d (n = 38) and 10 µg/kg/d (n = 21). Hormone levels at the adult estradiol 
dosage of 1 and 2 mg/day were taken together for analyses. As serum could not be 
collected from all patients at the adult oral estradiol dose, the repeated measurement 
was performed separately in the subgroup concerned (n = 19) for purposes of 
comparison with the last measurement available (5, 7.5 or 10 µg/kg/d) and with 
baseline measurement. Geometric mean and 95% confidence interval of the estimates 
are given. Spearman’s correlations were used to assess the relation between breast 
stage and serum E2 levels; between duration from breast stage B2-B4 and age at start 
of estrogen therapy; and between serum levels of E2 and serum levels of LH, FSH, 
SHBG, and E1. Student’s t-tests were performed to analyze the differences in uterine 
length, shape and volume between women having karyotype 45,X and those with a 
variant karyotype, and between woman who had spontaneous pubertal onset and 
those who had not. P-values < 0.05 were considered to be statistically significant. All 
calculations were performed with SPSS 11.5.
Results
Study subjects
In girls without spontaneous start of pubertal development, the mean age at start 
of puberty induction was 12.7 (0.7) years, with a range 11.8−15.0 yr. The mean 
GH duration before start of estrogen therapy was 6.2 (1.9) years. The mean GH 
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spontaneously, one of whom had regular menstrual cycles. The remaining five started 
estrogen therapy at GH discontinuation, at a mean age of 15.1 (1.1) years. 
Secondary sexual characteristics
The average age (50th percentile) (P10-P90) for attaining the different stages of 
breast and pubic hair development are shown in Table 1. The different breast stages 
advanced gradually, and were comparable to development in the normal Dutch 
female population [22], albeit with a two-year delay (Figure 2, Table 1). Six of the 
56 girls had some breast development (B2) without further spontaneous progression, 
and started estrogen treatment one year later according to the protocol. 
Table 1: Mean ± SD (range) age at which the different stages of secondary sexual 
characteristics were reached.
Turner population 
P50 (P10−P90)
Normal Dutch populationa 
n = 3562 
P50 (P10−P90
Stage: Breast stage Pubic hair stage Breast stage Pubic hair stage 
2
n = 56 
12.67 
(12.06−13.53)
n =56 
10.32 
8.28−12.36)
10.72 
(9.0−12.2)
11.01 
(9.4−12.5)
3
n = 54 
13.76 
(12.79−15.76)
n = 54 
11.87 
(10.07−13.67)
11.90 
(10.5−13.1)
11.89 
(10.6−13.2)
4
n = 49 
15.13 
(13.61−18.12)
n = 55 
13.15 
(11.57−14.72)
12.84 
(11.5−14.5)
12.68 
(11.4−14.3)
5
n = 23 
19.23 
(15.19−NA)
n = 46 
15.13 
(13.25−NA)
14.34 
(12.5−19.5)
13.76
(12.1−17.7)
a: Mul, D., et al, Pediatr Res, 2001. 50(4): p. 479-86. [22]
The development of pubic hair in the Turner girls was similar to that in the normal 
Dutch female population (Figure 3, Table 1). Seventeen of the TS girls started to have 
withdrawal bleedings 1.5 (1.2) years after start of dydrogesterone 5 mg/d, and 30 
started to have withdrawal bleedings 0.5 (0.6) years after start of a dydrogesterone 
dose of 10 mg/d.
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Figure 2: Breast stages according to Tanner in a normal Dutch reference population (top 
panel) [22] compared to that in girls with Turner Syndrome (lower panel) who started 17β-
estradiol at an age-appropriate time. Adapted from Mul et al [22] with permission.
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Figure 3: Pubic-hair stages according to Tanner in a normal Dutch reference population 
(top panel) [22] compared to that in girls with Turner Syndrome (lower panel) who started 
17β-estradiol at an age-appropriate time. Adapted from Mul et al [22] with permission.
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Figure 4: Geometric mean and 95% confidence interval at different oral 17β-estradiol 
dosages of serum estradiol (pmol/l)(5a), LH (IU/L)(5b), FSH (IU/L)(5c), SHBG (nmol/l)(5d), 
and estrone (pmol/l)(5e). 
Analysis of repeated measurements produced the following significant differences (P value 
< 0.05): a: compared to start E2, b: for the oral dosage of 7.5 and 10 μg/kg/d compared to 
preceeding dosage of 5 respectively 7.5 μg/kg/d, c: adult dose of 1 or 2 mg/day compared 
to the levels at the last oral dosage taken.
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Figure 4 shows the geometric mean and the 95% confidence interval of serum E2, E1 
LH, FSH, and SHBG concentrations at the different oral 17β-estradiol dosages. At 24.7 
pmol/l (95%CI 22−28), the mean serum E2 concentration at start of estrogen therapy 
(mean age 12.7(0.7) years) was comparable to that in prepubertal girls (mean age 
9.1 yr) with serum estradiol levels of 22 pmol/l (95%CI < 18−52) [24]. Measured at the 
expected peak concentration, the serum E2 concentration increased significantly to 
202 (95%CI 176−231) pmol/l at a 17β-estradiol dose of 5 µg/kg/d, which is comparable 
to normal late pubertal (breast stage 4/5) or adult serum E2 concentrations (B4: 162 
pmol/l 95%CI < 18−1094 pmol/l, B5: 182 pmol/l 95%CI 27−1108 pmol/l, or adults: 289 
pmol/l 95%CI 74−1075 pmol/l, respectively) [24]. The serum E2 levels at the adult 
oral dose of 1 or 2 mg/d (mean 703 pmol/l 95%CI 552−895 pmol/l) were significantly 
higher than the serum E2 levels at the preceding dose. Serum E1 concentrations rose 
significantly along with the increase in 17β-estradiol dosage.
Mean LH concentrations at an oral 17β-estradiol dose of 5 µg/kg/d were lower than 
before start of 17β-estradiol (6.4 IU/l 95%CI 4.7−8.8 IU/l and 10.6 IU/l 95%CI 9.0−12.4 
IU/l, respectively). The LH levels at oral 17β-estradiol dosages of 7.5 and 10 µg/kg/
d were higher relative to the levels at the 5 µg/kg/d, and also significantly higher 
than before start. FSH concentrations showed a significant decrease after the start of 
estrogen therapy. SHBG concentrations did not change after starting the lowest dose 
of 5 µg/kg/d, and decreased significantly with a dose of 7.5 and 10 µg/kg/d. The 
serum SHBG levels at the adult oral dose of 1 or 2 mg/d (mean 48 nmol/l 95%CI 43−55 
nmol/l) were significantly higher than the serum SHBG levels before start (37nmol/l 
95%CI 33−42 nmol/l) and than during the preceding estrogen dose. 
Table 2: Mean ± SD (range) of uterine dimensions during follow-up study 7.1 (2.2) years 
after start of estrogen therapy, and 4.8 (2.0) years after discontinuation of GH.
Total group
n = 39
Karyotype
45,X
n = 31
‘variant’
n = 8
Age (years) 19.9 ± 2.2
15.0 − 23.4
19.7 ± 2.1
15.0 − 23.2
20.7 ± 2.4
16.6 − 23.4
Uterus length (mm) 60.1 ± 15.9
25.0 − 87.0
58.9 ± 16.7
25.0 − 87.0
66.9 ± 11.4
49.0 − 83.0
Uterus volume (ml) 24.8 ± 15.0
4.4 − 57.9
22.3 ± 13.0*
4.4 − 57.5
34.5 ± 19.0
7.9 − 57.9
Fundo-cervical ratio 5.5 ± 0.5
0.8 − 2.8
1.4 ± 0.5
0.8 − 2.8
1.5 ± 0.3
1.1 − 2.0
*: Significant difference between patients with karyotype 45,X and ‘variant’ with P < 0.05.
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Uterus: Uterine dimensions are shown in Table 2. Uterine volume in patients with 
karyotype 45,X was significantly smaller than in patients with variant karyotype. 
There were no significant differences between patients with spontaneous start of 
puberty and those without. Fundo-cervial ratio (FCR) was infantile (FCR < 1) in four 
patients (10.2%), cylindrical (FCR≈1) in four, and heart-shaped (FCR > 1) in 31 (79.5%). 
None of the patients with variant karyotype had an infantile shaped uterus, and one 
out of the nine had a cylindrically shaped uterus.
Ovaries: Streaks or no ovaries were detected in 17 girls out of the 39. In four girls 
(one with spontaneous puberty) one ovary was detectable, while in 18 girls (two with 
spontaneous puberty) two ovaries were visualized. The mean ovarian volume of all 
ovaries measured (n = 40) was 2.5 (2.2) ml. The volumes of the ovaries detected in 
the girls with start of spontaneous puberty were not significantly larger than those 
measured in the girls without spontaneous start of puberty. The girl with regular 
menstrual cycles had ovarian volumes of 1.3 and 1.5 ml. 
Correlations
Age at start of estrogen therapy was negatively correlated with the duration from 
B2 to B4 (r = −0.30, P < 0.05). Serum E2 concentration was positively correlated with 
breast stage (r = 0.71, P < 0.001). Serum E2 concentration was negatively correlated 
with serum FSH (r = −0.31, P < 0.001), but not with serum LH (r = 0.01, P = 0.87), nor 
with serum SHBG (r = 0.04, P = 0.625). It was also strongly correlated with serum E1 
concentration (r = 0.81, P < 0.001).
Discussion
The main purpose of estrogen therapy in girls with Turner Syndrome (TS) is to induce 
puberty and feminization as physiologically as possible, without sacrificing adult 
height. The present study shows the results of puberty induction during GH treatment 
in girls with TS, starting at an age of 12.7 (0.7) years. Induction was started with a 
very low dose of 17β-estradiol for two years before the estrogen dose was slowly 
increasing. 17β-Estradiol is a natural estrogen, which has less pronounced effects on 
the coagulation factors, lipid profiles and blood pressure than synthetic estrogens 
[26]. The low dose did not affect height velocity [15]. 
Although it has previously been reported that normal progression through the 
breast stages is possible in girls with TS [7,11], the results are difficult to compare, 
as the form, dosage, and route of the estrogen treatment were not the same as in our 
study. Chernausek et al used conjugated equine estradiol in a daily dose of 0.3 mg 
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higher estrogen dose than used in our study [27]. As their dosage was thus relatively 
high with a faster dosage increase, it was not beneficial for adult height [11]. At start 
of puberty induction, the other study referred to above had a large age range (10.7 to 
17.7 years) [7]. 
Our own study showed that with a very low dose of oral estrogen therapy over two 
years, normal breast development occurs in the majority of Turner women, but two 
years later than in their peers; the estradiol dosage is then slowly increased. As adult 
height is not affected by this low dose, it is possible to start this estrogen regimen 
during GH therapy at an appropriate age. 
Our results also showed that the older the TS girls at start of estrogen therapy, the 
faster the progression through puberty. This can probably be explained by the faster 
increase in estrogen dose, which was increased to an adult dose after final height had 
been attained. This phenomenon mimics the natural situation in normal girls, where 
an earlier onset of puberty corresponds with a longer duration [28]. 
Pubic hair developed similar to normal, and had started in most girls before 
estrogen treatment was initiated. This indicates that, although ovarian androgen 
production is lacking, adrenarche in girls with TS proceeds normally, which is in 
agreement with earlier reports [29]. 
The levels of serum E2 at the lowest oral estrogen dose were comparable to normal 
late pubertal or adult serum E2 concentrations [24]. However, the E2 levels in these 
healthy girls and women showed a wide confidence interval, possibly because blood 
samples were taken irrespective of the day of the menstrual cycle. The lowest E2 
(5 μg/kg/d) dose suppresses LH and FSH. However, the double E2 dose (10 μg/kg/d), 
also providing double serum E2 levels, LH and FSH levels increased. This effect may 
be a result of changed sensitivity of the E2 feedback, possibly due to an increased 
age or to a higher tolerance. Furthermore, the E2 and E1 levels were measured at 
the expected highest serum concentration, which means that the mean serum value 
is lower. The lack of an increase in serum SHBG after starting estrogen substitution in 
the Turner girls, and the relatively high gonadotropin levels, both indicate that the 
overall serum E2 effect at the low estradiol dose was small. 
In postmenopausal women receiving 2 mg estradiol per day, gonadotropins 
decreased significantly [30,31], resulting in LH and FSH levels which are comparable 
[31] or lower [30] than the levels during treatment with the adult dose reported 
in our study. Whereas the lower 17β-estradiol dosage during GH therapy did not 
significantly increase SHBG levels, these levels increased significantly after the adult 
dose. This was comparable to the situation in postmenopausal women taking 2 mg of 
17β-estradiol, in whom SHBG levels also increased significantly [31].
In our Turner population, uterine volume was smaller (mean 24.9 ml, range 
4.4−57.9 ml) than that reported in normal female students of the same age who had 
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reported that the uterus had continued to grow several years after menarche, 
resulting in a larger uterine volume at young adulthood than in fully matured girls 
at the age of approximately 15 years. Most reports on uterine dimensions provide 
normative data up to the age of 15−16 years [33-36]. The uterine volume, length 
and shape in our Turner population were comparable to uterine dimensions in normal 
girls who have reached breast stage B5, and/or those aged 14−16 [33-35]. As normal 
uterine volume increases after breast stage B5 has been reached, or after the age 
of 15, uterine length and/or shape will increase simultaneously. This may indicate 
that uterus development in our Turner population at age 19.9 (2.2) was suboptimal 
compared to that in women of the same age. However, there is no normative data 
on uterine length and shape in women aged 15−25. Although Paterson et al reported 
similar uterine length in an estrogen-treated Turner population of a similar age range, 
uterine shape was less mature than in our population [8]. One explanation for the 
differences between their study and ours may be the age at initiation of the estrogen 
replacement and the period of estrogen therapy before ultrasound measurement, 
which were not reported in their paper. Furthermore, the form of estrogen treatment 
may have been of influence, as they used ethinyl estradiol, whose pharmaco-kinetics 
are different from those of 17β-estradiol. 
TS women participating in an ovum-donation IVF program were reported to have 
a lower successful pregnancy rate per embryo-transfer [37,38]. If TS women attain 
normal adult uterine dimensions, this may reduce the number of pregnancy-related 
problems they face in an ovum donation IVF program. It has been suggested that 
lacking small amounts of estrogens during childhood or starting estrogen replacement 
later than at the physiological age of the serum estradiol increase, resulting in a 
hypoplastic uterus, may be irreversible [8,9]. However, Snajderova et al [10] reported 
that in adult TS women with a median age of 21.4, a higher daily dose of estradiol 
was associated with a greater uterine length, and that uterine length was positively 
associated with uterine shape. These data suggest that possibly a higher estrogen 
dose may result in normal uterine dimensions at an adult age, and be more suitable 
for embryo transfer and pregnancy. An earlier report had already proposed that, for 
optimum endometrial response and improved outcome, higher constant estrogen 
replacement was needed before embryo transfer [37]. It is possible that the dose 
in our study was not sufficient for increasing uterus dimensions. Alternatively, other 
factors related to TS may underlie uterine dimensions that remain subnormal. But as 
puberty induction started two years after the onset of physiological pubertal, it is 
also possible that uterine development is subject to delay. 
Successful pregnancy requires an optimal response by the endometrium. In our 
population we did not measure endometrial thickness, as we did not standardize the 
timing of the ultrasound before the timed withdrawal bleeding.
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age to induce puberty in girls with TS, the breast development that follows is 
comparable to normal breast development, but with a two-year delay. Serum 
hormone levels do not provide additional information for evaluating the progression 
through puberty in a clinical setting. In addition, uterine dimensions in TS women 
aged nearly 20 years were comparable to those in normal fully matured girl aged 15. 
It nonetheless remains unclear whether subnormal uterine dimensions in young TS 
women are related to the dosage or duration of estrogen administration, or to other 
factors related to Turner syndrome. 
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Objective: To investigate whether long-term GH treatment influenced the risk factors 
for cardiovascular disease, carbohydrate metabolism, and body proportions in young 
TS women, several years after ending long-term GH treatment, and to compare them 
with normal and, if possible, untreated TS women.
Design: Follow-up study after randomized GH dose-response trial.
Methods: Thirty-nine patients with TS (20.0 ± 2.1 year) participated, 4.8 (1.9) year 
after GH discontinuation. Mean GH duration 8.7 (2.0) year; in 3 different GH-dosages 
(1.3, 2.0, and 2.7 mg/m2/d). 
Measurements: fasting glucose, insulin, serum lipids, blood pressure, body 
proportions.
Results: Several years after GH-discontinuation, insulin sensitivity remained lower; 
β-cell function and fasting insulin levels remained higher than pre-treatment. β-Cell 
function was positively influenced only by BMI. During GH treatment, diastolic BP had 
decreased. Several years after end of GH, diastolic BP had increased and was similar 
to pre-treatment levels. Diastolic BP was negatively influenced by GH-dose. Systolic 
BP was not influenced by GH dose or duration. Serum TC, LDL and HDL had further 
increased compared to 6 months after GH, resulting in higher TC, but also higher 
HDL levels compared to controls. AI remained constant, which is lower than controls. 
The BMI increased gradually during and after GH-therapy. During GH therapy, shape 
values of sitting height decreased, of the foot increased, and of the hand, biiliacal 
and biacromial diameter remained constant.
Conclusions: GH therapy in girls with TS has, besides height, additional beneficial 
effects on BP, serum lipids, and body proportions, except on foot length. Nearly five 
years after GH discontinuation the favorable effect of GH on BP and serum lipids was 
still noticeable. The GH-induced decreased insulin sensitivity, however, remained 
unchanged, possibly due to having TS. 
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Girls with Turner syndrome (TS) have two main characteristics: short stature 
and ovarian failure. Although they are not growth-hormone (GH) deficient, GH 
treatment is common in many countries [1]. This improves height during childhood 
and adulthood, and results in an adult height within the normal range [2-4]. Due to 
ovarian dysfunction, puberty has to be induced in most TS girls by exogenous estrogen 
treatment. 
Since TS was first described in seven female patients by Dr. H. Turner in 1938 
[5], it has become increasingly clear that the syndrome is associated not only with 
short stature and hypogonadism, but also with a number of diseases and conditions. 
As well as having a higher incidence of congenital cardiovascular malformations, TS 
women are also predisposed to cardiovascular disease (CVD), as CVD risk factors such 
as hypertension, hyperlipidemia, and insulin resistance occur more often in TS [6,7]. 
TS patients tend to be overweight [8], untreated TS women being more stocky than 
women in the normal population, with relatively short lower extremities, relatively 
large hands and feet, and relatively broad shoulders and pelvis [8-10].
Various investigators have examined the effect of GH treatment on these 
conditions. Our group previously reported [11] that increased GH-induced fasting 
insulin levels had fallen significantly six months after GH ended, but they were 
still higher than at start of GH therapy. Six months after GH, systolic and diastolic 
blood pressure SD-scores (SDS) were both significantly lower than before GH, but 
remained higher than normal. The serum lipid levels had also changed into more 
cardio-protective values. Although the pre-existing disproportion between standing 
height and sitting height in TS improved moderately during GH treatment, the 
disproportionate growth of the feet may have been negatively influenced by higher 
GH dosages [9]. 
The aim of this study was to investigate whether long-term GH treatment 
influenced the carbohydrate metabolism, risk factors for cardiovascular disease, 
and body proportions, several years after ending GH-treatment in young women with 
TS. Comparisons were made with normal women, and, if possible, with untreated TS 
women.
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Study subjects
Thirty-nine patients with TS, all participants in an earlier long-term GH trial, 
participated in this follow-up study. 
The original GH trial had initially involved 68 previously untreated TS girls [2], 
whose diagnosis was confirmed by lymphocyte chromosomal analysis. At inclusion, 
the chronological age (CA) of these girls ranged between 2 and 11 years; their 
height lay below the fiftieth percentile according to normal Dutch references. 
The exclusion criteria were abnormal thyroid function, associated endocrine and 
or metabolic disorders, growth failure underlain by other causes (e.g. emotional 
deprivation); hydrocephalus, previous use of drugs which could interfere with the GH 
treatment, and spontaneous puberty. Four girls dropped out of the study due to lack 
of motivation. 
Thirty-nine of the remaining 64 girls participated in the follow-up study, which 
took place 4.8 (1.9) years after GH treatment ended. Twenty-five did not participate 
in the follow-up study, 18 due either to lack of motivation caused by psychological 
problems, practical factors or lack of interest, one due to emigration, and six due to 
minor mental retardation or autism. Thirty-one girls of the 39 had karyotype 45,X, 
and eight had a variant karyotype. 
The Medical Ethics Committees approved both the GH trial and the protocol for 
the follow-up study. Written informed consent was obtained from the girls and/or 
their parents. 
Study design
GH trial: After stratification for chronological age and height standard deviation 
scores (SDS), the patients were randomly assigned to group A, B or C, which were 
assigned the following GH dosages: group A (n = 23) received 1.3 mg/m2 body 
surface/day (equivalent to 0.045 mg/kg); group B (n = 23) received 1.3 mg/m2/d 
during the first year, followed by 2 mg/m2/d (≈ 0.0675 mg/kg/d); and group C (n = 22) 
received 1.3 mg/m2/d during the first year, 2 mg/m2/d during the second year, and 
2.7 mg/m2/d (≈ 0.090 mg/kg/d) thereafter. Biosynthetic human GH (Norditropin, 
Norditropin simplex, Novo Nordisk A/S, Denmark) was given subcutaneously once daily 
at bedtime, the dose being adjusted every three months according to the calculated 
body surface. On the basis of the study protocol, GH treatment was discontinued 
when height velocity (HV) had been less than 1 cm over the past 6 months, or when 
the patient decided she was satisfied with the height she had reached.
In order to induce puberty, micronized 17β-estradiol (E2) was given to all girls 
aged 12 yrs and older who had had at least four years of GH treatment. During the 
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7.5 µg/kg/d in the third year, and 10 µg/kg/d thereafter. After two years of estrogen 
therapy, all these girls received cyclic progestagen therapy consisting of 5 mg/d for 
14 days of the month. Upon discontinuation of GH therapy, estrogen treatment was 
increased to an adult dose of 1 or 2 mg/day, and progestagen dosage was increased to 
10 mg/d. 
Follow-up of the GH trial: The GH trial involved short-term follow-up (ST-fu) 
of all girls six months after the end of GH. Long-term follow-up study (LT-fu) took 
place in 2003, mean (SD) 4.8 (1.9) years after discontinuation of GH. The LT-fu study 
existed of different parts, among quality of life evaluation, MRI-scans of the aorta, 
and uterine ultrasound, as described elsewere [12,13]. 
Measurements
The following measurements were performed at the start of the GH trial, at the end 
of GH, and at LT-fu: blood pressure (BP), height, weight, sitting height (SH), left 
hand length (Hand), left foot length (Foot), biacromial diameter (Biac), and bi-iliac 
diameter (Biil). Body mass index (BMI) was calculated. BP and BMI were also measured 
at ST-fu. 
Fasting blood samples were taken at start of the GH trial, after four years of 
GH therapy, at ST-fu, and at LT-fu to determine the following: glucose, insulin, 
glycosylated hemoglobin (HbA1c), serum total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL). The 
atherogenic index (AI) was calculated (TC/HDL). After centrifugation, all samples 
were frozen (−80°C) until assayed. 
To estimate insulin sensitivity and β-cell function, we used the HOmeostasis 
Model Assessment (HOMA) as described previously by Matthews et al [14,15]; this was 
subsequently validated [16]. The HOMA model is a structural model of glucose/insulin 
interaction, with mathematical equations describing the functioning of the major 
effector organs. HOMA-B (%) represents β-cell-function, and HOMA-S (%) represents 
insulin sensitivity, with high HOMA-S indicating high insulin sensitivity. 
Systolic and diastolic BP was determined four times with a single Dynamap 
Critikon 1846SX in sitting position using a cuff size corresponding to arm size. BP was 
expressed as an SD-score using age and sex-specific reference values [17]. TC, HDL, 
LDL, and AI were compared with those of a Dutch control group of the same age and 
sex [18].
The anthropometric measurements were performed according to Cameron [19], 
using a Harpenden anthropometer. The mean of two measurements was used for 
analyses. At end of GH-treatment and at LT-fu, we calculated the SD scores for height 
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the SDS of the measurements SH, Biac, Biil, Hand, and Foot were expressed as a shape 
value, adjusted for height SDS, using the formula [10]: Shape SH = (SH SDS − height 
SDS) /√(2-2r), in which r is the correlation coefficient between height and SH in the 
reference population. Values < −2 and > +2, were considered to lie outside the normal 
range. The data of Gravholt et. al. were used as a reference for untreated TS women 
[8]. To compare Gravholts data with ours, we calculated the mean shape values from 
the SDS of that study, since the same reference population was used as in our study. 
Assays
The plasma glucose level was measured at the local hospital laboratories, and plasma 
insulin was determined in one laboratory by IRMA (Medgenix, Biosource Europe; 
fasting normal range: 4-15 mU/l). HbA1c levels were measured in one laboratory as 
described previously [21]. References for lipid levels were measured using the same 
assays in the same laboratory as described previously [11]. 
Statistics
Unless indicated otherwise, results were expressed as mean (SD). For the analyses at 
baseline and during GH therapy, only the LT-fu participants (n = 39) were included. 
Repeated measurement models were used to compare the outcome variables over 
time and between the GH dosage groups. At LT-fu, backward multiple linear regression 
analyses were used to assess multivariable relationships. The dependent variables 
were systolic and diastolic BP SDS, fasting insulin, HOMA-B, HOMA-S, TC, HDL, and 
LDL. The following independent variables were entered into the model: GH dosage 
(mg/m2/d), GH duration (yrs), duration after GH discontinuation (yrs), BMI (kg/m2), 
karyotype (1 = 45,X, 2 = variant), and age (yrs). In the model for BP SDS, age and BP 
at start were included, as there was a significant difference between the GH-groups 
at start. In the model for the shape value of the foot, only the variables GH duration 
and GH dosage were entered. Independent variables with P-values < 0.1 were kept 
in the model; those with P-values < 0.05 were considered statistically significant. All 
calculations were performed with SPSS 11.5.
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Study subjects
Table 1 shows the characteristics of all participants in the long-term follow-up (LT-
fu) study. They were 20.0 (2.1) years old, ranging 15.7−23.4 years. Apart from the 
greater adult height attained in group C than in group A, there were no significant 
differences between the three GH dosage groups.
Table 1: Characteristics of the TS women participating in the long-term follow-up study.
Group A Group B Group C Total group
Number of girls/women 14 13 12 39
Age at long-term follow-up (years)  20.5 (1.6)  19.8 (2.1)  19.6 (2.5)  20.0 (2.1)
Age at GH discontinuation (years)  15.6 (0.7)  14.8 (1.4)  15.2 (1.1)  15.2 (1.2)
Age at start of E2 therapy (years)  12.9 (1.2)  13.0 (1.0)  12.9 (1.4)  12.9 (1.2)
Duration of GH therapy (years)   8.6 (1.3)   8.4 (2.6)   9.2 (1.9)   8.7 (2.0)
Duration after end of GH (years)   4.9 (1.4)   5.1 (2.4)   4.4 (2.0)   4.8 (1.9)
Height (cm) 157.9 (7.2) 163.8 (5.8) 164.7 (6.0)* 162.0 (6.9)
Karyotype (n) − 45,X : variant 12 : 2 12 : 1 7 : 5 31 : 8
Data expressed as mean (SD). * P < 0.05 compared to group A.
Measurements
LT-fu was 4.8 (1.9) years (range 1.5−9.1) after GH discontinuation, while short-term 
follow-up (ST-fu) was standardized at six months after GH discontinuation.
Carbohydrate metabolism: During the GH trial, none of the girls developed 
diabetes mellitus (DM). At LT-fu, one of the 39 girls showed signs of DM (fasting glucose 
10.5 mM, HbA1c 7.9%), and was referred for further analyses. She was excluded from 
the LT-fu carbohydrate evaluation. 
Over time, there were no differences between the three groups regarding changes 
in any of the parameters measured, or in differences between the GH dosage groups 
at any of the time points. All individual HbA1c values remained within the normal 
range throughout the years during and after GH treatment.
Mean fasting glucose and insulin levels increased from start up to year 4 of GH 
therapy (p < 0.01, p < 0.001 respectively), and were lower at ST-fu than at year 4 
of GH-therapy (p = 0.001, p < 0.05 respectively) (Figure 1). At ST-fu, glucose levels 
had returned to pre-treatment levels, whereas mean insulin levels had remained 
higher than those pre-treatment (p < 0.001). From ST-fu to LT-fu, mean glucose levels 
increased (p < 0.01), reaching levels that were not significantly different from those 
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S at year 4 of GH therapy (P = 0.09). However, mean glucose levels remained within 
the normal range. At LT-fu, mean fasting insulin levels had not changed significantly 
compared to ST-fu levels (P = 0.271), and were still higher than pre-treatment levels 
(p < 0.001). 
Insulin sensitivity (HOMA-S) decreased from start to year 4 of GH therapy 
(P < 0.001) (Figure 1), remaining constant thereafter (i.e., during ST-fu and LT-fu) 
at 75−85%. Beta-cell function (HOMA-B) increased from start to year 4 of GH therapy 
(P < 0.001), and remained constant thereafter (150−160%).
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Figure 1: Mean and 95% confidence interval for fasting glucose, insulin levels, insulin 
sensitivity (HOMA-S), and β-cell function (HOMA-B) in Turner Syndrome patients (n = 38) 
at start of GH therapy, after 4 year of GH therapy, 6 months after GH (Short-term fu), and 
4.8 (1.9) years after GH (Long-term fu). 
There where no differences between the three GH-dosage groups at any measured points 
in time. 
* P < 0.01 compared to preceding levels, # P < 0.01 compared to pre-treatment levels
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Figure 2: Systolic and diastolic blood pressure SDS in Turner Syndrome patients (n = 39) 
at start of GH therapy, end of GH, 6 months after GH (Short-term fu), and 4.8 (1.9) years 
after GH (Long-term fu). 
* P < 0.05 compared to preceding levels, # P < 0.05 compared to pre-treatment levels
Blood pressure: Changes over time in systolic blood pressure (BP) did not differ 
between the three GH dosage groups (P = 0.8). Systolic BP did not change during GH 
treatment (P = 0.57) (Figure 2). At ST-fu, systolic BP was lower than at the end of GH 
(P < 0.05) and than pre-treatment values (P < 0.05). Between ST-fu and LT-fu, mean 
systolic BP increased significantly from 111.4 (12.5) to 122.1 (14.2) mmHg, resulting 
in SD-scores higher than pre-treatment SD-scores (p < 0.05). 
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groups (P = 0.4). Diastolic BP showed a small decrease during GH treatment 
(P < 0.001) (Figure 2). Diastolic BP remained constant during the first six months after 
GH (Short-term fu)(P = 0.94), and was lower at ST-fu than pre-treatment (P < 0.001). 
Between ST-fu to LT-fu, mean diastolic BP increased from 67.0 (8.4) to 79.1 (11.4) 
mmHg, resulting in SD-scores no different from pre-treatment levels (P = 0.9). 
At LT-fu, 17 (44%) of the 39 women had a systolic BP above +1.3 SD-score (ninetieth 
percentile), six of whom had a variant karyotype. Eleven of them also had a diastolic 
BP above +1.3 SD-score (four with variant karyotype). 
Serum lipids: Changes over time in TC, LDL and triglycerides were not significantly 
different between the three GH dosage groups. At LT-fu, TC and LDL were higher than 
at ST-fu, resulting in TC levels higher and LDL levels lower than controls (Table 2). 
Triglycerides increased significantly after year 4 of GH therapy compared to pre-
treatment, after which there were no significant changes.
HDL was significantly different between the three groups at baseline, being 0.58 
(0.04) in group A, 0.69 (0.05) in group B, and 0.88 (0.04) in group C. From start to 
year 4 of GH therapy, HDL increased significantly in all three groups, resulting in 1.03 
(0.06) for group A, 1.09 (0.07) for group B, and 1.25 (0.06) for group C. At year 4, 
groups A and C were no longer different from group B, though the difference between 
A and C remained. Thereafter, there were no longer any differences between the 
three GH dosage groups. At LT-fu, HDL was higher than at ST-fu, and than in controls.
Table 2: Lipid levels before, during and after GH treatment.
Start After 4 years 
GH therapy
Short-term 
follow-up
Long-term 
follow-up
Controlsa
(n = 703)
TC 4.20 (0.66) 3.91 (0.50)b 4.20 (0.69)c 4.98 (0.83)bbccdd* 4.7 (0.7)
HDL 0.71 (0.19) 1.12 (0.23)bb 1.42 (0.34)bbcc 1.70 (0.40)bbccd** 1.3 (0.3)
LDL 2.65 (0.70) 1.98 (0.43)bb 2.23 (0.59)bbc 2.64 (0.63)ccdd* 2.9 (0.7)
AI 6.20 (7.91) 3.61 (4.49)bb 3.07 (3.70)bbc 3.05 (3.95)bbc** 3.6 (4.8)
Trigl 0.95 (1.48) 1.30 (2.11)bb 1.17 (1.76)b 1.22 (2.04)b
a: Dutch control group [18]. Data are expressed as mean (SD). TC: total cholesterol, AI: 
Atherogenic index = TC/HDL, Trigl: triglycerides. 
Repeated measurement analyses: No differences in changes over time between the three 
groups in TC, LDL, and Trigl. 
Differences between groups in HDL and AI at baseline as described in the text. Differences 
over time: b: P < 0.05, bb: P < 0.001 vs start; c: P < 0.05, cc: P < 0.001 vs 4 years GH; 
d: P < 0.05, dd: P < 0.001 vs. ST-fu. *: P < 0.01, **: P < 0.001 LT-fu vs. controls.  
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three groups, being 7.3 (0.2) in group A, 6.0 (0.2) in group B, and 5.0 (0.2) in group 
C. From start to year 4 of GH therapy, AI decreased significantly in all three groups. A 
and C were no longer different from B, but the difference between A and C remained. 
At LT-fu, AI was the same as at ST-fu, and was lower than in controls.
BMI: Over the years there were no significant differences between the three GH 
dosage groups with regard to the standard deviations scores for BMI. BMI (kg/m2) 
was 22.6 (5.0) at end of GH, 23.3 (5.3) at ST-fu, and 26.5 (5.1) at LT-fu, a significant 
increase (P < 0.001). At LT-fu, BMI was between 20−25 kg/m2 in 15 of the 39 women 
(38.5%), between 25–30 kg/m2 in 18 women (46%) and > 30 kg/m2 in six women 
(15.5%). 
Body proportions: Although the change over time between the three GH dosage 
groups was significantly different for SH shape values (SV), the changes for SV of Biac, 
Biil, Hand and Foot were not. During GH treatment, SH SV decreased (P < 0.01), foot 
SV increased (P < 0.001), and SV of hand, Biac and Biil did not change significantly 
(P = 0.08, p = 0.44, and P = 0.86 resp.) (Figure 3). 
Between end of GH and LT-fu, SH SV in group A increased slightly, but significantly, 
while it did not change significantly in group B and C. Biac and Biil SV also increased 
after end of GH (both P < 0.001). Hand and foot shape values did not change after GH 
discontinuation. 
Multiple regression analyses
At LT-fu, the following relationships were found.
HOMA-S was not associated with any of the tested variables. HOMA-B was positively 
influenced only by BMI (B 6.5, P < 0.01), explaining 18.5% of the variability. Fasting 
insulin levels were positively associated with BMI (B 1.4, P < 0.001).
Age and systolic BP at start of GH-treatment influenced systolic BP. GH dose or 
duration was not of influence on systolic BP at LT-fu. Diastolic BP was negatively 
influenced by GH dose (B −1.0, P = 0.001), indicating that the higher GH dose, the 
lower the diastolic BP at LT-fu, corrected for the diastolic BP at start. After adding 
age at start of the GH treatment to the model, the GH dosage influence remained 
significant. Karyotype (45,X vs. variant) influenced diastolic BP, with a higher diastolic 
BP in patients with variant karyotype, with a difference of 0.86 SDS.
Serum TC and LDL were positively associated with the time-period after GH, also 
after adjustment for age. Thus, the longer the time-period after GH, the higher the 
serum TC and LDL. HDL was not associated with any of the variables tested. 
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not by GH duration (P = 0.18). Thus, the higher the dose, the greater the relative size 
of the foot. 
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Figure 3: Mean (SD) body proportions at baseline, end of GH, and long-term follow-up 
for group A (white), B (light grey), and C (dark grey). Black bars shows reference for 
untreated TS women (n = 79) with a mean age of 35.7 (0.9) years [8]. 
* P < 0.05 compared to preceding levels.
Discussion
Several years after GH, insulin sensitivity remained low, while β-cell function and 
fasting insulin levels remained high. Previously, we hypothesized that the higher insulin 
levels after GH might result from a higher BMI [22,23], as several studies showed 
a positive correlation between insulin levels and BMI in normal children and adults 
[22,23]. A positive association of BMI with β-cell function, and with fasting insulin 
levels at LT-fu several years after GH therapy supports this possible explanation. Now, 
however, because untreated young TS women have been reported to have a higher 
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S prevalence of insulin resistance and impaired glucose tolerance [24], we believe this 
phenomenon may also be related to TS. Salgin et al recently presented data of insulin 
and glucose levels in untreated TS women, aged 29.9 (16.5−46.6) years. They showed 
an insulin sensitivity of 103 (78.6)%, which is not significantly different compared to 
81.6 (46.5)% in our GH treated TS women, aged 20.0 (2.1) years [25]. Recently it was 
suggested that haploinsufficiency for an unknown X-chromosome gene (or genes) may 
be responsible for impaired β-cell function in TS [26]. Alternatively, the persistence 
of low insulin sensitivity and high β-cell function may be explained by the GH therapy 
administered. Although no association with GH dosage or GH duration was known, 
such an effect could not be ruled out. 
During GH therapy, diastolic BP had decreased significantly. Nearly five years after 
ending GH therapy, diastolic BP had increased, and was similar to pre-treatment 
levels. Systolic BP did not change during GH treatment. For untreated TS women 
there is no comparable data: in one study the untreated TS woman were older than 
our TS women [8]; in a second it was unclear whether the population studied had 
received GH [7].
It is reasonable to assume that GH treatment had a positive effect on diastolic BP, 
as the diastolic BP had decreased during and increased after end of GH therapy. This 
assumption is supported by the fact that, even several years after the GH, its effect 
on diastolic BP had been sustained: patients who had received a higher GH dose, had 
a lower diastolic BP, also after adjusting for the BP at start. The lack of significant 
difference between the GH dosage groups may be explained by a non-dose-response 
effect of GH on diastolic BP. GH-dose and duration was of no influence on systolic BP. 
The increased BMI at LT-fu can not explain the increased blood pressure, as is was 
not a significant variable. GH therapy has also been reported to lower diastolic and 
systolic BP in adult GH-deficient patients [27]. 
During the first four years of GH therapy we found a decrease in TC, LDL, and 
atherogenic index (AI), and an increase in HDL and triglycerides. Six months after 
GH, TC, LDL and HDL had increased, resulting in a decreased AI. Similar results were 
reported after GH in GH-deficient patients [28]. There was a similar trend in serum 
lipid levels in small children born small for gestational age during and six months 
after GH treatment [29]. Several years later, at the LT-fu, serum TC, LDL and HDL had 
further increased, resulting in higher TC, but also higher HDL levels than in controls. 
However, LDL and the AI remained lower than in controls. The TC, HDL and LDL levels 
were similar to those reported in untreated TS women aged 33.2 (7.9) years [30]. A 
longer time-period after end of GH was associated with higher TC and LDL levels. This 
finding supports the hypothesis that GH may have had protective benefits in TS girls, 
which were still noticeable several years after ending GH treatment, as the AI was 
lower than in controls. 
binnenwerk_banink.indd   144 20-8-2006   12:53:44
145
C
ha
pt
er
 7
Lo
ng
-t
er
m
 f
ol
lo
w
-u
p 
af
te
r 
G
H
 t
he
ra
py
 i
n 
T
SBMI increased gradually during and after GH therapy. At an average age of 20, 
fewer than 40% of the TS women had a normal BMI (below 25). The average BMI of our 
TS group was similar to that of an untreated adult group of TS women, although the 
age difference was 7−15 years [7,8]. A large study in the U.S.A. (n = 2468) reported 
that the BMI SDS in girls with TS increased with age, starting approximately at age 
nine [31]. The authors did not find any influence of GH therapy on the magnitude 
of increase. These findings suggest that mechanisms specific for TS are responsible 
for age-related increase in BMI SDS. In a randomized placebo controlled study in 
TS girls by Gravholt et al, two months of GH therapy significantly reduced fat mass 
(FM), and increased lean body mass (LBM), whereas BMI remained unchanged [32]. 
Unfortunately, in our study we did not investigate body composition. 
Previously, our group reported a moderate improvement in the disproportion 
between height and sitting height (SH), and a further increase in the disproportion 
between foot length and height. After a GH duration of nearly nine years, up to adult 
height, we can confirm these earlier reports. The disproportion between SH and 
height nearly normalized, whereas disproportion between hand, biacromial diameter 
(Biac), biiliacal diameter (Biil), and height remained unchanged during GH therapy. 
The disproportion of the foot increased during GH therapy, as stated previously. While 
it was not possible to test this statistically, untreated adult TS women seemed to 
have larger disproportion of Biac and Biil (Figure 3)[8]. A possible explanation of this 
discrepancy may be a GH effect. Although shape values of Biac and Biil did not change 
significantly during the years of GH treatment, GH therapy may have prevented 
deterioration. Another possibility may be measurement errors, as the bodily fat may 
influence the measurements. However, the untreated women reported a BMI similar 
to that of our TS population. The increased BMI also may be responsible for the 
differences between measurements of Biac and Biil noted during ST-fu and LT-fu. 
The increased proportion between height and sitting height at LT-fu may be 
due to further growth of the spine after GH and to a higher estrogen dose. Another 
explanation may be, again, the increased BMI, which led to more bodily fat on the 
buttocks. In untreated adult women there was also a disproportion between foot 
length and height [8], and in our GH-treated TS women there was a GH dosage effect. 
We can thus confirm our previous conclusions that the disproportionate growth of 
the feet is part of the natural development in TS, albeit influenced by higher GH 
dosages.
When reviewing the results of this study, one has to consider the following. 
Firstly, as not all participants of the GH trial participated in the LT-fu, there may be 
a selection bias. This seems unlikely, however, as the results of BP, fasting insulin, 
glucose, and serum lipid levels of the LT-fu participants during GH therapy, were 
similar to those previously reported for the whole group on these parameters [11]. 
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S Secondly, it would have been ideal to compare these results to those in untreated 
young TS women. However, as most countries have regarded GH therapy as an 
accepted treatment in TS for several years, it almost impossible to find an age-
comparable untreated TS population; in general, most studies in untreated TS women 
are performed in an older TS population. 
On the basis of our results, we conclude that, as well as height gain, GH therapy 
brings women with TS additional benefits regarding diastolic BP, serum lipids, and 
some body proportions. Nearly five years after GH the favourable effect of GH 
on serum lipids was still noticeable, but waning. The effect on diastolic BP had 
disappeared, as it had returned to pre-treatment levels. The lower GH-induced 
insulin sensitivity, however, remained unchanged, possibly due to having TS. 
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e Abstract
In Turner’s syndrome (TS), an increased risk for cardiovascular malformations exists, 
including aortic dilation of unknown cause. Abnormal biophysical wall properties may 
play an important role. Magnetic resonance imaging has been successfully used to 
assess aortic size and wall distensibility. 
The aim of this study was to assess aortic biophysical properties and dimensions in 
TS. 
Thirty-eight former participants of a growth hormone (GH) dose-response study in 
TS (mean age 12 ± 2 years, mean body surface area 1.7 ± 0.2 m2) and 27 controls (mean 
age 21 ± 2 years, mean body surface area 1.8 ± 0.1 m2) were enrolled. Previously, 
patients had been assigned to 1 of 3 groups treated with different GH-dosages: group 
A (0.045 mg/kg/day), group B (0.067 mg/kg/day), and group C (0.09 mg/kg/day). 
All underwent magnetic resonance imaging ≥ 6 months after GH discontinuation 
to determine aortic dimensions and distensibility at 4 predefined levels: (1) the 
ascending aorta, (2) the descending aorta, (3) the level of the diaphragm, and (4) the 
abdominal aorta. 
Patients had larger aortic diameters at all but level 4 and tended to have reduced 
distensibility at level 3. Distensibility in group A was significantly less compared with 
that in group C at level 4. Compared with controls, patients in group A had larger 
aortic diameters at all but level 4 and reduced distensibility at level 4. The results for 
patients in groups B and C were not different from those for controls. 
In conclusion, patients with TS formerly treated with GH have dilated aortas and 
signs of impaired wall distensibility. The severity of abnormalities seems related to 
the GH-dose, with a beneficial effect of a larger GH-dose on the abnormalities.
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Structural cardiovascular malformations occur in up to 76% of patients with the 
Turner’s syndrome (TS) [1,2]. Coarctations of the aorta and bicuspid aortic valve are 
most common and represent, respectively, 25% to 30% and 25% to 35% of cardiovascular 
malformations in TS [1-3]. Aortic dilation has been regarded as less common (6.5%) 
[2]. However, in recent studies using magnetic resonance imaging (MRI), aortic dilation 
was found in 25% to 50% of patients with TS and cardiovascular malformations [1,3,4]. 
The most common non-structural cardiovascular disease in TS is arterial hypertension 
[5]. The number of reports on aortic dissection in TS is increasing [2,6]. A function of 
the large arteries is the transformation of pulsatile flow into continuous flow, known 
as the “Windkessel” phenomenon. This phenomenon is determined by the biophysical 
properties of the aortic wall. Biophysical wall properties can be assessed using non-
invasive imaging tools, allowing the in vivo quantification of the effects of altered 
arterial wall composition [7]. MRI has been proven accurate and reproducible for this 
purpose [7]. The aim of this study was to assess biophysical properties and dimensions 
of the aorta in TS.
Methods
Patients
For this prospective MRI evaluation study, we approached all 64 participants who had 
completed our previous growth hormone (GH) dose-response study in TS [8]. Thirty-
eight patients (59%) agreed to participate. During the GH trial, biosynthetic human 
GH (Norditropin, Novo Nordisk A/S, Bagsvaerd, Denmark) was given in 3 different 
dosages: patient in group A received 1.3 mg, those in group B 2 mg, and those in 
group C 2.7 mg/m2 body surface area (BSA)/day (approximately 0.045, 0.067, and 
0.09 mg/kg/day, respectively), as described previously by van Pareren et al [8]. To 
induce puberty, micronized 17β-estradiol was given orally from the age of 12 years, 
after ≥ 4 years of GH treatment. At the start of GH therapy, diastolic blood pressure 
was significantly lower in group C than in the other 2 subgroups, resulting in a lower 
mean blood pressure in group C than in group A. GH therapy was continued until final 
height. All patients had discontinued GH treatment for ≥ 6 months. 
Twenty-seven healthy age-, gender- and BSA-matched controls were included. 
Height, weight and blood pressures were measured, and BSA was calculated. Apart 
from the generally accepted contraindications for MRI, no exclusion criteria were 
used. The medical ethics committee approved MRI evaluation. Written informed 
consent was obtained from all participants.
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Figure 1: MR angiography of the aorta in TS: a typical example. 
A. The predefined levels of measurement: 1. ascending aorta. 2. descending aorta. 3. level 
of the diaphragm ,and 4. abdominal level 
B. Aortic area (mm²) variation over the cardiac cycle
MRI protocol
Imaging was performed on a GE 1.5-T CV/i scanner with software version 9.1 
(GE Healthcare, Milwaukee, USA) using a 4-channel, phased-array torso coil. 
An anatomic overview of the area of interest was obtained in multiple directions 
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gated, fat-suppressed, 2-dimensional, single-shot, steady-state, free precession 
technique. These images were used for planning subsequent scans. Images of the 
aortic anatomy were obtained for reference using a high-resolution magnetic 
resonance 3-dimensional angiographic protocol and a double dose of gadolinium-
diethylenetriamine pentaacetic acid (0.2 mmol/kg, Magnevist, Schering AG, Berlin, 
Germany). Flow measurements were performed using a standard 2-dimensional flow-
sensitized scan. The scans were planned perpendicular to the aorta at 4 predefined 
locations: (1) the ascending aorta at the level of the pulmonary artery bifurcation, 
(2) the descending aorta at the level of the pulmonary artery bifurcation, (3) the 
descending aorta at the level of the diaphragm, (4) the abdominal aorta at the level 
of the superior mesenteric artery (Figure 1). The flow sensitivity of the sequence was 
set to 180 cm/s (and increased if phase aliasing occurred) and the in-plane spatial 
resolution to 1 mm, with a 256 x 256 scanning matrix [7]. Temporal resolution was 
approximately 50 ms, and 30 cardiac phases were reconstructed retrospectively [7]. 
Breath-hold time varied between 25 to 40 seconds per measurement depending on 
heart rate. Imaging parameters were as follows: 2-dimensional fast spoiled gradient-
echo, repetition time 6 to 7 ms, echo time 3 ms, flip angle 20°, readout bandwidth 90 
kHz, slice thickness 6 mm, and 4 lines/segment. A fifth measurement was performed 
through the sinus of Valsalva to quantify aortic valve gradients. During each flow 
measurement, peripheral blood pressure was measured at the level of the brachial 
artery using a sphygmomanometer cuff. 
Image analysis and calculations
Flow images were quantitatively analyzed using MEDIS Flow analysis software version 
2.0 (MEDIS Medical Imaging Systems, Leiden, the Netherlands). Vessel areas were 
manually drawn for each cardiac phase (30 phases), and maximal and minimal aortic 
areas were selected (Figure 1). Distensibility (10ˉ³ mm Hgˉ¹), defined as the relative 
area change for a pressure increment, was calculated by means of the following 
equation [9]: 
D = (Amax − Amin) / (Amin x [Pmax − Pmin]), 
where D is distensibility, Amax is the maximal (systolic) aortic area (square 
millimeters), Amin is the minimal (diastolic) aortic area, Pmax is systolic blood pressure 
(mm Hg), and Pmin is diastolic blood pressure. Mean blood pressure was calculated 
using the following equation: mean blood pressure = ([2 x Pmin] + Pmax) / 3.
Aortic diameters (square millimeters), aortic diameters indexed for BSA 
(millimeter per square millimeter), and the ascending/descending aortic diameter 
ratio were calculated using vessel areas. Values outside the mean ± 2 SDs range 
from our controls were considered abnormal. Pressure gradients were calculated 
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a maximal flow velocity of 3 m/s (gradient > 36 mm Hg) was regarded as indicating 
an aortic valve stenosis of importance. A coarctation of the aorta was defined to be 
hemodynamically important in the presence of a pressure gradient > 20 mm Hg (on 
the basis of the measurement of maximal flow velocity). 
 
Statistical analysis
Analysis was performed using SPSS statistical software version 11.5 (SPSS, Inc., 
Chicago, Illinois). Results are expressed as mean ± SD. A p value ≤ 0.05 was considered 
to indicate significance unless specified otherwise. Differences in aortic diameter and 
aortic distensibility between patients and controls were tested using the independent 
Student’s t-test and analysis of covariance (with correction for systolic and diastolic 
blood pressures), respectively. To deal with multiple comparisons a p value ≤ 0.0167 
was considered to indicate significance when a GH dosage group was compared with 
the controls. Differences among dosage groups were tested using analysis of variance 
for diameters and analysis of covariance (with correction for systolic and diastolic 
blood pressure) for distensibility. Two dummy variables were designed to distinguish 
among dosage groups. We corrected for multiple group comparisons using Bonferroni’s 
method. Spearman’s correlation coefficients were calculated for the assessment of 
bivariate correlations.
Results
Patients 
The 38 patients with TS included in the present study were a representative sample of 
the original population on the basis of voluntary participation in this MRI evaluation. 
One patient previously received metal implants during scoliosis surgery and was 
excluded from final analysis because of substantial MRI artifacts. Characteristics 
of patients and controls are listed in Table 1. Among subgroups, differences were 
found only for final height and blood pressure (Table 1). Mean plasma levels of high-
density lipoproteins, low-density lipoproteins, triglycerides, apolipoprotein-A1, and 
apolipoprotein-B were normal and did not differ among subgroups (data not shown). 
Cardiac histories showed bicuspid aortic valve in 10 patients (26%), tricuspid 
aortic valves in 25 patients (66%), and inconclusive valve anatomies in the remaining 
3 patients (1 in each GH subgroup). Bicuspid valves were diagnosed in 3 patients 
in group A, 5 patients in group B, and 2 patients in group C (P = NS). In all but 1 
patient, the aortic valve pressure gradient was < 35 mm Hg. One patient had severe 
aortic valve stenosis (Doppler peak velocity 5 to 6 m/s). One type 2 atrial septal 
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edefect had been surgically closed. Three other patients underwent surgical repair for 
aortic coarctation, with a residual but stable Doppler gradient of 15 to 20 mm Hg in 1 
patient.
Table 1: Characteristics of patients and controls
Group A
n = 13 
(35%)
Group B
n = 13 
(35%)
Group C
n = 11 
(30%)
Total Patients 
n = 37 
(100%)
Controls
n = 27
Age (years) 20 ± 2 20 ± 2 19 ± 2 20 ± 2 21 ± 2
Height (cm) 158 ± 7* 164 ± 6* 165 ± 6*† 162 ± 7* 172 ± 7
Height SDS‡ −1.7 ± 1.2* −0.7 ± 0.9* −0.5 ± 1.0*† −1.0 ± 1.2* 0.6 ± 1.1
Height gain (cm)§ 12 ± 4 15 ± 4 18 ± 7 15 ± 5 − 
Height gain SDSІІ 1.7 ± 0.7 2.6 ± 0.8 2.0 ± 1.1 1.6 ± 0.9 − 
BSA (m²) 1.7 ± 0.2 1.8 ± 0.2 1.7 ± 0.1 1.7 ± 0.2 1.8 ± 0.1
Systolic blood pressure (mmHg) 129 ± 17* 116 ± 8† 113 ± 12† 119 ± 15 115 ± 10
Diastolic blood pressure (mmHg) 77 ± 12* 69 ± 8 64 ± 9† 70 ± 11* 64 ± 9
Mean blood pressure (mmHg) 94 ± 13* 84 ± 7 80 ± 10† 86 ± 12* 81 ± 9
Duration GH-Therapy (years) 9 ± 1 8 ± 3 9 ± 2 9 ± 2 − 
GH-discontinuation (years) 5 ± 2 5 ± 2 4 ± 2 5 ± 2 − 
Estrogen-Therapy (years) 8 ± 2 7 ± 2 6 ± 2 7 ± 2 − 
* Statistically significant difference compared to controls. † Statistically significant difference 
compared to group A. ‡ Height for age: references healthy Dutch girls [24]. § Final height − 
projected adult height at start of GH-treatment (calculated using the Lyon equation) [8]. ІІ Final 
height SDS − height SDS at start GH therapy: references untreated Turner girls [25].
Aortic anatomy
In 5 patients, anatomic aortic coarctations were diagnosed on MRI. Of these patients, 
2 had had previous surgical coarctectomies. In 1 patient, the aortic coarctation had 
not previously been diagnosed. Pressure gradient of importance were found in 2 of 5 
patients (27 and 28 mm Hg). In a sixth patient, tapering of the descending thoracic 
aorta over a length of about 8 cm starting at the isthmus was observed. One patient 
had a right aortic arch. Peak velocity measurement at the sinus of Valsalva in the 
patient with known severe aortic valve stenosis was > 5.5 m/s (maximal setting) and 
< 3.0 m/s in all others. No pathology was found in controls.
Aortic diameters
The patient with severe aortic valve stenosis was excluded from analysis of ascending 
aortic diameters, and the 2 patients with aortic coarctations with gradients > 20 mm 
Hg were excluded from the analysis of descending aortic diameters. All 3 were 
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e excluded from the analysis of the ascending/descending aortic diameter ratio. Aortic 
diameters are listed in Table 2. Absolute ascending aortic diameters were dilated 
(greater than the mean +2 SDs in controls) in 11 patients (30%), and diameters indexed 
for BSA were dilated in 18 patients (49%). Ascending/descending aortic diameter 
ratios were larger in patients (1.5 ± 0.3 in patients vs. 1.4 ± 0.1 in controls, P = 0.05). 
In 13 patients (35%), this ratio was abnormally large (greater than the mean + 2 SDs in 
controls). No differences among subgroups were found.
Table 2: Aortic diameters (mm/m²).
Controls Total patients Group A Group B Group C
Level 1 15.2 ± 1.2 
n = 27 (100%)
    17.6 ± 2.6*†
n = 36 (97%)
  17.4 ± 2.0†
n = 13 (100%)
      18.2 ± 3.3*†
n = 12 (92%)
   16.5 ± 1.6†
n = 11 (100%)
Level 2 10.9 ± 1.2
n = 27 (100%)
11.8 ± 1.9†
n = 35 (95%)
12.8 ± 2.2†
n = 11 (85%)
10.9 ± 1.6
n = 13 (100%)
11.7 ± 1.4
n = 11 (100%)
Level 3  9.6 ± 0.7
n = 27 (100%)
10.4 ± 1.2*
n = 36 (97%)
   11.2 ± 1.4*†
n = 13 (100%)
    9.8 ± 0.6
n = 13 (100%)
10.3 ± 1.0
n = 10 (91%)
Level 4    8.5 ± 0.6
n = 27 (100%)
8.7 ± 0.9
n = 34 (92%)
 9.1 ± 1.0
n = 13 (100%)
    8.5 ± 0.7
n = 10 (77%)
    8.6 ± 1.0
n = 10 (91%)
* Statistically significant difference compared to controls, absolute diameters (mm²). 
† Statistically significant difference compared to controls, diameters adjusted for BSA 
(mm/m²)
Aortic distensibility
The 2 patients with aortic coarctation were excluded from the analysis of data for 
the descending aorta. Distensibility measurements are listed in Table 3 and shown 
in Figure 2. Aortic distensibility was negatively correlated with systolic and diastolic 
blood pressure at levels 3 (systolic blood pressure r = −0.67, P < 0.001, diastolic blood 
pressure r = −0.39, P < 0.05) and 4 (systolic blood pressure r = −0.60, P < 0.001, 
diastolic blood pressure r = −0.35, P < 0.05). After correction for systolic and diastolic 
blood pressure, patients still tended to have smaller distensibility at level 3 (P = 0.07). 
Analysis of GH subgroups showed aortic distensibility corrected for blood pressure in 
group A to be smaller at level 4, with a tendency for smaller distensibility at levels 
1 (P = 0.05), and 3 (P = 0.07) compared with controls. Distensibility did not show a 
significant correlation with time duration after the discontinuation of GH treatment 
at any of the levels of measurement.
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Figure 2: Aortic distensibility per level of measurement. 
GH groups: Con = controls, A = 0.045 mg/kg/d, B = 0.067 mg/kg/d, C = 0.09 mg/kg/d. 
* Statistically significant difference compared to controls. † Statistically significant 
difference compared to group A . ‡ Statistically significant difference compared to controls 
adjusted for diastolic and systolic blood pressures. § Statistically significant difference 
compared to group A adjusted for diastolic and systolic blood pressures
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Controls Total patients Group A Group B Group C
Level 1 5.3 ± 1.2
n = 27 (100%)
   4.7 ± 2.3*
n = 36 (97%)
   4.1 ± 1.7*
n = 13 (100%)
 4.7 ± 2.5
n = 13 (100%)
5.5 ± 2.7
n = 10 (91%)
Level 2  5.2 ± 1.2 
n = 27 (100%)
5.7 ± 2.4 
n = 35 (95%)
5.0 ± 2.3
n = 11 (85%)
  5.9± 2.4
n = 13 (100%)
6.3 ± 2.6
n = 11 (100%)
Level 3   7.5 ± 2.2
n = 27 (100%)
   6.4 ± 1.9*
n = 36 (97%)
   5.4 ± 2.0*
n = 13 (100%)
6.5 ± 1.5
n = 13 (100%)
    7.4 ± 1.7†
n = 10 (91%)
Level 4  8.4 ± 2.2
n = 27 (100%)
 7.3 ± 2.5 
n = 32 (86%)
      5.8 ± 2.4*‡
n = 13 (100%)
8.1 ± 2.4
n = 10 (77%)
      8.6 ± 1.9†§
n = 9 (82%)
Statistically significant difference: * compared to controls, † compared to group A, ‡ compared 
to controls adjusted for diastolic blood pressure and systolic blood pressure, § compared to 
group A adjusted for diastolic blood pressure and systolic blood pressure.
Discussion
The present study shows that patients with TS have larger aortic diameters (millimeter 
per square meter) at all thoracic levels of measurement and larger ascending/
descending aortic diameter ratios than controls. Less aortic distensibility was found 
at levels 1 and 3 before correction for blood pressure and a tendency (P = 0.07) 
at level 3 after this correction in patients compared with controls. Therefore, we 
conclude that the aorta in TS shows abnormal dimensions and signs of impaired wall 
function. Furthermore, we assessed the influence of received GH-dose on aortic 
distensibility. We discuss here the results corrected for blood pressure. Distensibility 
increased with increasing GH-dose (Figure 2), which resulted in significantly smaller 
distensibility in patients who received the smallest GH-dose compared with those 
who received the largest dose at aortic level 4. Moreover, we found group A to have 
less aortic distensibility compared with controls at level 4 and a tendency towards 
less distensibility at levels 1 (P = 0.05) and 3 (P = 0.07). No differences from controls 
were found in the other 2 subgroups. Our results point toward normalization of aortic 
distensibility with increasing GH-dose and suggest GH to have a beneficial influence 
on aortic wall properties in TS.
Previous studies have shown that mean aortic root diameter is larger in patient 
with TS than controls [1,3,10]. Dilation of the ascending aorta was found in 18% to 33% 
of patients [1,10]. Dilation and dissection most frequently (in 50% to 70% of patients), 
but not exclusively, occurred in the ascending aorta [2,11]. We found ascending aortic 
diameters to be dilated in 11 patients (30%) (greater than mean +2 SDs in controls) 
and even in 18 patients (49%) when diameter was indexed for BSA. In accordance 
with previous findings, the ascending aorta / descending aortic diameter ratio was 
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(35%) [1,4,2]. In TS, the ascending/descending aortic diameter ratio should be 
interpreted with some caution because of the frequently encountered abnormalities 
at the classic coarctation site that may influence this ratio [1,6]. Furthermore, the 
concurrent dilatation of the ascending and descending aorta, as we found in TS, may 
result in a false-normal outcome of this ratio. We conclude that mean ascending 
aortic diameters are dilated in 30% to 50% of patients with TS formerly treated with 
GH. Furthermore, we found that dilation of the aorta was not limited to the aortic 
root and/or ascending aorta but was present throughout the entire thoracic aorta. 
Abnormalities were most prominent in patients who had previously received the 
smallest GH dose. 
The number of reports on aortic dissection in TS, especially during pregnancy, is 
increasing [2,6]. Postmortem findings similar to arterial cystic media degeneration 
seen in Marfan’s syndrome have been described in TS [2,13]. Increased incidence of 
complications after surgery for coarctation has been reported in TS as a result of 
apparent friability of the aortic wall [2]. A recent study showed increased carotid-
femoral pulse wave velocity, increased carotid intima-media thickness, and a greater 
carotid augmentation index in TS [10]. These reports support the hypothesis that 
connective tissue abnormalities might play a role in TS. Our findings, especially those 
in subgroup A, bear similarity to results found in Marfan’s syndrome on aortic wall 
distensibility and support the theory that connective tissue abnormalities play a role 
in aortic disease in TS [14,15]. MRI-determined aortic distensibility has been shown to 
be decreased in a variety of cardiovascular diseases [7]. Our findings support the use 
of MRI-determined measurements for the (early) detection of aortic wall dysfunction 
and the quantification of intervention-related effects on wall function [7].
Aortic distensibility in normal subjects is negatively correlated with age, the 
progression of atherosclerosis, an abnormal lipid profile and postmenopausal state in 
women [16-18]. With increasing age, plasma levels of anabolic hormones, such as GH 
and insuline-like growth factor-I, decrease. GH replacement can reverse age-related 
catabolic changes [16]. In women, postmenopausal estrogen replacement therapy 
has been shown to reduce age-associated increases in arterial stiffness [17,18]. 
Patients with GH deficiencies show wall thickening of large arteries and a tendency 
toward decreased arterial wall compliance [19,20]. In response to GH treatment for 
GH deficiency, arterial wall thickness decreases and compliance increases [19,20]. 
Our patient subgroups did not differ in (1) age; (2) plasma levels of cholesterol, 
triglycerides, apolipoprotein-A1, and apolipoprotein-B; or (3) estrogen treatment 
protocol. Because all our patients were treated with GH, we cannot quantify the sole 
effect of estrogen replacement therapy on aortic wall distensibility in TS.
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interaction of smooth muscles, collagen, and elastin proteins. This mixture of 
elements with different elastic properties results in a nonlinear arterial pressure-
volume relation. In rats, GH was found to influence collagen metabolism and 
change the mixture of fibrous elements in the aortic wall [21]. In young rats, GH 
increased aortic extensibility [21]. In accordance with these findings, our results in 
TS indicate a positive effect of GH on aortic wall distensibility. Like others, we found 
distensibility to be negatively correlated with systolic and diastolic blood pressure 
[22]. We therefore present distensibility results corrected for blood pressure. The 
aortic pressure-diameter curve has a linear, elastin-determined and an exponential, 
collagen-determined part. An increase in blood pressure within the exponential 
part results in a decrease of aortic distensibility [23]. With aging, the curve shifts 
downward and to the right (age-related aortic dilation), through what pressure 
changes may occur in the exponential part [23]. In young subjects, like our patients, 
pressure changes are expected to occur in the linear part. However, the degenerative 
aortic wall alterations described in TS may change the age-specific behavior. 
There are only few data on degenerative alterations in TS, no quantitative data on 
progression of such alterations over time, and no data on possible changes in wall 
composition in TS in relation to GH treatment. 
On the basis of our data, we think GH treatment has a (direct or indirect) beneficial 
effect on the biophysical properties of the aortic wall in TS. Further evaluation of the 
role of GH, arterial blood pressure, and their interaction on aortic distensibility in TS 
is required. Limitations of this study are that it provides a cross-sectional evaluation 
in a population with a small age range, thus limiting analysis of age and time effects. 
This study was not designed to determine the optimal GH dose leading to normal 
aortic function or to determine the exact mechanism in which GH affects the aortic 
wall. 
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Growth hormone (GH) treatment in short children, who are not GH-deficient, seems 
conflicting. It has, however, been proven to be beneficial for growth velocity and 
adult height in short children born small for gestational age (SGA) and children with 
Turner Syndrome (TS) [1-9], the two populations described in this thesis. 
In the present doctoral dissertation, various aspects of GH treatment have been 
described that were beyond the effects of GH treatment on height. Until adult height, 
the short SGA children received 1 or 2 mg GH/m2/day, and TS girls received 1.3, 2 or 
2.7 mg GH/m2/day. 
Overall, this thesis focuses on the following: 1. circulating IGF-I levels during and 
after GH-administration (chapters 2 and 3); 2. quality of life shortly before and after 
reaching adult height (chapter 4 and 5); 3. pubertal development in TS both near the 
end of GH and after termination (chapter 6); and 4. on sequel effects of GH treatment 
in TS several years after end of treatment (chapter 7 and 8). In this chapter our 
main findings are presented, compared and discussed, followed by methodological 
considerations. 
The effects of long-term GH treatment on free-dissociable IGF-I
GH acts on peripheral organs such as the liver to stimulate production of IGF-I, which 
is synthesized by the liver and, to a lesser extent, by many non-hepatic tissues. In the 
circulation, IGF-I is bound mainly to IGF-binding proteins (IGFBP), six classes of which 
have been identified (IGFBP- 1 to − 6) [10]. These binding proteins prolong plasma 
half-life and modulate the metabolic action of IGF-I. The major carrier protein of 
IGF-I in the circulation is GH-dependent IGFBP-3, which normally accounts for more 
than 90% of the IGF-binding [11]. Under normal circumstances, less than 1% of the 
total plasma IGF-I pool is considered to be present in the unbound free form, which 
is also the biologically active form [12,13]. This free IGF-I exchanges rapidly with the 
tissue compartments [10]. 
Many organs and tissues contain IGF-I receptors. IGF-I plays a significant role 
in many conditions, as it does during normal organ development. While it is also 
involved in tissue function and maintenance [14], IGF-I may also have a role during 
pathophysiological processes such as atherosclerosis and diabetes mellitus [15,16]. 
As GH stimulates IGF-I production, GH-treatment may add to its growth-promoting 
effects. 
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under strictly controlled conditions, we used the DSL IRMA, which employs solid-phase 
antibodies directed against unbound IGF-I. It has been suggested that this assay in 
fact determines the sum of truly free IGF-I and readily IGFBP-dissociable IGF-I, which 
has been hypothesized to represent a more biologically relevant pool than free IGF-I 
alone [12]. 
We also established a normative range of values for serum free IGF-I. Serum 
samples were collected from healthy children who underwent minor surgery (116 
girls and 211 boys, aged 0−17 years). Serum free IGF-I levels in healthy boys and girls 
appeared to increase with age, and were higher in prepubertal girls than in boys, 
which is in agreement with earlier reports [12,13,17].
We compared free IGF-I levels in sera obtained after an overnight fast with those 
derived in the non-fasting state, using 13 healthy adult volunteers working in our 
department. No significant differences were found, which was in agreement with 
a previous report showing that, despite a marked elevation in IGFBP-1, overnight 
fasting did not alter circulating free IGF-I levels [18]. 
Most samples were analyzed at the end of the study, several years after they had 
been collected. Although our experience suggests that IGF-I and IGFBP-3 in EDTA 
plasma or serum is very stable − the values do not change significantly even after ten 
years of storage at −80°C − we did not have an opportunity to examine the stability 
of free IGF-I after long-term storage. However, we obtained similar results with free 
IGF-I when we repeated the tests after a year of storage.
— SGA —
We found that untreated short SGA children, either with or without GH-deficiency 
(GHD), have normal free IGF-I levels. Total IGF-1 and IGFBP-3 levels, however, were 
significantly lower than normal, which is in line with previous reports [19-22]. As 
lower free IGF-I levels have been reported in untreated GHD children and adults, 
[12,17,23], the pathophysiology of short stature in GHD children may be different 
from that in SGA subjects with GHD. 
Under several conditions with primary abnormalities in GH secretion (e.g. 
acromegaly and GHD), there is usually a close relationship between serum free IGF-I 
levels, total IGF-I levels and the total IGF-I/IGFBP-3 molar ratios [24]. In short SGA 
children, however, these levels differed from each other with regard to direction 
and magnitude. At baseline, total IGF-I and IGFBP-3 levels were significantly lower 
than controls, but free IGF-I levels were normal. Neither was there any correlation 
between free IGF-I SDS and total IGF-I SDS. 
This discrepancy between free and total IGF-I in short SGA children may be 
explained by subtle alterations in the binding of IGF-I to its various binding proteins 
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binding). Another explanation may be that short stature in SGA is caused by genetic 
variations in the IGF-I gene or IGF-I receptor gene that alter IGF-I binding or IGF-I 
signaling pathway. Several polymorphisms in the IGF-I gene and its receptor have 
been reported in short SGA children [25, 26]. 
Although free IGF-I increased during GH-treatment, it remained largely within 
the normal range, whereas total IGF-I increased to a greater extent than free IGF-1, 
the mean reaching the +2 SDS. In short SGA children we did not find a relationship 
between total IGF-I and growth response or adult height, the major bioactive 
endpoint of IGF-I. In contrast, baseline free IGF-I levels predicted the efficacy of 
GH therapy, in terms both of short-term growth response and of adult height. When 
predicting growth response to GH treatment in short SGA children, free IGF-I levels 
should therefore be taken into account before GH-therapy starts.
Untreated short children born SGA, either with or without GHD, had normal 
free IGF-1 levels, whereas total IGF-I and IGFBP-3 were lower. 
In GH-treated SGA children, baseline serum free IGF-I was a better predictor 
for short term growth response and adult height than were total IGF-I, IGFBP-3, 
or total IGF-I/IGFBP-3 molar ratio.
— Turner Syndrome — 
In untreated girls with TS, serum free IGF-I levels were as low as total IGF-I and 
IGFBP-3. The GH-IGF axis was similar to that reported in GHD, a primary abnormality 
in the GH secretion, showing a close relationship between serum free IGF-I levels, 
total IGF-I levels, and total IGF-I/IGFBP-3 molar ratios [24]. 
Though mean free IGF-I levels increased during GH therapy, they stayed within the 
normal range. Mean total IGF-I SD-scores were higher than the free IGF-I SD-scores, 
and even exceeded the upper normal range. While similar observations have been 
reported for GH-treated children and adults with GHD, there are also conflicting 
reports [12,24,27,28]. 
Additionally, in GH treated TS girls, total IGF-I levels and the total IGF-I/IGFBP-3 
molar ratio were no proper representatives of free IGF-I levels. The predictive value 
of serum total IGF-I and this ratio is much higher for several biological endpoints of 
IGF-I bioactivity in TS girls, than that of free IGF-I. Besides measuring serum total 
IGF-I levels, measuring serum free IGF-I levels does not seem to play an additional 
role in predicting growth response, adult height, or insulin sensitivity in girls with 
TS. In this respect it is important to emphasize that the kinetics of free IGF-I in the 
•
•
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ncirculation differ strikingly from those of total IGF-I. Under normal circumstances, 
free IGF-I has a very short half-life (about 14 min) compared to the much larger 
pools of binary and ternary complex IGFBP-bound IGF-I. GH-induced changes 
in plasma levels of IGFBP-1, −2, −3, and −5 may have different effects on steady-
state concentrations of free-IGF-I and total IGF-I levels. A GH-dose-dependent 
rise in free IGF-I levels may be compensated by increased clearance of free-IGF-I 
from the circulation to tissue compartments that results from the very short half 
life of free IGF-I. Gravholt et al also suggested that higher clearance of free IGF-
I from the circulation might explain the paradoxical inverse correlation between 
free IGF-I levels in adult TS patients and the degree of IGFBP-3 proteolysis 
[29]. The recently developed sensitive IGF-I kinase receptor activation assay 
(KIRA) [30], which enables the determination of IGF-I-receptor activating IGF-I 
concentrations, may help clarify the bioactive capabilities of circulating IGF-I levels. 
The extent of low free dissociable IGF-I in untreated girls with TS is the same as 
that of total IGF-I and IGFBP-3 levels.
In GH-treated girls with TS, total IGF-I and the total IGF-I/IGFBP-3 molar ratio 
have a much higher predictive value for several biological IGF-I endpoints, 
specifically IGF-I bioactivity, than free IGF-I levels.
Free IGF-I in short SGA versus TS children 
In both study populations, GH therapy increased serum levels of free IGF-I, total 
IGF-I and IGFBP-3 to a similar extent. However, girls with Turner syndrome received 
a higher GH dose than the SGA children. While baseline free IGF-I helped predict 
short-term growth response and adult height In SGA children, in Turner girls it did not 
help to predict bioactive outcome of IGF-I. In Turner girls, total IGF-I and the total 
IGF-I/IGFBP-3 molar ratio seem to have a much higher predictive value for several 
biological endpoints of IGF-I bioactivity, whereas such a relationship between total 
IGF-I levels and growth response or adult height was lacking in short SGA children. 
To understand the differences in the results between the SGA and the Turner 
population, it is necessary to understand the basic etiology of short stature in both 
populations. It is widely suggested that the characteristic Turner features are caused 
by haploinsufficiency of specific homologous X-Y genes which escape X-inactivation. 
Haploinsufficiency of the SHOX gene (short stature homeobox containing gene on the 
X-chromosome) leads to skeletal abnormalities and growth failure [31-33]. Similarly, 
on the basis of the phenotypical differences between patients with Leri-Weill 
dyschondrosteosis (haploinsufficiency of SHOX) and patients with Turner syndrome, 
•
•
binnenwerk_banink.indd   167 20-8-2006   12:53:48
168
C
ha
pt
er
 9
G
en
er
al
 d
is
cu
ss
io
n it has been concluded that haploinsufficiency of the SHOX gene accounts for most, 
but not all of the TS height deficit [34]. However, it has yet to be established which 
mechanisms underlie the growth failure caused by haploinsufficiency of SHOX and/or 
other factors. 
To attain normal height, girls with TS required a higher GH dose than short SGA 
children (1.3 mg/m2/day vs. 1 mg/m2/d). However, while a higher dose of 2 or 
2.7 mg/m2/d was even more beneficial in Turner girls, a higher dose in short SGA 
children (2 mg/m2/d) did not further increase adult height [3,4]. Turner girls attained 
near normal heights with supraphysiological GH and IGF-I levels, indicating that they 
needed higher levels of GH and IGF-I to attain a normal growth effect. This indicates 
that, as suggested previously, a role in the short stature of Turners syndrome may 
be played by lower sensitivity to growth factors [35,36], which may originate pre- 
or post- IGF-I or GH-receptor. A post-receptor defect within the cell seems more 
likely as, for an optimal response, both IGF-I and GH need to be in supraphysiological 
levels. Furthermore, TS is a chromosomal disorder which affects some or all of the 
body cells. 
The GH-IGF axis in Turner girls responded as expected during GH-treatment 
(similarly to GHD patients). In addition, 76% of the adult height in TS could be 
predicted by auxological and treatment-elated parameters [4]. The lack of association 
between free IGF-I levels and IGF-I bioactive outcome parameters such as height can 
be explained by an increased shift to the tissue compartments caused by the very 
short half-life of free IGF-I. Total IGF-I is a better predictor in GH-treated girls with 
Turner syndrome, as it has a longer half-life in the circulation.
In contrast, with respect to their etiologies and to prenatal and postnatal growth 
disorders, the group of SGA children is a very heterogeneous group (Chapter 1). A 
variety of factors are therefore likely to contribute to the lack of postnatal catch-
up growth − making it difficult to draw a single unequivocal conclusion. Previously, 
it was suggested that a role in the etiology of the prenatal and postnatal growth 
retardation might be played by genetic factors, such as deletions or polymorphisms in 
the genes encoding for growth factors or growth factor receptors. But while several 
polymorphisms in the IGF-I gene and its receptor have been reported in short SGA 
children [25,26], none has led to the exact etiology of short stature in SGA. 
It has also been suggested that subtle alterations in the binding of IGF-I to its 
various binding proteins (eg changes in enzymatic proteolysis of IGFBP-3 and, as a 
consequence, reduced IGF-I binding), may lead to alteration of the ratio of total and 
free IGF-I, and thus bioactive IGF-I. 
IGFBP-3 is not only the major carrier protein for IGF-I, it also presents IGF-I to 
its receptor, regulates IGF-I trafficking, and has IGF-I independent effects on cells. 
Besides free IGF-I, IGFBP-3 was a predictor for adult height in the GH-treated SGA 
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IGFBP-3, thereby explaining the combination of normal free IGF-I levels and low total 
IGF-I levels. Alternatively, it may also provide less IGF-I at its receptor, resulting in a 
smaller effect. However, this theory would not explain the lower levels of total IGF-I.
The various etiologies of shortness in SGA children may explain why it was possible 
to predict only 42% of adult height [3]. However, when baseline free IGF-I was 
included in the prediction model, the prediction of adult height increased to 55%, 
while total IGF-I and IGFBP-3 were of no predictive value. This suggests that binding 
of IGF-I to its binding proteins may be different in short SGA children.
The response of the GH-IGF axis in short SGA children during GH-treatment 
was not as predictable as in TS girls. The suggested shift of free IGF-I to the tissue 
compartments, as might have occurred during GH treatment in TS, could not be ruled 
out. Nevertheless, free IGF-I levels may play an important role in future evaluation of 
GH therapy in short SGA children, and possibly when further exploring the etiology of 
shortness in SGA.
Quality of life after long-term GH therapy
A fundamental goal of medical intervention, and thus of GH-treatment, is to improve 
quality of life (QoL), which is conceptualized as a multidimensional construct 
encompassing several domains, including physical, emotional and social well-being. 
In both our study populations, health-related QoL (HRQoL) was measured using 
standardized and validated questionnaires, of which there are two different kinds: 
generic questionnaires and disease-specific or disorder-specific questionnaires. 
A generic questionnaire allows for screening in a healthy population, and enables 
standardized comparisons across health conditions. However, it may not be as 
responsive to changes in disease- or disorder-specific symptoms, and typically does 
not measure specific symptoms and treatment (side) effects relevant to particular 
disease or disorder group. Several studies have shown that the use of a generic 
questionnaire for a special disorder or disease makes it possible to miss relevant QoL 
issues [37-40]. In contrast, specific questionnaires may be more sensitive to specific 
clinical changes in patients with a particular disease or disorder, and may be more 
informative in specific patient populations. Unfortunately, specific questionnaires are 
unable to provide comparisons across populations with a specific disease or disorder, 
or in healthy populations.
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Using a specific self-report questionnaire (TNO-AZL-Child-QOL-Short stature 
(TACQOL-S)) after long-term GH-therapy, our study showed that SGA children had 
a better health-related QoL (HRQOL) regarding ‘physical abilities’, ‘contact with 
adults’ and ‘body image’ than untreated SGA adolescents. However, when a generic 
questionnaire such as the child health questionnaire (CHQ) was used, there were 
no such differences. As stated previously, if a generic questionnaire were used for a 
special disorder or disease, relevant QoL issues might be missed [37-40]. The items 
of the TACQOL-S are more sensitive for effects of short stature on QoL outcome. 
Our study shows that in addition to generic QoL measurements, height-specific QoL 
measurements are very informative in growth studies. 
A generic self-report questionnaire showed that GH-treated and untreated SGA 
adolescents had a near-normal QoL. However, whereas the GH group had been 
extremely short at start and normalised during GH treatment, the untreated group 
had never been as short as the GH group, and had a height SDS just below the normal 
range for many years, and just within the normal range at the time of the QoL 
evaluation.
Adults were less surprised when they heard the actual age of the GH-treated 
adolescents than when they heard the actual age of the untreated adolescents. The 
adolescents in the GH-group felt that they were treated more age-appropriately by 
adults than those in the untreated group. Also in the GH-treated SGA population, 
the closer their height was to that of their parents, the happier they were with their 
body. SGA adolescents who were taller experienced fewer behaviorally related social 
problems. These data emphasize the importance of feeling equal to one’s peers. 
It has been suggested that psychological support in learning to cope with the 
psychosocial problems related to short stature would be a less invasive alternative to GH 
treatment. To our knowledge, however, no structural psychological program has yet been 
proved either to be effective or to be of practical use, whereas GH treatment in SGA 
has not only improved participants’ adult height, but has also significantly reduced total 
problem behaviour, externalising behaviour and self perception [41,42]. It also has been 
shown that, over time, the taller children showed less problem behaviour [41]. 
The disorder-specific TACQOL-S showed that GH-treated children born SGA had 
a significantly better quality of life with regard to physical abilities and contact 
with adults, and fewer problems with body image than untreated children born 
SGA. 
After long-term GH therapy, CHQ, a generic QoL, showed that adolescents had a 
near-normal HRQoL.
In addition to generic QoL measurements, height-specific QoL measurements 
should be used in growth studies. 
•
•
•
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Young TS women have a normal or even better HRQoL than normal Dutch age-matched 
women. This HRQoL was measured after most of them had reached a height within the 
normal range and after they had started bodily feminization at an age comparable to 
that of their peers. 
As stated previously, in addition to a generic QoL instrument, a height-specific 
QoL instrument should be applied in growth studies to measure specific relevant 
QoL issues. At the time of the QoL-evaluation, the TS population, had to use ‘adult’ 
QoL-questionnaires, as the mean age was nearly 20 years. A height-specific QoL 
questionnaire was not available for adults. In order to assess the therapy’s possible 
influence on the QoL of young TS women, we used an additional questionnaire 
containing subjective parameters. This included questions such as ‘Are you satisfied 
with your adult height?’ and ‘Are you satisfied with your breast development?’. A 
number of HRQoL-scales were positively influenced by satisfaction with adult height 
and/or breast development. 
Similarly, social functioning was positively influenced when physical appearance 
did not lead to an increase in feelings of insecurity − data which helps emphasize the 
importance of feeling equal to one’s peers. GH and estrogen treatment brought about 
normal height and breast development in most of the girls [4,43], narrowing the 
differences with their peers. Because short stature and delayed pubertal development 
can have a significant negative influence on HRQoL [44,45], we hypothesize that 
GH treatment and age-appropriate puberty induction may normalize HRQoL in TS 
women.
Estrogen substitution may also have a direct, positive influence on several aspects 
of HRQoL. Estrogens improve motor performances and motor speed in TS [46,47], and 
may therefore increase the QoL item that applies to motor performances. Estrogens 
significantly decrease aggressive and delinquent behavior in girls with TS [48], and 
may therefore produce a better score on the HRQOL item relevant to aggressive 
emotions. All in all, we therefore hypothesize that estrogen therapy that starts at an 
appropriate age is beneficial for the HRQoL in TS women. 
On some of the scales, the TS women showed a remarkably high HRQoL. In 
Chapter 5, we discussed the possibility that they might have undergone what is 
called ‘response shift’ [49], i.e. a change in their internal standards or values. This 
phenomenon has been reported in the elderly [50], who excluded some age-related 
problems or ‘morbidity’ when assessing their susceptibility to illness. With regard to 
our study, however, we cannot say whether the relatively high HRQoL scores were 
associated with a shift in internal standards or reflected a real health effect.
As a majority of adults with TS are infertile, the consequences of infertility on the 
HRQoL may become a more prominent issue in the future of the Turner women we 
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influence on the HRQoL of women with TS, we recommend that further research be 
conducted. 
After long-term GH-treatment and puberty induction at an appropriate age, 
young women with TS have a normal HRQoL.
The relatively high scores on some of the HRQoL-scales in TS women may be 
explained by an estrogen effect, or possibly by a response shift. The latter would 
indicate that these women had acquired a different internal reference.
TS women’s satisfaction with their height and/or breast development positively 
influences several HRQoL scales, including social functioning and physical 
functioning.
GH and estrogen treatment may have positively influenced HRQoL in young 
women with TS. 
 
QoL in short SGA versus TS children 
Both in SGA adolescents and the Turner women, the data emphasize the importance 
of feeling equal to one’s peers. The generic questionnaires suggested that, after 
long term GH-treatment, both groups had a normal or near-normal QoL relative to 
a sample of the general population. This was after most patients in both groups had 
reached a height within the normal range. Additionally, using exogenous estrogen 
substitution, the TS women had started bodily feminization comparable to that of 
their peers. 
A height-specific QoL questionnaire was not available for adults. Because, at 
the time of the QoL-evaluation, the TS population was slightly older than the SGA 
population, ‘adult’ QoL-questionnaires had to be used. The SGA population could 
use the specific ‘child’ QoL-questionnaires available. As described above, we used 
an additional questionnaire containing subjective parameters to assess the therapy’s 
possible influence on the QoL of young TS women.
We cannot conclude that HRQoL had improved. This is due to the lack of baseline 
data: the GH-trials in SGA started in 1991, and those in TS in 1989, when the 
importance of HRQol as an important outcome measure was less recognized than it is 
today. The questionnaires used in both studies were developed only during early and 
mid-nineties, thus after the start of the GH-trials. Although there was an untreated 
parallel SGA group, none of the studies had included a randomized control group for 
ethical reasons. 
•
•
•
•
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untreated SGA adolescents or TS women. Very recently, Carel et al described the 
health-related quality of life (HRQoL) in GH-treated TS women [55]. While they 
found normal HRQoL in TS without any significant influence of GH treatment related 
variables, such as adult height or estimated height gain, our own data showed that 
height gain had a significant influence on ‘daily activities’ and ‘role limitations due 
to physical health problems’. Our own study showed that satisfaction with height 
and/ or breast development had a significant positive influence on several scales of 
the HRQoL. Very recently, it was reported that 18 months of GH treatment improves 
QoL in acquired or idiopathic GHD children [56].
It should be emphasized that SGA and TS affect more than height alone. While SGA 
has also been associated with lower intelligence, poor academic performance, lower 
social competence and behavioral problems [57-59], girls with TS have been described 
as more immature, having lower self-esteem, and being hyperactive [48,60,61]. As 
well the positive effect that GH-induced height gain may have on HRQoL, GH may 
influence other mechanisms contributing to the HRQoL. Recently, our group showed 
that, after long-term GH treatment, SGA children had less problem behavior and 
greater self-esteem than at start of GH treatment [62]. Over time, taller children had 
less problem behavior. 
With regard to the TS women, the lack of longitudinal data makes proof impossible. 
However, it is likely that GH and estrogen treatment improved psychosocial 
functioning, as discussed previously [63]. Also in children with GH-deficiency (GHD) 
and idiopathic short stature (ISS), positive behavioral changes were reported during 
GH treatment [42]. This indicates that GH-treatment may improve several aspects 
in short children, not only height. GH may improve QoL in children or adolescents by 
mechanisms unrelated to growth. 
GH-therapy has also been reported to improve QoL in GHD adults [64-67], thus 
supporting our hypothesis that GH is capable of improving aspects of QoL besides 
height. It being well established that the placebo effect in GH-controlled trials lasts 
only three months after start of GH treatment, this is unlikely to be a placebo effect 
[68,69].
 Although − as stated above − TS women may have undergone what is called ‘response 
shift’ [49] (i.e. a change in internal standards or values), we could not find any evidence 
of an internal shift in the SGA population studied, and therefore think it played no role 
in GH-treated SGA adolescents. There is nonetheless a slight possibility that the shorter 
adolescents experienced a response shift. This might explain the nearly normal QoL in 
the untreated SGA group, which was significantly shorter than in the GH-treated group. 
Further follow-up will show whether GH treatment also has an effect on their life 
achievements.
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which is also reflected in the development of puberty. In TS women, puberty was induced 
at an appropriate age. Because in the SGA children in our group, start, progression, and 
duration of puberty were comparable to those in the normal Dutch population [70], the 
QoL outcome was not influenced by a delayed or precocious puberty in GH treated SGA 
children.
GH may improve QoL through mechanims unrelated to growth.
Future research will show whether GH treatment also affects life achievement.
Pubertal development in TS
The main objective of estrogen therapy in girls with TS is to induce a sufficient degree 
of puberty and feminization as physiologically as possible without sacrificing adult 
height. As previously shown in chapter 5, TS women who were satisfied with height 
and/or breast development have a better QoL in social and physical functioning. We 
showed that, using a very low dose of oral estrogen therapy, the majority of Turner 
women had normal breast development, albeit with a two-year delay. As it does not 
affect adult height, the low dose makes it possible to start this estrogen regimen 
during GH therapy at an age-appropriate time [4,71]. A recent study reports that the 
administration of GH with a very low dose of estrogens (0.2 mg estradiol per month 
i.m.) at the age of 12 years enhanced height velocity more than GH alone, while also 
preserving height potential [71]. In one third of the subjects, however, this dosage 
did not bring bodily feminization. It may thus be possible to start estrogen at an 
even lower age without sacrificing adult height, and to start bodily feminization at 
an appropriate age. For estrogen therapy to have the greatest benefit on adult height 
and bodily feminization, not to mention other positive influences of estrogens, the 
optimal dosage and age of initiation should be established in further research. 
Estrogen action depends on the presence of the estrogen receptors (ERs). 
Research in hypophysectomized and oophorectomized rats has demonstrated that 
GH treatment increases the expression of ERs in breast tissue [72]. Although the 
mechanism underlying stunted growth in TS is not well understood, despite normal 
pretreatment GH levels, GH treatment improves growth velocity. Theoretically, the 
GH therapy also may have increased the amount of ERs in the breast tissue of the TS 
girls, thereby increasing the sensitivity of the breast tissue to estrogen treatment, 
which led in turn to normal breast development using a low estrogen dose. 
•
•
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than that reported in normal women of the same age (61 ml, range 37−130 ml) [73]. 
Uterine volume, length and shape were comparable to those in normal girls who had 
reached breast stage B5, and/or were aged 14−16 years. This underdevelopment of 
the uterus in the young TS women may be explained by the estrogen dose. If so − 
due to the association reported between a higher estrogen dose and greater uterine 
length, and also to the uterine length reported to be positively associated with uterine 
shape − a higher estrogen dose might lead to normal uterine dimensions in adulthood 
[74]. Alternatively, as the induction of puberty started two years after physiological 
pubertal onset, it is also possible that uterine development was delayed. Yet again, 
remaining subnormal uterine dimensions may be explained by other factors related 
to TS. 
Young women with GH-deficiency (GHD) also had a smaller uterus than normal 
women, despite GH therapy [75]. In GHD women of similar age, the uterus length 
was nearly comparable tot that of our TS women (67mm in GHD, range 47−84mm 
versus 60mm in TS, range 25−87mm respectively). This suggests that the growth and 
development of the uterus is possibly due to the influence not only of estrogens, but 
also of other factors, such as GH or IGF-I, which may act directly or indirectly by the 
expression of ER. To confirm this theory, however, further research will be required. 
Pubic hair developed much as normal, and in most girls had started to do so 
before estrogen treatment was initiated. This indicates that, despite the absence of 
ovarian androgen production, adrenarche in girls with TS proceeds normally, which is 
in agreement with earlier reports [76]. 
Turner women produce neither ovarian estrogen nor ovarian androgen. Studies 
in postmenopausal women have demonstrated that a combination of estrogen and 
androgen therapy increased well-being while providing beneficial effects on bone, 
lipids, body composition, sexual functioning, and quality of life [77-80]. The effect 
of the estrogen/androgen therapy was greater than the effect of estrogen therapy 
alone [77]. In TS women, a combination of estrogen/androgen therapy may also 
be beneficial. Indirectly, this may also be suggested by Ross et al, who reported 
improved performance of the working memory in TS girls treated with the androgen 
oxandrolone over two years [81]. The benefits of androgen therapy in women with TS 
should be clarified in future research. 
Although levels of the serum estradiol (E2) at the lowest oral estrogen dose 
were comparable with normal E2 concentrations in late pubertal and adult serum 
[82], it is evident from the lack of an increase in serum SHBG and the remaining 
high gonadotropin levels that the overall serum E2 effect was low. The lowest E2 
(5 μg/kg/d) dose suppresses LH and FSH. However, at the double E2 dose (10 μg/kg/d), 
also providing double serum E2 levels, LH and FSH levels increased. This effect may 
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or to a higher tolerance. The LH and FSH levels in postmenopausal women receiving 2 
mg estradiol per day were comparable [83] or lower [84] than the levels reported in 
our study at the adult dose of 1 or 2 mg/d estradiol. 
Finally, the route of administration may be important for optimal replacement 
therapy. Although oral administration has its advantages, the intestinal and hepatic 
first pass metabolism causes the bioavailability of oral estrogens to fluctuate. To avoid 
the first pass effect, transdermal patches containing 17β-estradiol can be used to 
mimick spontaneous pubertal hormonal changes, inducing normal puberty [85,86] and 
avoiding the excessively high levels of estrone that are seen after oral administration 
of estrogens. While oral forms of administration cause estrone to accumulate in the 
body, continuous wearing of the transdermal estradiol patches for three weeks did 
not result in any accumulation of estradiol or estradiol metabolites [87]. 
It has been reported that, when percutaneous gel is used to induce puberty in 
girls with TS, secondary sexual characteristics and uterine growth proceed gradually, 
mimicking natural puberty [88]. However, the results of gel on growth velocity 
were unclear. Future research should evaluate whether transdermal patches and/
or percutaneous gel are the optimal oestrogen treatment for inducing puberty in 
girls with TS at an age similar to that in girls with spontaneous puberty, and without 
negative impact on final height.
In girls with TS, a low dose of 17β-estradiol can be used for puberty induction 
at an appropriate age. Breast development in these girls is then comparable to 
that in normal Dutch girls. 
Serum hormone levels do not provide additional information for evaluating the 
development of the puberty induced. 
Uterine dimensions at the age of nearly 20 years were comparable to those in a 
normally matured girl at the age of 15 years.
It remains unclear whether subnormal uterine dimensions in young Turner 
women are related to the timing or dosage of the estrogen therapy, or to factors 
related to Turner syndrome. 
•
•
•
•
binnenwerk_banink.indd   176 20-8-2006   12:53:49
177
C
ha
pt
er
 9
G
en
er
al
 d
is
cu
ss
io
nSafety aspects several years after long-term GH treatment in TS
Insulin and glucose metabolism
To estimate insulin sensitivity and β-cell function, we used the Homeostasis model 
(HOMA in %), a structural model of glucose/insulin interaction, with mathematical 
equations describing the functioning of the major effector organs [89-91]. During GH 
therapy, insulin sensitivity was reduced and fasting insulin and β-cell function were 
increased. There was no difference between the three GH dosage groups. At short-
term follow-up, which was six months after ending long-term GH treatment, insulin 
and glucose metabolism were unchanged. Nearly five years after GH-discontinuation, 
parameters of insulin sensitivity, β-cell function and fasting insulin levels were 
still unchanged relative to levels measured four years after start of GH-treatment 
and measured at short-term follow-up. Insulin sensitivity remained constant at 
approximately 75−85%, and β-cell function at approximately 150−160%. 
In untreated young TS women, a higher prevalence of insulin resistance and 
impaired glucose tolerance has been reported [92]; more recently it was also 
suggested that haploinsufficiency for one or more unknown X-chromosomal genes 
may be responsible for a finally impaired β-cell function in TS [93]. As several studies 
have shown a positive correlation between insulin levels and BMI in normal children 
and adults, the higher insulin levels after GH may also result from increased BMI 
[94,95]. This possible explanation is supported by the positive association of BMI with 
β-cell function and with fasting insulin levels found several years after GH therapy. 
Very recently, however, it has been suggested that impaired peripheral and hepatic 
insulin sensitivity in TS is caused by an intrinsic defect independent of fat mass that is 
related to the karyotype in TS [96]. 
Salgin et al recently presented data on insulin and glucose levels in untreated TS 
women aged 29.9 (16.5−46.6), whose insulin sensitivity was 103 (78.6)%. This value 
is not significantly different from the 81.6 (46.5)% in our GH-treated TS women aged 
20.0 (2.1) years [96]. Despite this, and despite the lack of an association with GH 
dosage or GH duration, a possible effect of the GH therapy itself cannot be completely 
ruled out. The findings that insulin sensitivity had not changed nearly five years after 
the end of GH treatment may suggest a partly irreversible or a very slowly reversible 
phenomenon. In a large epidemiological study on GH-treated children and adolescents 
(n = 23 333), the incidence of type 1 diabetes mellitus was not affected [97]. There 
was, however, a more than expected increased incidence of type 2 diabetes mellitus. 
The authors assigned this finding to an acceleration of the disorder in predisposed 
individuals [97].
Mean fasting glucose levels increased significantly from six months after GH 
discontinuation to nearly five years after end of GH treatment. However, the 
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research should clarify whether these glucose levels continue to increase, and 
whether impaired glucose tolerance will be reached. In addition, future research 
should clarify whether this impaired insulin sensitivity is the result of TS, increased 
BMI, the long-term GH-therapy itself, or a combination of these factors. Since insulin 
sensitivity can be affected by TS and a high BMI, the sole influence of long-term GH 
treatment is difficult to assess. Follow-up of other long-term GH-treated populations, 
such as children who were born small for gestational age, may help provide an 
answer.
Nearly five years after end of GH treatment in TS, insulin sensitivity was 
decreased (75−85%), and β-cell function was increased (150−160%).
Insulin sensitivity in untreated women aged 29.9 (16.5−46.4) with TS was 
similar to that in our GH treated TS women, aged 20.0 (2.1): this is 103 (78)% 
vs. 75−85%.
Nearly five years after end of GH treatment in TS, glucose levels were slightly 
higher than six months after end of treatment, but within the normal range.
Blood pressure (BP)
Although GH therapy lowered diastolic BP, nearly five years after end of GH treatment 
it was similar to its pre-treatment levels. Systolic BP did not change during GH 
treatment, and was not influenced by GH dose or duration. Nearly five years after 
end of GH treatment, however, systolic BP was higher than pre-treatment levels. 
Untreated TS women aged 35.7 (9.3) years, and thus approximately 15 years older 
than our TS population, had a higher systolic and diastolic BP than our group of GH 
treated TS women [98].
One may conclude that GH treatment overall had a positive effect on diastolic BP, 
especially in the light of the fact that, even several years after the discontinuation of 
hormone treatment, there was a continued association between BP and the dosage of 
GH: diastolic BP was lower in patients whose dose has been higher, also after adjusting 
for the BP at start. The lack of significant difference between the GH dosage groups 
may be explained by a non-dose-response effect of GH on diastolic BP. The increased 
BMI at LT-fu did explain the increased blood pressure. In adult GH-deficient patients 
it has also been reported that GH therapy tended to reduce systolic and diastolic BP 
[99]. 
•
•
•
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nNearly five years after end of GH treatment, diastolic BP had increased, despite 
a decrease during GH-therapy. 
Systolic BP did not change during GH therapy. The GH dose or duration was of 
no influence on systolic BP.
Nearly five years after end of GH treatment, systolic BP was higher than pre-
treatment values, and diastolic BP was similar to pre-treatment values.
Serum lipids 
We measured fasting serum lipid levels at baseline, 4 years after start of GH therapy, 
six months after end of GH treatment (short-term follow-up), and a mean of 4.8 (1.9) 
years after end of GH treatment (long-term follow-up). Several years after end of 
GH treatment, serum total cholesterol (TC), low-density lipoprotein (LDL), and high-
density lipoprotein (HDL) had all increased relative not only to the values 4 year after 
start of GH treatment, but also to the values six months after end of GH treatment. 
After start of GH therapy, the atherogenic index (AI = TC/HDL) had decreased, and 
remained constant for several years after end of GH treatment.
GH treatment thus has a positive effect in girls and young women with TS on serum 
lipids, adding to the positive effect on serum lipids described after discontinuation 
of treatment in GH-deficient patients [100]. A similar trend has also been observed in 
GH-treated short children born small for gestational age (SGA) [101].
Nearly five years after end of GH treatment, serum HDL had further increased, 
and, relative to the level six months after end of GH treatment, atherogenic 
index was constant. However, TC and LDL had also increased.
Body mass index (BMI)
BMI increased gradually during and after GH-discontinuation. At an average age of 
20 years, fewer than 40% of the TS women had a normal BMI (below 25 kg/m2). In a 
large study in the USA among GH-treated TS (n = 2468) [102], BMI SDS increased with 
age, starting approximately at age nine. GH did not influence the magnitude of the 
increase.
•
•
•
•
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n Nearly five years after end of long-term GH-therapy, the mean BMI in the 
women with TS was 26.5 (5.1) kg/m2. Of the TS women aged 20.0 (2.1) after 
long-term GH therapy, 38.5% had a BMI between 20−25 kg/m2, 46% were obese 
(BMI 25−30 kg/m2), and 15.5% were morbid obese (> 30 kg/m2). GH did not 
influence the magnitude of the increase in BMI.
Aortic dimensions
Using MRI-techniques several years after end of GH treatment, young women with 
TS had larger mean aortic diameters (mm/m²) at all thoracic levels measured, and 
a larger mean ascending/descending aorta diameter-ratio than controls matched for 
age and BMI. The advantage of the ascending/descending aorta diameter ratio is that 
it can be adjusted for intrinsic variation. A ratio lower than 1.5 is assumed to be 
normal [103-105]. In our study, this ratio was higher than +2 SD-score − based on 
the matched controls − in 27% of the cases aged 19.9 years, although a very recent 
study in 18-year-old GH-treated TS women [106] reported no increase in the ratio of 
ascending/ descending aorta. It should nonetheless be remembered that concurrent 
dilatation of the ascending and descending aorta, as we found in our TS population, 
may result in a false normal outcome of this ratio. 
In almost 30% of cases, the diameter of the ascending aorta was higher than +2 
SDS of the matched controls. After adjustment for BSA this figure was even 49%. 
The abnormality was most prominent in patients who had received the lowest GH 
dose (1.3 mg/m2/d). Previous studies using MRI reported ascending aorta diameters 
to be dilated in a substantial percentage of patients (18−33%), 31% of the studied 
population was treated with GH for an average of 4 years [103,105].
One rare but potentially devastating result of aortic dilatation is aortic dissection, 
which has been reported several times in women with TS [107,108]. An obvious reason 
for this finding is that the factors known to predispose for aortic dissection are seen 
more frequently in TS than in normal women; these include hypertension, bicuspid 
aortic valve, and cardiac malformations [109,110]. It has also been suggested that 
the higher risk for arterial dilation and dissection in women with TS may be explained 
by a connective tissue defect [108,110].
In our study, we found that dilation of the aorta was not limited to the aortic 
root or ascending aorta, but was present throughout the entire thoracic aorta, and, 
although differences between the GH dosage was lacking, was more prominent in 
patients who had received the lowest GH dose. A very recent study in 18-year-old GH-
treated TS women reported no differences in aortic diameter between GH-treated 
and untreated women [106], concluding that GH does not produce an adverse effect 
upon aortic structure. In the study in question, however, the average duration of the 
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that GH therapy does not have an adverse effect on aortic structure, but may even 
have protective effects on aortic wall properties. These results may be confirmed 
in future studies that include larger GH-treated study groups or MRI measurements 
made at a higher age.
Ascending and descending aorta diameter was larger in young TS women than 
in controls matched for age and BMI. The ascending aortic diameter was dilated 
in 30−50% of the women with TS. Dilatation of the aorta was not just limited to 
the ascending part, but was present throughout the entire thoracic aorta.
GH therapy does not have an adverse effect on aortic structure. On the 
contrary, it may even have beneficial effect, as the abnormalities seemed to be 
more prominent in patients who had received the lowest GH-dose.
Aortic distensibility
Impaired aortic wall function may alter aortic distensibility. Several years after end 
of GH treatment, we found lower aortic wall distensibility in TS women than in age- 
and BMI-matched controls. Distensibility was higher in the patients who had received 
the highest GH dose than in those who had received the lowest. At the ascending 
aorta and abdominal descending aorta, the difference between the group with the 
highest dose and that with the lowest was significant; at the level of diaphragm, it 
was nearly significant (P = 0.07). 
Aortic distensibility in normal subjects is negatively correlated with age, 
progression of atherosclerosis and an abnormal lipid profile [111]. Between GH-dosage 
groups there were no differences with regard to age or serum lipid levels, which do 
not therefore explain the differences in distensibility between the GH-dosage groups. 
Levels of GH and IGF-I, which are both anabolic hormones, decrease with increasing 
age. GH replacement can reverse age-related catabolic changes [111]. Patients with 
GH-deficiency (GHD) have been reported to have wall thickening in large arteries 
and a tendency towards a lower arterial-wall compliance than in controls [112,113]. 
GH treatment in GHD patients decreased the arterial wall thickness and increased 
wall compliance [112,113], supporting our finding of a possible positive GH-effect on 
aortic wall distensibility in TS. 
Ironically, there are similar aortic abnormalities in patients with TS, which 
is associated with short stature, and patients with Marfan syndrome, which is 
associated with tall stature. Not only do both have a higher risk of enlargement of 
the ascending aorta, both are reported to have a higher risk for aortic dissection. 
•
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distensibility has also been found in patients with Marfan syndrome [114]. As the 
underlying pathophysiology of aortic disease in Marfan syndrome is primarily the 
result of the expression of a mutant form of the protein fibrillin, it may be possible 
that the underlying pathophysiology of aortic disease in TS is also a connective-
tissue disease. However, such an etiology has not been identified in TS, making it too 
early to transfer to TS knowledge and guidelines relating to Marfan syndrome. For 
example, in Marfan syndrome the aortic root dimensions progress with age [115]. In 
TS, the likelihood of such a progression is not yet known. Another example in Marfan 
syndrome is that beta-blocker therapy reduces blood pressure and increased aortic 
distensibility [116]; in TS, however, the role of beta-blocker therapy in preventing 
aortic disease − especially during pregnancy − remains to be investigated.
The aorta in young women with TS showed decreased aortic wall distensibility, 
which is a sign of impaired aortic wall function. 
In the group with the lowest GH-dose, aortic distensibility was significantly 
lower than in matched controls, whereas both other GH-dosage groups showed 
no significant differences relative to matched controls. In women with TS, GH 
seemed to have a beneficial influence on aortic wall properties.
Body proportions
Several years after discontinuation of GH therapy in TS, we found a moderate 
improvement with regard to the disproportion between height and sitting height (SH) 
that had existed before treatment, and an increase in the disproportion between 
height and foot length relative to baseline data. The disproportion between SH and 
height nearly normalized, whereas disproportion between hand, biacromial diameter 
(Biac), biiliacal diameter (Biil), and height remained unchanged relative to baseline. 
Untreated adult TS women, however, appear to have a larger disproportion between 
height, Biac and Biil [98]. GH therapy possibly prevented the disproportion from 
getting worse. Although there was also a disproportion between the height and foot 
length in untreated adult women [98], the foot length was associated with the GH-
dosage used. 
•
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nGH therapy normalized the pre-existing disproportion between height and 
sitting height.
GH may have prevented worsening of the disproportion between height and 
biacromial diameter, and biiliacal diameter.
The increase in the disproportion between height and foot length was due 
partly to the natural development of TS and partly to GH-dosage.
Methodological considerations
Strength of the studies
The design of the present research has several strengths. 
First, subject recruitment in both studies was restricted to well-defined criteria. 
For the SGA study, the inclusion criteria were applied by one and the same person. For 
the TS study, the TS diagnosis was confirmed by lymphocyte chromosomal analyses, 
and, once again, the inclusion criteria were applied by the same person. 
Second, both studies were multicenter studies that took place in the Netherlands 
and included academic hospitals. Over the years, all measurements were carried out 
by the same five researchers (Arne van Teunenbroek (TS), Wouter de Waal (SGA), 
Theo Sas, Yvonne van Pareren, and Ellen Bannink) and the same research nurses (Anne 
van der Wiel (TS), Ingrid van Slobbe (TS), and Janneke van Nieuwkasteele (SGA)). 
This consistency lessened the risk of inter-individual bias, and may have stimulated 
compliance with the therapy. 
Third, over the years most of the laboratory measurements were performed in the 
same laboratory. With regard to the IGF-I and IGFBP measurements, the reference 
values for healthy children were also determined in the same laboratory [117,118], 
thereby reducing the variability between different laboratories.
Fourth, both studies were randomized prospective long-term longitudinal studies, 
not ‘pseudo-longitudinal’ studies. Pseudo-longitudinal describes changes over time 
on the basis of data seen only once per subject, such as that used in studies to derive 
cross-sectional growth charts for children [119].
Weaknesses of the studies
Firstly, due to ethical considerations, neither study − SGA or TS − used a control group 
of untreated children, though a randomized untreated control group might have 
been of additional value in the studies on quality of life (QoL). The lack of such a 
control group was of less importance showing a GH-effect in the other parameters 
measured, as different GH dosages were used, and the development of the different 
•
•
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however, it is difficult to establish the long-term effects of the GH therapy: because 
such therapy has been an accepted indication in Turner syndrome for many years, 
there are no representative data in an untreated group of young women with TS.
Secondly, the SGA study sample might be too various with respect to underlying 
pathology, and therefore to accompanying pathology. Short SGA is a diagnosis based on 
auxological parameters. The underlying pathophysiology is unknown; genetic factors 
and environmental (intrauterine) factors may both be related to the underlying cause 
[120,121]. The natural development of certain aspects may therefore differ within 
the group. Future research will reveal the underlying pathophysiology of shortness 
in SGA, possibly bringing greater understanding of the pathology related to the SGA 
syndrome, and possibly leading to a more specific and thus successful treatment of 
the health problems related to being born SGA.
While the pathology underlying TS has been identified − i.e. the total or 
partial absence of one of the X-chromosomes in all or some of the body cells − the 
underlying pathophysiology of Turner features (such as short stature, impaired 
lymphatic development, and the increased risk of developing diabetes mellitus 
and cardiovascular diseases) is not yet known. There are genotypic or phenotypic 
differences that may influence the growth response and other effects of GH 
treatment.
A final weakness may have been the number of children in the present studies. 
As the QoL and long-term follow-up studies were added to the original GH-trial, not 
all patients were motivated to participate. Although there were no indications of 
selection bias per individual study, this could not be ruled out completely. 
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Around the world, issues for debate are still being raised by long-term GH therapy in 
populations who are not GH-deficient. After more than 15 years of experience with 
GH therapy in short children born SGA and in girls with Turner syndrome, the time 
has come to sum up the results of these two long-term studies. The following chapter 
summarizes the most important aspects of all results of both GH-trials, evaluates the 
benefits and costs of the GH treatment, and ends by answering the question “Was it − 
and is it − all worthwhile?” 
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SGA
Name author/ 
researcher
Effect of GH treatment in short children born SGA
Growth and adult height
After two years of GH treatment, most patients grew to within the 
normal range.
After fi ve years of GH treatment, most children grew along their target
height range, and the difference in growth-response of short children 
born SGA between those receiving 2 mg/m2/day and those receiving 
1 mg/m2/day was small, and statistically signifi cant only in the children 
who remained prepubertal during the study. 
In most children, a dose of 1 mg proved to be as effective as the higher
dose of 2 mg/m2/day. Only those with an extremely short stature may 
thus need a higher GH dose to normalize height.
Long-term continuous GH treatment in short children born SGA led to 
a normalization of height in childhood and a normal adult height in 85% 
of the children, though 98% attained an adult height within their target 
range.
Thus, in conclusion, GH treatment leads to normal height during 
childhood and adulthood in short children born SGA.
—
—
—
—
—
WJ de Waal [1] 
TCJ Sas [2]
YK van Pareren [3]
Predictors of adult height
Adult height SD-score = 0.02 + 0.29 x TH SD-score + 0.42 x height 
SD-score at start + 0.20 x (calendar age – bone age) at start + 0.07 x GH 
dose.
42% of the variance in adult height SD-score could be explained.
In GH-treated SGA children, baseline serum-free IGF-I was a better 
predictor for short-term growth response and adult height than were 
total IGF-I, IGFBP-3, or total IGF-I/IGFBP-3 molar ratio. It increases the 
predicted variance of adult height up to 55%.
—
—
—
YK van Pareren [3]
EMN Bannink 
(present thesis)
Additional effects of GH treatment
Bone maturation
Five-year of GH showed, during the fi rst 2 years of GH, a GH dose-
independent acceleration of bone maturation that was not progressive 
during further GH treatment. This appeared to be infl uenced by the 
natural bone age development in these children at the age of 7 to 10 
years.
—
WJ de Waal [1] 
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Cardiovascular risk factors 
GH treatment in short children born SGA did not negatively infl uence
glucose levels, even with dosage up to 2 mg/m2/day. 
GH treatment induced higher insulin levels, indicating more insulin 
resistance, which normalized after end of GH treatment. 
Long-term GH treatment had no adverse effects on body composition, 
blood pressure, and serum lipids. 
The benefi cial effect of GH on blood pressure, systolic and diastolic,
remained after discontinuation of GH.
Although most children had normal serum lipid levels, we found an 
indication for clustering of risk factors for DM type 2 and 
cardiovascular disease in adolescents with relatively higher BMI. 
—
—
—
—
—
TCJ Sas [2]
YK van Pareren [3]
Body proportions
Body proportions in short SGA children were not negatively infl uenced 
by six years GH treatment with 1 or 2 mg/m2/day.
—
TCJ Sas [2]
Psychosocial functioning
Over 8 yrs of GH treatment, test scores for IQ and psychosocial 
functioning improved for most children, starting signifi cantly below 
average and becoming similar to those of Dutch peers. Similarly, the 
taller a child became over time, the less problem behavior he or she 
showed. 
—
YK van Pareren [3]
Puberty
GH treatment did not affect serum DHEAS levels.
The age at onset of puberty of GH-treated children born SGA was 
comparable with that of normally statured AGA children, regardless of 
treatment with 1 or 2 mg/m2/day.
Age at menarche and progression of puberty in girls were comparable 
with those in the normal population, regardless of treatment with 1 or 
2 mg/m2/day.
Duration of puberty and the pubertal height gain were not signifi cantly
different between the GH dosage groups.
—
—
—
—
VH Boonstra [4]  
Quality of life
Using the disorder-specifi c TACOL-S, GH-treated children born SGA 
had a signifi cantly better quality of life in terms of physical abilities 
and contact with adults, and fewer problems with body image 
than untreated children born SGA. A generic QoL showed that SGA 
adolescents had a near-normal HRQoL after long-term GH therapy. GH 
may have improved QoL through mechanisms unrelated to growth.
—
EMN Bannink 
(present thesis)
Short children born SGA related results
Endogenous GH production
In 50−60% of the short-statured children born SGA, there were signs of 
GH insuffi ciency, and 25% showed low GH peaks during GH-provocation 
tests. 
—
WJ de Waal [1] 
IGF-I polymorphism
There was an association between a polymorphism of the IGF-I 
gene and low-serum IGF-I levels in a group of short children born SGA. 
Genetically determined low-serum IGF-I levels may cause not only a 
reduction in birth length, weight and head-circumference, but also 
persistent short stature and small head-circumference during childhood 
and adulthood (proportionate small).
The IGF-I gene thus may be one of the links between low birth weight 
and an increased risk of adult disease.
—
—
NJT Arends [5]
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Puberty
Children born SGA had neither a disturbed adrenarche nor a higher 
incidence of premature pubarche.
Prepubertal short SGA girls had normal serum AMH levels, indicating 
a normal follicle pool size. Short adolescent SGA girls did not have a 
relatively small ovarian follicle pool. 
Compared to AGA young men, young men born SGA, with or without 
short stature, had normal serum inhibin B, LH, FSH and testosterone 
levels. Serum AMH levels were signifi cantly higher in young men born 
SGA. This indicates that small size at birth, which might refl ect fetal 
growth restriction, does not reduce the number of Sertoli cells, and 
has no effect on testicular function in men born SGA.
—
—
—
VH Boonstra [4]
 
Growth factors
Untreated short children born SGA, either with or without GHD, had 
normal free IGF-1 levels, whereas total IGF-I and IGFBP-3 were lower. 
—
EMN Bannink 
(present thesis)
Short SGA and GH treatment: “Was it − and is it − all worthwhile?” 
Eighty-five percent of the GH-treated SGA children attained normal adult height, and 
98% attained a height within their target height range. This represents a height gain 
of 11−13 cm in girls and 12−14 cm in boys. In up to twelve years of treatment, GH 
treatment had no major adverse effects. However, fasting insulin levels and total 
insulin production after glucose loading rose significantly during GH treatment, and 
although the decreased insulin sensitivity induced during GH treatment disappeared 
after the end of GH treatment, the long-term consequences of decreased insulin 
sensitivity induced during childhood should still be investigated. 
On the basis of our studies we recommend GH treatment in short SGA children, 
who are otherwise at increased risk for short stature as adults. GH treatment not only 
improves adult height, it also improves blood pressure and serum lipids, as well as 
IQ, psychosocial functioning, and certain domains of these children’s quality of life. 
It does not have any influence − either negative or positive − on start of puberty or 
pubertal progression. 
In other words, although GH treatment has several positive effects beyond its 
positive influence on height in short children born SGA, the long-term sustainability 
of these effects remains to be investigated. Future studies have to clarify whether 
long-term GH treatment during childhood reduces development of adult diseases in 
patients born SGA. Follow-up will also show whether, in adulthood, these GH treated 
patients go on to attain relatively greater personal, vocational and overall life 
achievements at the long term.
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Turner Syndrome
Name author/ 
researcher
Effects of GH treatment in girls with Turner Syndrome
Growth and adult height
GH treatment in girls with TS led to a normalization of height during 
childhood, with 83% of the girls achieving a normal adult height, and 
63% gaining an adult height within their target height range.
A GH dose of 1.3 mg/m2/day led to a height gain of 11.9 (3.6) cm; a 
dose of 2 mg/m2/day led to a height gain of 15.7 (3.5) cm; and a dose 
of 2.7 mg/m2/day led to a height gain of 16.9 (5.2) cm. The TS women 
who used a GH dose of 2 or 2.7 mg/m2/day were signifi cantly taller 
than the ones who used 1.3 mg/m2/day. Between the two highest GH 
dosages given there was no signifi cant difference in adult height. 
Giving injections more than once a day did not increase the effect of 
GH on adult height.
Low doses of estrogens at a normal pubertal age did not interfere with 
the capability of GH treatment to normalize adult height in girls with 
TS
—
—
—
—
TCJ Sas [6]
YK van Pareren []
Predictors of adult height
Adult height SD-score = −2.29 + 0.8 x Height SD-score at start + 0.81 
x group with highest GH dosage (2.7 mg/m2/d; yes = 1/no = 0) 
+ 0.68 x group with intermediate dose (2.0 mg/m2/d; yes = 1/no = 0) 
+ 0.24 x Height velocity in 1st year (cm) + 0.087 x calendar age at start 
(yr). 
76% of the variance in adult height SD-score could be explained. 
The optimal dose depends on height and age at start of treatment, 
and fi rst year height velocity.
If GH is started at an early age, adult height will not be affected by 
early initiation of estrogen.
In GH-treated girls with TS, total IGF-I and the total IGF-I/IGFBP-3 
molar ratio seem to have a much higher predictive value for several 
biological IGF-I endpoints, including height, and therefore for IGF-I 
bioactivity, than free IGF-I levels have.
—
—
—
—
—
TCJ Sas [6]
YK van Pareren [3]
EMN Bannink 
(present study)
Additional effects of GH treatment
Bone maturation
Bone maturation during GH treatment was positively related to the 
degree of bone age retardation at start of study and negatively related 
to baseline calendar age. 
—
A van Teunenbroek [7]
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Bone mineral density (BMD)
Most girls had a normal BMD during childhood. 
During GH treatment, BMD increased signifi cantly. After end of GH 
treatment and the increase of estrogen dosage to adult levels, the 
BMD reached adult values.
—
—
TCJ Sas [6]
Growth factor levels
In agreement with other studies, our studies show a decrease in 
GHBP-levels. However, the GHBP-levels were not dose or 
administration-frequency dependent.
Free IGF-I levels remained mainly within the normal range, while total 
IGF-I levels rose to the upper normal range, and even exceeded it.
—
—
A van Teunenbroek []
TCJ Sas [6]
EMN Bannink 
(present thesis)
Cardiovascular risk factors
Although long-term GH treatment with GH dosages up to 
2.7 mg/m2/day had no adverse effect on glucose metabolism, it 
induced hyperinsulinaemia, thereby indicating relative insulin 
resistance. Six months after end of GH treatment, insulin levels 
decreased to values close to or equal to pretreatment values.
Several years after end of GH treatment, glucose metabolism remained 
low in young women with TS, leading to lower insulin sensitivity 
(75−85%) and higher β-cell function (150−160%). In untreated TS women 
aged 29.9 (16.5−46.4) years, insulin sensitivity was not signifi cantly 
different from that in our GH-treated TS women, aged 20.0 (2.1).
Several years after discontinuation of GH, glucose levels were slightly 
higher than they were six months after discontinuation.
During GH treatment, the lipid profi les changed in a more 
cardioprotective direction, with a signifi cant reduction in the ratio of 
total cholesterol to HDL cholesterol, i.e. the atherogenic index (AI).
Six months after end of GH treatment, lipid levels were more 
benefi cial regarding the development of cardiovascular disease than 
in a normal control group, suggesting a positive effect of the GH and 
estrogen treatment in TS.
Several years after end of GH treatment, serum TC, LDL, and HDL were 
higher than they had been six months after GH-discontinuation. The AI 
remained constant.
The decrease in diastolic blood pressure during and six months after 
end of GH treatment suggests a positive effect of the GH and estrogen 
treatment in TS. 
Several years after end of GH treatment, systolic and diastolic BP were 
higher than at six months after end of GH treatment. 
Several years after end of GH treatment, systolic BP was higher than 
pre-treatment values, and diastolic BP was similar to pre-treatment 
values.
—
—
—
—
—
—
—
—
—
A van Teunenbroek [7]
TCJ Sas [6]
YK van Pareren [3]
EMN Bannink 
(present thesis)
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Effects on the heart
GH treatment using up to 2.7 mg/m2/day for up to 7 years caused 
no adverse cardiovascular effects. The structure of the heart muscle 
increased proportionally with general development. LV activity, heart 
axis and BP showed an age-dependent development, with values well 
within the normal range. 
GH therapy does not have an adverse effect on aortic structure. On 
the contrary, it may even have a benefi cial effect, as the abnormalities 
seemed to be more prominent in patients who had received the lowest 
GH dose. However, there were no signifi cant differences between GH 
dosage groups.
In the group with the lowest GH dose, aortic distensibility was 
signifi cantly lower than in matched controls, whereas both other 
GH dosage groups showed no signifi cant differences from matched 
controls. GH seemed to have a benefi cial infl uence on aortic wall 
properties in women with TS.
—
—
—
A van Teunenbroek [7]
TCJ Sas [6]
EMN Bannink 
(present thesis)
Body proportions
GH therapy normalized the earlier disproportion between height and 
sitting height, and possibly preventing worsening of the disproportion 
between height, biacromial diameter and biiliacal diameter.
The increased disproportion between height and foot length was due 
partly to the natural development of TS, and was also infl uenced 
partly by the GH dosage used. The development of large feet can play 
a role in a girl’s decision to discontinue GH treatment in the last phase 
of growth.
—
—
A van Teunenbroek [7]
TCJ Sas [6]
EMN Bannink 
(present thesis)
Psychosocial functioning
Even after normalization of height and puberty induction at a 
normal pubertal age, some TS women still experienced psychosocial 
problems. Although it is likely that GH and estrogen treatment 
improved psychosocial functioning, it did not normalize it for some 
women. 
—
YK van Pareren [3]
Puberty
In girls with TS, the use of a low dose of 17β-estradiol to induce 
puberty at an appropriate age resulted in breast development 
comparable to that in normal Dutch girls. 
—
EMN Bannink 
(present thesis)
Quality of life
Young women with TS had a normal HRQoL after long-term GH-
treatment and puberty induction at an appropriate age. 
The relatively high scores on some of the HRQoL-scales in TS women 
can be explained by an estrogen-effect or by a possible response shift, 
indicating that they might have acquired a different internal reference.
In the TS woman, personal satisfaction with their height and/or breast 
development positively infl uenced several HRQoL scales, including 
social functioning and physical functioning. 
GH and estrogen treatment may have positively infl uenced HRQoL in 
young women with TS.
GH may improve QoL through mechanisms unrelated to growth.
—
—
—
—
—
EMN Bannink 
(present thesis)
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Body mass index (BMI)
Nearly 5 years after the end of long-term GH therapy at an age of 
20.0 (2.1) years, the mean BMI was 26.5 (5.1) kg/m2 in the women with 
TS; 38.5% had a BMI between 20 – 25 kg/m2, 46% were obese (BMI 
25−30 kg/m2), and 15.5% were morbid obese (> 30 kg/m2). GH did not 
infl uence the magnitude of the increase in BMI.
—
EMN Bannink 
(present thesis)
Turner syndrome related results
TS Prediction models
In girls with TS, the Turner-specifi c adult height prediction methods 
were valuable additions to existing methods for predicting adult 
height. 
—
A van Teunenbroek [7]
Cardiovascular risk factors
Together with the predisposition in TS for insulin resistance, the 
positive relationship between insulin and BMI should prompt clinicians 
to do their utmost to prevent further weight-gain in girls and women 
with TS.
—
YK van Pareren [3]
Body proportions
Relative to their height, untreated girls with TS had a relatively large 
trunk, relatively large hands and feet, and relatively broad shoulders 
and pelvis.
—
TCJ Sas [6]
EMN Bannink 
(present thesis)
Puberty
Serum hormone levels do not provide additional information for 
evaluating the development of the puberty induced. 
Uterine dimensions at the age of nearly 20 years were comparable to 
those in a normally matured girl at the age of 15.
It remains unclear whether subnormal uterine dimensions in young 
Turner women are related to the estrogen dosage administered, or to 
factors related to Turner’s syndrome.
—
—
—
EMN Bannink 
(present thesis)
Growth factors
Untreated girls with TS had lower levels of free dissociable IGF-I, to an 
extent similar to the decrease in total IGF-I and IGFBP-3.
—
EMN Bannink 
(present thesis)
Aortic dimensions and distensibility
Ascending and descending aorta diameter is larger in young TS women 
than in controls matched for age and BMI. The ascending aortic 
diameter is dilated in 30−50% of the women with TS. Dilation of 
the aorta is not just limited to the ascending part, but is present 
throughout the entire thoracic aorta.
The aorta in young women with TS showed decreased aortic wall 
distensibility, which is a sign of impaired wall function.
—
—
EMN Bannink 
(present thesis)
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? Turner syndrome and GH treatment: “Was it − and is it − all worthwhile?”
Eighty-three percent of the GH-treated Turner girls attained normal adult height, 
and 63% gained a height within their target height range − overall, a height gain of 
between 12 and 17 cm.
The Turner study also showed that GH treatment lasting up to thirteen years 
produced no major adverse effects. However, while dosages during treatment of up to 
2.7 mg/m2/day produced no adverse effect on glucose metabolism, they did induce 
increased serum insulin levels, indicating relative insulin resistance. Nearly five years 
after end of GH treatment, insulin metabolism remained affected in young women 
with TS, leading to lower insulin sensitivity (75−85%) and a higher β-cell function 
(150−160%). Nonetheless, insulin sensitivity at age 20 (2.1) was not significantly 
different from that in untreated TS women aged 29.9 (16.5−46.4) years (81.5 (46.5)% 
vs. 103.2 (78.6)%). Similarly, the disproportion between height and foot length was 
increased, partly due to the natural development of TS, but also influenced by the 
GH dosage used.
On the basis of our studies we therefore recommend GH treatment in TS girls, as 
it has been proven to be effective, and to have several positive additional effects 
besides height improvement.
GH treatment has a positive effect on blood pressure, bone mineral density, and 
serum lipids. And although, nearly 5 years after end of GH treatment, the effect 
on blood pressure had disappeared, that on lipid levels remained. GH treatment 
also seemed to have had a positive effect on quality of life, aortic distensibility and 
structure, and the disproportion between height and sitting height. Furthermore, it 
did not seem to influence BMI or left ventricular mass. Additionally, we found that GH 
and estrogen treatment are likely to have improved psychosocial functioning. In other 
words, GH treatment in TS girls has several positive effects beyond that on height. 
We should also stress the beneficial effects of additional appropriate-age-started 
estrogen substitution, such as those on quality of life, and probably on cardiovascular 
risk factors. Future studies should clarify whether the combination of long-term 
GH treatment with the age-appropriate start of estrogen treatment helps create a 
greater likelihood of better personal, vocational and overall life achievements, and 
also whether it reduces earlier cardiovascular risks in TS. If possible, these studies 
should also explore the decreased insulin sensitivity brought about by the long-term 
GH treatment or inherent to TS.
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− Small for gestational age −
SGA is a description of size at birth, not of a disease, syndrome or disorder. In this 
population, the heterogeneity of the underlying pathology can be broad and varied, 
with environmental (intrauterine), metabolic and genetic factors being related to the 
underlying cause [8,9]. The natural development of certain aspects may therefore 
differ between subgroups within the SGA-population. Future research that reveals the 
mechanisms underlying shortness in SGA may lead to understanding of the pathology 
related to the SGA syndrome. It may also provide better, more specific treatments for 
the health problems related to being born SGA, and improve prediction of positive 
and negative reactions to GH. 
Among the mechanisms on which research might focus are the IGF-I gene, IGF-I 
receptor gene, and the IGFBP-3 gene, as they are all involved in the potency of IGF-I, 
which is involved in prenatal and postnatal growth. IGF-I is also involved in longevity 
[10], low IGF-I levels being positively associated with degenerative diseases such as 
cardiovascular diseases, atherosclerosis and diabetes, which are also involved in the 
SGA syndrome.
Another aspect that needs to be clarified is whether prematurity influences the 
development of the risk factors faced by children born SGA. After birth, most babies 
first lose weight, before they start growing in length and weight, while the intra-
uterine process of growing would have continued. Further research should therefore 
establish 1.) whether children born SGA preterm are more at risk of shortness and of 
developing adult diseases than those born SGA at term, 2.) whether preterm children 
born SGA who are AGA by the time they are at term face similar risks of shortness 
and of developing adult diseases as those born SGA at term; and 3.) whether preterm 
children born AGA who are SGA when they are at term are also at risk of shortness at 
adulthood and of developing adult diseases.
While long-term GH therapy has been proved to be effective, long-term follow-
up studies need to confirm the beneficial effects of this treatment during childhood 
relative to adult diseases such as hypertension, diabetes mellitus type II, and 
cardiovascular disease.
This study showed that, six months after end of GH treatment, GH-induced relative 
insulin resistance had returned to levels similar to those in peers. These results 
should now be confirmed several years after end of GH treatment. Similarly, follow-
up studies should investigate the long-term consequences of GH-induced decreased 
insulin sensitivity during childhood. 
binnenwerk_banink.indd   203 20-8-2006   12:53:55
204
C
ha
pt
er
 1
0
W
ha
t 
ha
ve
 w
e 
le
ar
ne
d 
fr
om
 a
ll 
th
es
e 
ye
ar
s 
of
 G
H
 t
he
ra
py
? GH increased IGF-I levels as high as +2 SDS; in adulthood, high IGF-I levels are 
associated with cancer risk [11-14]. The studies in question were conducted in 
subjects who were at an age at which the preexisting risk for cancer is much higher 
than it is during childhood. It remains to be seen whether high IGF-I levels during 
childhood also cause a higher cancer risk in adulthood. Until causality can be ruled 
out, this group of GH-treated SGA adults should be monitored in follow-up settings. 
GH seems to have a positive influence on QoL measured at adolescence. These 
data should now be confirmed in a longitudinal trial. Longer-term follow-up would 
show whether or not GH-treated SGA patients’ life achievements (i.e. personal and 
vocational achievements) have improved more than those of untreated short SGA 
patients. 
− Turner syndrome −
Long-term GH treatment has been proved to be effective, and to have several favorable 
aspects in TS. In addition, age-appropriate low-dose estrogen substitution has proved 
effective in inducing puberty without sacrificing adult height. Furthermore, estrogens 
have additional beneficial effects beyond starting feminization. Investigation should 
nonetheless take place with regard to uncertainties about the combination of long-
term GH treatment and low-dose estrogen treatment.
Nearly five years after end of GH treatment, glucose metabolism in young women 
with TS remains low, leading to lower insulin sensitivity (75−85%) and higher β-cell 
function (150−160%). Salgin et al, as discussed earlier, recently presented data 
on insulin and glucose levels in untreated TS women aged 29.9 (16.5−46.6) years, 
showing an insulin sensitivity of 103 (78.6)%, which is not significantly different from 
the 81.6 (46.5)% in our GH-treated TS women aged 20.0 (2.1) years [15]. 
Despite a significant difference between insulin sensitivity of the GH treated and 
the untreated TS women, and despite the lack of an association of insulin sensitivity 
or β-cell function with GH dosage or GH-duration, it cannot be ruled out that GH 
therapy itself had an effect on glucose metabolism. Although our group previously 
suggested that the higher post-GH levels might be the result of higher BMI, it was 
suggested very recently that impaired peripheral and hepatic insulin sensitivity in TS 
may be caused by an intrinsic defect that is independent of fat mass but related to the 
karyotype in TS [15]. It has also been suggested that a beta-cell dysfunction causes 
a higher prevalence of diabetes mellitus in TS women [16]. More definitive answers 
may be provided by studies on the etiology of glucose metabolism in women with TS; 
these may show whether this lower insulin sensitivity is related to GH, to TS syndrome 
(including increased BMI), or to a combination, and whether the disturbances in 
glucose metabolism are karyotype related. Answers may also be provided by follow-
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for gestational age. 
Nearly five years after end of GH treatment, positive effects on lipid levels were 
still measurable, whereas positive effects on blood pressure had disappeared. TS 
women are predisposed to hypertension, though this is of unknown etiology. Whether 
GH and estrogen treatment provided protection for cardiovascular diseases in TS 
women on the longer term, remains to be investigated. Future research in TS should 
therefore include the etiology of hypertension, the need for treating hypertension, 
and the proneness to cardiovascular diseases in TS. 
Women with TS are at a relatively high risk of aortic dilatation and dissection, 
though no cause for this has as yet been established. A similarly high risk of aortic 
dilatation and dissection is found in Marfan syndrome, a syndrome involving tall 
stature. Nearly five years after end of GH treatment, we found dilatation of the 
ascending aorta in 30−50% of women with TS; rather than being restricted to the 
ascending part, this was present throughout the entire thoracic aorta. In young 
women with TS, we also found relatively low distensibilities of the aortic wall, a sign 
of impaired wall function. 
While it has been suggested that the evaluation and treatment of TS should be 
similar to that used in people with Marfan syndrome, great care should be taken in 
extrapolating any knowledge of Marfan syndrome to TS, of which etiology may be of 
an entirely different order. In Marfan syndrome, aortic dilatation increases with aging; 
in TS it is not yet known whether there is any progression of the aortic dimensions 
and distensibility. Follow-up of groups of TS women, preferably larger groups, 
should therefore be performed for monitoring aortic abnormalities, including aortic 
distensibility, as this may have consequences for treatment of e.g. hypertension. It 
should also be investigated whether beta-blocker therapy benefits TS women, also 
those without obvious signs of hypertension. 
The finding that GH therapy had no adverse effect on aortic structure or 
distensibility − even seeming to have protective effects on aortic wall properties − 
should be examined in future studies which expressly include a larger GH-treated 
study group with longitudinal measurements, or MRI measurements at a higher age.
During GH treatment, IGF-I levels increase as high as +2 SDS. High IGF-I levels at 
an adult age are associated with cancer risk [11-14]. All these studies were performed 
at an age when the preexisting risk for cancer is much higher than during childhood. 
As stated above under the recommendations for future research in SGA, it remains to 
be investigated whether high IGF-I levels during childhood also increase cancer risk 
in adulthood. Until causality can be ruled out, this group of GH-treated TS women 
should be monitored in follow-up settings. With regard to our previous discussion 
on the possibility of an increased shift of free IGF-I to the tissue compartments (see 
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? chapter 3), it would be interesting to determine IGF-I concentrations activating IGF-
I-receptor. As the recently developed sensitive IGF-I kinase receptor activation assay 
(KIRA) [17] is able to do this, it might be helpful in clarifying the bioactive capabilities 
of circulating IGF-I levels.
During GH treatment, estrogen treatment was started at a low dose, without 
sacrificing adult height [18,19]. We showed that this dose was sufficient for a 
feminization process comparable to that of normal peers, albeit with a two-year 
delay. Although a recently published study reports that GH with an even lower dose of 
estrogens enhanced height velocity while preserving height potential [19], the dosage 
in question failed to bring about bodily feminization in one third of the subjects. This 
nonetheless implies that it may be possible to start estrogen therapy at an even lower 
age without sacrificing adult height, and to start bodily feminization at an appropriate 
age. Future research is thus needed to establish the dosage and initiatial age of which 
estrogen therapy might most benefit adult height and bodily feminization. As well as 
establishing other potentially positive influences of estrogens, such research might 
determine whether 1.) transdermal patches and/or percutaneous gel are the best 
oestrogen treatment for inducing puberty in TS girls at an age similar to that of girls 
with spontaneous puberty without negative impact on adult height, and 2.) whether 
these methods are preferable to oral estrogens. 
When QoL is measured at young adulthood, it seems to have been positively 
influenced by GH. These data should also be confirmed in a longitudinal trial. Follow-
up will show whether or not personal, vocational and overall life achievements in GH-
treated Turner women have improved.
As a majority of adults with TS are infertile, the consequences of infertility on the 
HRQoL may become a more prominent issue in the future of the Turner women we 
studied. Infertility may significantly influence the HRQoL [20-23]; to determine its 
influence on the HRQoL of women with TS, we recommend that further research be 
conducted. 
The progression booked in possibilities for oocyte donation and cryopreservation 
are promising. Human ovarian tissue containing immature primordial follicles has 
been successfully cryopreserved. A possible future prospect is cryopreservation of 
ovarian tissue containing immature follicles before the onset of early menopause, but 
methods of replantation and in-vitro maturation still need to be developed [24,25].
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 By definition, 2.3% of the children is born Small for Gestational Age (SGA), which 
is a length and/or height < −2 standard deviation (SD). Most children born SGA show 
catch-up growth during the first years of life. Approximately 10% of them remain 
short with a height below the normal range. Previously, this study showed that long-
term growth hormone (GH) treatment in short SGA children resulted in an adult height 
within the normal range in 85%, and in 98% a height within the target height range 
(i.e. the midparental height). The mean gain in height is 11−13 cm in girls and 12−14 
cm in boys.
In Turner syndrome (TS), one of the main characteristics is short stature. The mean 
adult height of women with TS is approximately 20 cm below normal, which is about 
148 cm in the Netherlands. GH treatment in girls with TS resulted in an adult height 
within the normal range in 83%, and in 63% a height within the target height range. 
The mean height gain is between 12 and 17 cm. Another major characteristic of TS 
is gonadal dysgenesis, leading to ovarian failure in 80−100% of the Turner patients. 
Most girls do not enter puberty spontaneously due to a lack of estrogen production. 
Therefore, puberty is induced by administration of exogenous estrogens. Route, 
timing, dose, and form of estrogen therapy are still issues of debate. 
These studies investigated different aspects of long-term GH treatment in children 
born SGA (n = 72) and girls with TS (n = 65). The effects of long-term GH treatment on 
the IGF-system, especially the free fraction of IGF-I (chapter 2 and 3), and the quality 
of life after ending GH treatment (chapter 4 and 5) are discussed. In TS girls we 
described the pubertal development and uterine dimensions, after puberty has been 
induced starting with a low estrogen dose during GH treatment, at an appropriate 
age (Chapter 6). Several years after the end of GH treatment, we measured serum 
lipids, insulin and glucose metabolism, body mass index (BMI) and body proportions in 
39 TS girls (chapter 7). At the same time, we also investigated aortic dimensions and 
aortic distensibilities, representing aorta wall function (chapter 8). 
Chapter 1 provides a general overview of the literature regarding SGA and TS. In 
this chapter definitions, etiology, prevalence and clinical characteristics of these two 
patient populations are described. In addition, it gives a summary of the previously 
reported results of the GH treatment regarding the growth effects, safety aspects, 
and other possible GH effects. In the girls with TS, the puberty induction is discussed. 
At the end of this chapter, a time-frame is given of these two long-term GH studies 
(SGA study started in 1991 and the TS study started in 1989), and an overview of the 
different doctoral dissertations resulting from these studies. Finally, the objectives 
of the different studies presented in this dissertation are described.
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Insulin-like-growth-factor-I (IGF-I) plays an important role in both pre- and postnatal 
growth and development and its serum levels are regulated by both metabolic 
and genetic factors; GH is one of the main regulators of IGF-I. In the circulation, 
IGF-I is bound mainly to IGF-binding proteins (IGFBP), of which six classes have 
been identified (IGFBP- 1 to − 6). The major carrier protein of circulating IGF-I is 
IGFBP-3, which normally accounts for more than 90% of the IGF-I binding. Under 
normal circumstances, less than 1% of the total plasma IGF-I pool is present in the 
unbound free form, which is considered to be the biologically active form.
During GH treatment, total IGF-I levels rise to high-normal and supraphysiological 
levels. IGFBP-3 also increases during GH therapy, however, less markedly. No reports 
are available on free IGF-I levels during GH treatment are available, nor on the 
contribution of free IGF-I in predicting growth response. 
To interpret the measured free IGF-I levels, we established normative range values 
for circulating free IGF-I in collected serum samples of healthy children aged 0−17 
years (116 girls and 211 boys).
Chapter 2 describes the effects of long-term GH treatment on free IGF-I, total IGF-
I, IGFBP-3 levels and the molar ratio of total IGF-I/IGFBP-3 in the GH treated SGA 
population. Furthermore, we evaluated whether measuring free IGF-I levels adds 
value in evaluating the GH treatment, by means of its (relative) contribution in 
predicting of first year growth response and/or adult height. Free IGF-I, total IGF-
I, IGFBP-3 and the molar ratio of total IGF-I/IGFBP-3 were determined at baseline, 
after 1 and 5 years of GH treatment, at the end of GH treatment, and 6 months after 
the end of GH treatment. 
Untreated SGA children showed a normal mean free IGF-I SDS (−0.2 (1.2) SDS), 
not related to total IGF-I. During GH therapy, free IGF-I increased significantly, but 
remained within the normal range (1.6 (0.7) SDS). In contrast, untreated SGA children 
showed reduced levels of total IGF-I and IGFBP-3 (−1 SDS). During GH therapy, total 
IGF-I rised in a larger extent than free IGF-I did (up to 2.0 (0.8) SDS). Under normal 
circumstances, total and free IGF-I are closely related. However, in small SGA 
children there was no correlation between total IGF-I and free IGF-I. In chapter 2 this 
discrepancy is discussed. Multiple regression analysis showed a negative correlation 
between baseline free IGF-I SDS and one-yr growth response and adult height, also 
after adjusting for baseline total IGF-I SDS. Total IGF-I, IGFBP-3, or their ratio showed 
no correlations with growth response. These data showed that free IGF-I was a 
better predictor for short-term growth response as well as for adult height in GH 
treated SGA children than were total IGF-I, IGFBP-3, or their ratio. This suggests 
a possible role for free IGF-I measurement in predicting the effect of GH therapy 
in short SGA children. 
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IGF-I, IGFBP-1, 2, 3 levels and the molar ratio of total IGF-I/IGFBP-3 in GH treated 
girls with TS. Furthermore, we verified relationships between free IGF-I levels and 
total IGF-I, IGFBP-1, 2 and 3. Additionally, we examined whether free IGF-I, total IGF-
I, IGFBP-3 or the total IGF-I/IGFBP-3 molar ratio were related to the IGF-I bioactivity 
outcome parameters, such as adult height, height gain, glucose- and insulin levels, 
and aorta wall distensibility. Free IGF-I, total IGF-I, IGFBP-3, −2, and −1, and the 
molar ratio of total IGF-I/IGFBP-3 were determined at baseline, after 1, 2, 3 and 5 
years of GH treatment, before the start of estrogen therapy, during the final year of 
GH treatment, 6 months after and 4.8 (2.0) years after end of GH treatment. 
Untreated girls with TS showed free IGF-I levels which were comparable to total 
IGF-I levels (approximately −1 SDS). During GH treatment, mean free IGF-I levels 
remained < +2 SDS, whereas mean total IGF-I and total IGF-I/IGFBP-3 ratio were > +2 
SDS. There were no differences in free IGF-I levels between the three GH groups, 
whereas total IGF-I and ratio levels were significantly higher in the highest GH group. 
Total IGF-I levels or the ratio total IGF-I/IGFB-3 levels did not accurately represent 
free IGF-I levels. Total IGF-I and the ratio predicted the IGF-I bioactivity better 
then the free fraction of IGF-I did. In chapter 3 we discussed that these results may 
be explained by an increased shift of free IGF-I from the circulation to the tissues 
compartments. This theory needs to be explored further in vivo and in vitro studies.
Quality of life
Improving or maintaining quality of life (QoL) is one of the main goals of a medical 
intervention, such as GH treatment. QoL can be measured using standardized and 
validated questionnaires, encompassing several domains, including physical, 
emotional en social well-being. Two different kinds of QoL questionnaires can be 
distinguished: a generic and a disease- or disorder specific questionnaire. A generic 
questionnaire allows for screening in a healthy population, and enables standardized 
comparisons across health conditions. However, it may not be as responsive to 
changes in disease- or disorder specific symptoms. The disease/disorder specific 
questionnaire may be more sensitive to specific changes in patients with a particular 
disease or disorder. Unfortunately, specific questionnaires are unable to provide 
comparisons across populations, or comparison with a healthy population. 
Chapter 4 describes the QoL in the SGA children with a mean age of nearly 16 years, 
after almost 10 years of GH treatment. We used a generic questionnaire, the ‘Child 
Health Questionnaire’ (CHQ), and a specific questionnaire, specially developed for 
a population with short stature, the ‘Short stature QoL questionnaire’ or TACQOL-
S. Two groups of adolescents born SGA without spontaneous catch-up growth were 
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GH treatment, the GH-group had a mean height of −3.1 SDS, whereas the mean height 
of the untreated group was −2.3 SDS. At time of the QoL evaluation, mean height of 
the GH group was -0.6 SDS, and of the untreated group −1.8 SDS.
The GH group reported a better QoL than the untreated group on the domains 
‘physical functioning’ and ‘contact with adults’, measured with the disorder specific 
questionnaire. Additionally, also fewer problems with body image were reported in 
the GH group. The ‘effect sizes’ of the differences in QoL outcomes of the GH group 
versus the untreated group were large, but did not reach statistical significance. 
‘Effect size’ contributes to an understanding of the differences between groups. 
‘Effect size’ is a tool for measuring the (clinical) effect of the difference; a statistical 
significant difference might not be synonymous with what is of clinical importance. 
We ended up with the advise to use, in addition to a generic questionnaire, a height-
specific questionnaire for measuring the influence of GH treatment on QoL. 
Chapter 5 describes the QoL in 49 young women with TS girls after long-term GH 
therapy and induced puberty at an appropriate age. They were 19½ years of age, and 
had a height gain of 1.7 SDS, resulting in an adult height of −1.2 SDS compared to the 
normal Dutch population. Additionally, we analyzed whether QoL was influenced by 
auxological parameters, pubertal development, or subjective parameters. Puberty 
onset was started before the age of 13 using low dose of oral estrogens. Two different 
adult generic questionnaires were used: the SF36 and the TAAQOL. An additional 
questionnaire provided information on socio-economic status, living situation, and 
subjective parameters, such as their experience with having typical Turner features, 
the GH treatment and the puberty induction. For example, the following questions 
were asked: “Do you think that other people can see that you have Turner syndrome?” 
If answered ‘yes’, “does that bother you?”, “Are you satisfied with your adult height/ 
breast development?”.
Young women with TS who reached normal height and had age-appropriate 
pubertal development showed normal QoL. Remarkably, the TS women had higher QoL 
scores on some of the QoL domains, which might be explained by an estrogen effect 
or by a possible response shift, indicating a different internal reference in women 
with TS. Satisfaction with height and breast development had a positive influence on 
several QoL scales, such as social and physical functioning. We hypothesized that GH 
and estrogen treatment positively influenced QoL in young women with TS.
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Chapter 6 describes the pubertal development in 56 girls with TS, using a low dose of 
17β-estradiol orally, starting during GH treatment at an appropriate age of 12 years. 
The pubertal development is described and compared to that of normal Dutch peers. 
Previously, our study demonstrated that estrogens in a low dose did not negatively 
influence height velocity or adult height. Additionally, it was determined whether 
serum hormone levels, such as estradiol, estone, LH, FSH, SHBG, contribute to the 
evaluation of pubertal progression. In 39 women with TS, the uterus dimensions were 
measured by ultrasound techniques, at an age of nearly 20 years, using an adult oral 
estrogen dose.
The breast development and pubic hair development were comparable to that of 
normal Dutch girls, however the breast development was 2 years delayed. In a clinical 
setting, serum hormone levels provided no additional information for evaluating 
pubertal progression. After age-appropriate pubertal induction, uterine dimensions 
in women aged nearly 20 were subnormal, and comparable to those of normal girls 
aged 15 years with breast stage B4/5. It remains unclear whether this was related to 
E2-dosage or duration, or factors related to TS. 
Safety aspects several years after the end of long-term GH treatment 
in TS
Chapter 7 describes several safety aspects nearly 5 years after the end of the GH 
treatment in 39 TS women, aged 20 years. The mean GH duration was nearly 9 years. 
The described measurements are: ‘Body mass index’ (BMI), fasting glucose and insulin 
levels, serum lipids, blood pressure, and body proportions. These were compared 
with levels before and during GH treatment, correlations were made, and possible 
GH effects were examined. Additionally comparisons were made with normal women, 
and, if possible, with untreated TS women.
Nearly 5 years after the end of the GH treatment, insulin sensitivity remained 
lower; β-cell function and fasting insulin levels remained higher than pre-treatment. 
The β-cell function was positively influenced only by BMI. The diastolic blood pressure 
was inversely related to GH dose, indicating a higher GH dose was related to a lower 
diastolic blood pressure. The GH dose or duration had no influence on the systolic 
blood pressure. Serum total cholesterol (TC), LDL and HDL had further increased 
compared to 6 months after GH, resulting in higher TC, but also higher HDL levels 
compared to controls. AI (TC/HDL) remained constant, which was lower than the 
AI in controls. The BMI increased gradually during and after GH-therapy. During GH 
treatment, the shape value sitting height decreased, and therefore improved, the 
shape value foot length increased, and therefore worsened, and shape values of hand 
length, biacromial- and biiliacal diameter remained constant.
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benefits regarding blood pressure, serum lipids, and some body proportions. Nearly 
5 years after GH the favorable effects of GH on serum lipids was still noticeable, but 
waning. The effect on diastolic blood pressure had disappeared, as it had returned to 
pre-treatment levels. The lower GH-induced insulin sensitivity, however, remained 
unchanged, possibly due to having TS.
Chapter 8 describes aorta dimensions and biophysical properties of the aorta by 
measuring the aortic size and wall distensibility in 38 TS women at an age of nearly 
20 years, after long-term GH treatment. The results were compared to the aortic 
measurements of 27 age, sex and BMI matched controls. All underwent ‘Magnetic 
Resonance Imaging’, MRI, to determine aortic dimensions and distensibility at 
four predefined levels: 1) in the ascending aorta at the level of the pulmonary 
artery bifurcation, 2) in the descending aorta at the level of the pulmonary artery 
bifurcation, 3) at the levels of the diaphragm, 4) the abdominal aorta at the levels of 
the superior mesenteric artery. 
The TS women had dilated aortas, with a larger aortic diameter at all but level 4, 
the abdominal aorta, compared to the matched controls. In the TS women there were 
signs of impaired aortic wall distensibility. The severity of abnormalities appeared 
to be related to the GH dose, with a beneficial effect of a larger GH dose on the 
abnormalities. 
Chapter 9 discusses the results of the various studies in the context of the literature 
and the clinical implications.
Chapter 10 provides an overview of all the results of these two long-term GH trials, 
starting in 1991 (SGA study) and in 1989 (Turner study). Additionally, the question 
arises: “Was it − and is it − all worthwhile?”, and will be discussed. The chapter 
ends with the strengths and the limitations of the studies and suggestions for future 
research.
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Samenvatting
Per definitie wordt 2,3% van de kinderen te klein geboren (onder de –2 standaard 
deviatie). De meeste kinderen die te klein waren bij de geboorte voor de 
zwangerschapsduur (small for gestational age, SGA), halen deze groeiachterstand 
in gedurende de eerste jaren na de geboorte. Ongeveer 10% behoudt echter een 
kleine lengte. Eerdere onderzoeksresultaten uit deze langlopende studie hebben 
aangetoond dat groeihormoon (GH) behandeling bij SGA kinderen met en persisterend 
kleine lengte in een meerderheid leidt tot normalisatie van de lengte tijdens de 
kinderjaren en een verbeterde volwassen lengte. Uiteindelijke zal 85% een normale 
volwassen eindlengte bereiken en 98% een volwassen lengte binnen de ‘target height 
range’, dat willen zeggen binnen de gemiddelde ouderlengte. Meisjes hebben een 
lengtewinst van 11-13 cm en jongens van 12-14 cm.
Bij meisjes met het syndroom van Turner is kleine lengte één van de opvallendste 
kenmerken. Zonder GH behandeling behalen zij een volwassen lengte die ongeveer 
20 cm onder het gemiddelde ligt, in Nederland is dat ongeveer 148 cm. Met GH 
behandeling wordt bij een meerderheid van de meisjes met Turner syndroom (TS) 
een normale lengte tijdens de kinderjaren en een verbeterde volwassen lengte 
behaald. Uiteindelijk bereikt 83% van de TS meisjes een normale volwassen lengte en 
63% een volwassen lengte binnen de ‘target height range’. De totale lengtewinst ligt 
gemiddeld tussen de 12 en 17 cm. Een ander opvallend kenmerk bij de meeste meisjes 
met TS is de afwezigheid van spontane puberteit als gevolg van de afwezigheid van 
functionerende ovaria, welke de oestrogenen produceren. De puberteit wordt bij 
de meeste TS meisjes geïnduceerd met behulp van exogene eostrogeentherapie. De 
route, tijdstip van starten, dosis, en de vorm zijn nog immer een punt van discussie. 
De studies beschreven in dit proefschrift onderzochten verschillende aspecten 
van langdurig GH behandeling bij SGA kinderen met een persisterende kleine lengte 
(n = 72) en meisjes met TS (n = 65). De invloed van de langdurige GH behandeling 
op het IGF-systeem, met name de vrije fractie van het IGF-I (hoofdstuk 2 en 3), en 
de kwaliteit van leven na de GH behandeling (hoofdstuk 4 en 5) worden besproken 
en bediscussieerd. Bij de meisjes met TS wordt de puberteit beschreven, die 
geïnduceerd werd met een lage dosis oestrogenen, waarmee werd gestart tijdens 
de GH behandeling op een adequate leeftijd. Daarnaast worden uterusdimensies 
onderzocht (hoofdstuk 6). Een aantal jaren na het beëindigen van de GH behandeling 
werden bij 39 TS meisjes de lipiden-, insuline- en glucosehuishouding, body mass 
index (BMI) en lichaamsverhoudingen onderzocht (hoofdstuk 7). Ook werd een aantal 
jaren na het beëindigen van de GH behandeling gekeken naar de aorta, de aorta 
breedte en de elasticiteit van de aortawand in deze patiënten groep (hoofdstuk 8). 
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gHoofdstuk 1 geeft een overzicht van de literatuur betreffende SGA en TS. Hierin 
worden definities, etiologie, prevalenties en klinische kenmerken beschreven van 
deze twee patiënten populaties. Ook worden de resultaten van de GH behandeling, 
de veiligheidsaspecten, en andere mogelijke GH effecten beschreven. Bij de meisjes 
met het syndroom van Turner wordt de puberteitsinductie besproken. Tenslotte 
wordt er een overzicht gegeven van de eerdere onderzoeksresultaten van deze twee 
langlopende studies (SGA studie gestart in 1991 en de TS studie gestart in 1989), de 
daaruit resulterende proefschriften, en de doelstellingen van de verschillende studies 
die gepresenteerd worden in dit proefschrift.
Serum IGF-I waarden
De insuline-achtige groei-factor-I (insulin-like growth factor, IGF-I) speelt een 
belangerijke rol bij groei en ontwikkeling, zowel voor als na de geboorte. De 
waarden van IGF-I in het bloed worden gereguleerd door metabole en genetische 
factoren, waarbij groei hormoon (GH) een van de belangrijkste regulatoren is. In de 
circulatie is IGF-I voornamelijk gebonden aan eiwitten, de zogenaamde IGF-binding 
proteïnen (BP), waarvan 6 klassen zijn geïdentificeerd (IGFBP1 t/m 6). IGFBP-3 is het 
belangrijkste bindingseiwit en bindt ongeveer 90% van het circulerende IGF-I. Onder 
normale omstandigheden is minder dan 1% van het totaal IGF-I ongebonden in de 
circulatie, het zgn vrij IGF-I. Het vrij IGF-I wordt verondersteld de biologisch actieve 
vorm te zijn van IGF-I. 
Tijdens GH behandeling stijgen de totale IGF-I waarden tot hoog-normale en 
suprafysiologische waarden. Ook de waarden van IGFBP-3 stijgen onder invloed van 
GH. Het is nog niet eerder onderzocht wat de invloed is van GH behandeling op de 
vrije fractie van IGF-I, en of het vrij IGF-I een voorspellende waarde zou kunnen 
hebben bij het evalueren van de GH behandeling.
Om de gemeten vrij IGF-I waarden te kunnen interpreteren, hebben wij referentie 
waarden gemaakt in de leeftijdsrange van 0-17 jaar mbv serum samples van gezonde 
kinderen (116 meisjes en 211 jongens).
Hoofdstuk 2 beschrijft de effecten van langdurige GH behandeling op vrij IGF-I, totaal 
IGF-I, IGFBP-3 en de molaire ratio van totaal IGF-I/ IGFBP-3 in de GH behandelde SGA 
populatie. Daarbij wordt ook onderzocht of het meten van vrij IGF-I toegevoegde 
waarde zou kunnen hebben in het evalueren van de GH behandeling. Dit is uitgevoerd 
door het vrij IGF-I, totaal IGF-I, IGFBP-3 en de molaire ratio van totaal IGF-I/ IGFBP-3 
te meten op de volgende tijdstippen: voor start van de GH behandeling (baseline), na 
1 en 5 jaar GH behandeling, bij het beëindigen van de GH behandeling, en een half 
jaar na het beëindigen van de GH behandeling. 
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Tijdens GH behandeling stijgen de vrij IGF-I waarden, maar blijven binnen de normale 
range. Totaal IGF-I en IGFBP-3 zijn verlaagd in onbehandelde kleine SGA kinderen. 
Tijdens GH behandeling stijgt het totaal IGF-I méér dan het vrije IGF-I. Onder 
normale omstandigheden is er een sterke relatie tussen totaal IGF-I en vrij IGF-I, 
echter bij kleine SGA kinderen was er geen relatie aantoonbaar. In hoofdstuk 2 wordt 
over deze gevonden discepantie gediscussieerd. Een belangerijke bevinding van onze 
resultaten is dat baseline vrij IGF-I een betere voorspeller was voor de 5 jaars groei 
respons op GH behandeling en de volwassen lengte, dan totaal IGF-I, IGFBP-3 of de 
totaal IGF-I/ IGFBP-3 ratio Dit suggereert een mogelijke relevante bijdrage voor de 
vrij IGF-I meting bij het voorspellen van het effect van de GH behandeling bij kleine 
SGA kinderen.
Hoofdstuk 3 beschrijft de effecten van de langdurige GH behandeling op vrij IGF-I, 
totaal IGF-I, IGFBP-1, 2, 3 en de molaire ratio van totaal IGF-I/IGFBP-3 bij de GH 
behandelde meisjes met TS. Daarbij worden ook de relaties onderzocht tussen de 
IGF-I bioactiviteit en vrij IGF-I, totaal IGF-I, IGFBP-3 of de totaal IGF-I/IGFBP-3 ratio, 
en welke van deze metingen de IGF-I bioactiviteit het beste voorspelt. Dit wordt 
gemeten aan de hand van aantal parameters zoals volwassen lengte, lengte winst, 
glucose- en insuline waarden, en aortawand elasticiteit. Dit is uitgevoerd door het 
vrij IGF-I, totaal IGF-I, IGFBP-1, 2, 3 en de molaire ratio van totaal IGF-I/IGFBP-3 te 
meten op de volgende tijdstippen: voor start van de GH behandeling (baseline), na 
1, 2, 3 en 5 jaar GH behandeling, voor het starten van de oestrogeen behandeling, 
bij het beëindigen van de GH behandeling, en een half jaar na het beëindigen van 
de GH behandeling. Vervolgens zijn de relaties gelegd dmv correlaties en multipele 
regressie analyses. 
De meisjes met TS zonder GH behandeling hebben vrij IGF-I spiegels die 
vergelijkbaar zijn met totaal IGF-I spiegels (rond de −1 SDS). Tijdens GH behandeling 
stijgen de vrij IGF-I waarden, maar blijven gemiddeld binnen de normale range, 
terwijl de waarden van totaal IGF-I en van de totaal IGF-I/IGFBP-3 ratio boven de 
normale range van +2 SDS stijgt. De waarden van totaal IGF-I of de ratio hebben geen 
goede correlatie met de waarden van vrij IGF-I. Totaal IGF-I en de ratio voorspellen 
de IGF-I bioactiviteit beter dan de vrije fractie van IGF-I. In hoofdstuk 3 wordt 
bediscusseerd dat deze bevindingen mogelijk verklaard kunnen worden door een 
verhoogde shift van het vrije IGF-I vanuit de circulatie naar de weefsels. Deze theorie 
zal in de toekomst verder onderzocht moeten worden. 
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Het verbeteren of handhaven van kwaliteit van leven (KvL) is een van de hoofddoelen 
van een medische interventie, inclusief GH behandeling. KvL wordt gemeten aan 
de hand van gestandaardiseerde en gevalideerde vragenlijsten die verschillende 
domeinen omvatten zoals fysiek, emotioneel en sociaal welbevinden. Er worden 2 
typen KvL vragenlijsten onderscheiden: een generieke en een ziekte/aandoening 
specifieke vragenlijst. De generieke vragenlijst maakt het mogelijk om te screenen 
in een normale gezonde populatie, waardoor verschillende patiëntenpopulaties 
vergeleken kunnen worden met de normale populatie. Deze vragenlijst is echter 
minder gevoelig voor ziekte/ aandoening specifieke symptomen. De ziekte/ 
aandoening specifieke vragenlijst is meer gevoelig voor specifieke vernaderingen 
bij patiënten met een bepaalde ziekte of aandoening. Helaas kunnen deze KvL 
uitkomsten niet vergeleken worden met de gezonde populatie. 
Hoofdstuk 4 beschrijft de KvL van de SGA populatie met een gemiddelde leeftijd van 
bijna 16 jaar, na bijna 10 jaar GH behandeling. Hierbij is een generieke vragenlijst, 
de ‘Child Health Questionnaire’, gebruikt en een vragenlijst specifiek ontwikkeld voor 
een populatie met kleine lengte, de zgn ‘kleine lengte KvL vragenlijst’. Er worden 2 
groepen kinderen SGA geboren met elkaar vergeleken: een groep SGA kinderen met 
(n = 44) en zonder (n = 28) GH behandeling. De GH behandelde SGA kinderen hadden 
bij het starten van de GH behandeling een gemiddelde lengte van −3.1 SDS, terwijl 
de onbehandele SGA geboren kinderen een lengte hadden van −2.3 SDS. Ten tijde van 
het meten van de KvL had de GH behandelde groep een lengte van −0.6 SDS, terwijl 
de onbehandelde groep een lengte had van −1.8 SDS.
Onze resultaten laten zien dat de GH behandelde groep een betere KvL had op 
de domeinen ‘fysieke capaciteiten’ en ‘contact met volwassenen’, gemeten met de 
aandoening specifieke vragenlijst. Ook werden er minder problemen gerapporteerd 
met betrekking tot lichaamsbeeld. Ondanks het ontbreken van significantie, waren 
de ‘effect sizes’ van de verschillen in KvL uitkomsten van de GH groep versus de 
onbehandelde groep groot. ‘Effect size’ is een maat voor het meten van het (klinisch) 
effect van het verschil, bv een heel klein verschil kan significant zijn, maar klinisch 
niet van belang, zoals bv een bloeddrukverschil van 2 mmHg, en vice versa. Als 
laatste pleiten wij in dit hoofdstuk ervoor om naast een generieke KvL vragenlijst, 
een lengte-specifieke KvL vragenlijst af te nemen voor het meten van het effect van 
GH op de KvL. 
Hoofdstuk 5 beschrijft de KvL van 49 GH behandelde TS meisjes na het behalen van 
hun volwassen lengte. Zij hadden een gemiddelde leeftijd van 19½ jaar, een volwassen 
lengte van −1.2 SDS vergeleken met de normale bevolking, en een lengtewinst van 
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g 1.7 SDS. De gemiddelde leeftijd waarop de puberteit begon was onder de 13 jaar. 
Hierbij zijn 2 verschillende volwassen generieke vragenlijsten gebruikt: de SF36 en de 
TAAQOL. Daarnaast is er een vragenlijst toegevoegd die aanvullende informatie geeft 
over oa socio-economische status, woonsituatie, en vragen betreffende subjectieve 
parameters, zoals uiterlijke kenmerken, de GH behandeling en de puberteitsinductie. 
Er werden bv vragen gesteld, zoals “Kun je aan jouw uiterlijk zien dat je het syndroom 
van Turner hebt? Zo ja, waaraan en vindt je dat vervelend?”, “Ben je tevreden met je 
lengte/ borsten”.
Onze resultaten laten zien dat jonge vrouwen met TS een normale KvL hebben 
na langdurig te zijn behandeld met GH en een op adequate leeftijd geïnduceerde 
puberteit. Op een aantal domeinen scoren de TS vrouwen een opvallend hoge KvL, 
soms zelfs beter dan gezonde leeftijdsgenoten. Deze opvallend goede KvL uitkomsten 
kunnen mogelijk verklaard worden door een oestrogeen effect of door een mogelijke 
‘response-shift’, dwz een veranderde interne referentie. De TS vrouwen die tevreden 
waren met hun behaalde lengte en de borstontwikkeling hadden een betere KvL op 
bepaalde domeinen dan de TS vrouwen die dat niet waren, dit was oa op sociaal en 
fysiek functioneren. Wij concluderen dat GH en oestrogeen behandeling mogelijk een 
positieve invloed hebben op de KvL in jonge vrouwen met TS.
Puberteitsontwikkeling
Hoofdstuk 6 beschrijft de puberteitsontwikkeling in 56 meisjes met TS, waarbij met 
een lage dosis oestrogenen begonnen is tijdens de GH behandeling op een leeftijd van 
12 jaar, welke vervolgens langzaam werd opgehoogd. De puberteitsontwikkeling werd 
vergeleken met de puberteitsontwikkeling van nomale Nederlandse leeftijdsgenoten. 
In een eerdere studie is al aangetoond dat de dosis oestrogenen gebruikt in deze 
studie, geen negatieve invloed had op de groeisnelheid en de volwassen lengte. 
Daarnaast werden verschillende hormoonspiegels, oa oestradiol, oestron, LH, FSH, 
SHBG, geëvalueerd in het kader van de puberteitsprogressie. In 39 vrouwen met 
TS werden de uterus dimensies gemeten op een leeftijd van bijna 20 jaar, bij een 
volwassen dosering oestrogenen.
De borstontwikkeling en schaamhaarontwikkeling waren vergelijkbaar met 
normale Nederlandse meisjes, echter de verschillende borstontwikkelingstadia 
werden 2 jaar later bereikt. Gemeten hormoonspiegels in het bloed habben geen 
aanvullende klinische waarde bij de evaluatie van de puberteitsprogressie. Na 
een leeftijds adequate inductie van de puberteit, waren de uterus dimensies bij 
TS vrouwen op de leeftijd van bijna 20 jaar subnormaal, en vergelijkbaar met die 
van normale gerijpte meisjes op een leeftijd van 15 jaar. Het is onduidelijk of dit 
gerelateerd is aan de oestrageen dosis of –duur, of aan factoren die gerelateerd zijn 
aan het hebben van TS.
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gVeiligheidsaspecten enkele jaren na het beëindigen van de GH 
behandeling in TS
Hoofdstuk 7 beschrijft lange termijnseffecten na het beëindigen van de GH 
behandeling. Dit werd gedaan dmv verschillende metingen in 39 TS vrouwen, bijna 5 
jaar na het beëindigen van de GH behandeling. De TS vrouwen waren bijna 20 jaar. De 
gemiddelde GH behandelduur was bijna 9 jaar. De metingen die verricht waren zijn: 
‘body mass index’ (BMI), nuchtere glucose en insuline, serum lipiden, bloeddruk, en 
lichaamsverhoudingen. Vervolgens werden deze vergeleken met waarden van vóór 
en tijdens de GH behandeling, werden er verbanden gelegd, en werd onderzocht of 
GH een effect heeft gehad op de betreffende metingen. Ook werden de uitkomsten 
van de metingen vergeleken met normaal en, indien mogelijk, met onbehandelde TS 
vrouwen.
Bijna 5 jaar na het beëindigen van de GH behandeling bleef de insulinegevoeligheid 
in TS vrouwen lager dan vóór GH behandeling, de β-cel functie en nuchtere insuline 
waarden bleven hoger dan vóór GH behandeling. De β-cel functie werd alleen 
beïnvloedt door de BMI. De diastolische bloeddruk werd negatief beïnvloedt door 
de GH dosis, dwz een hogere GH dosis was gerelateerd aan een lagere diastolische 
bloeddruk. De GH dosis of duur had geen invloed op de systolische bloeddruk. De serum 
lipiden totaal cholesterol, HDL en LDL waren na het stoppen van de GH behandeling 
verder doorgestegen. Echter de atherogene index (totaal cholesterol/ HDL) was 
constant gebleven, welke lager was dan die van contoles. De BMI is gedurende en 
na de GH behandeling langzaam gestegen. Gedurende de GH behandeling was de 
zithoogte kleiner geworden en dus verbeterd, de voetlengte relatief groter geworden 
en dus verslechterd, en de handlengte, biacromiale- en biiliacale diameter waren 
relatief constant gebleven.
Wij concluderen dat GH behandeling in meisjes met TS, naast de lengte, bijkomende 
positieve effecten heeft op de bloeddruk, serum lipiden en lichaamsverhoudingen, 
met de uitzondering van de voetlengte. Bijna 5 jaar na het beëindigen van de GH 
behandeling is het voordelige effect van de GH behandeling op serum lipiden nog 
zichtbaar. De verlaagde insuline gevoeligheid echter, was onveranderd, mogelijk 
passend bij het hebben van TS. 
Hoofdstuk 8 beschrijft aorta dimensies en biofysische eigenschappen van de aorta 
aan de hand van de aorta compliantie (elasticiteit) in 38 TS vrouwen op een leeftijd 
van bijna 20 jaar, na langdurige GH behandeling. Dit werd gedaan dmv ‘magnetic 
resonance imaging’, oftwel MRI onderzoek. De uitkomsten werden vergeleken met 
27 leeftijd, sexe en BMI gematchte controles. De diameter en de elasticiteit van de 
aorta werd op 4 plaatsen in de aorta gemeten, wetende: 1) in het opstijgende deel 
ter hoogte van de bifurcatie van de a. pulmonalis, 2) in het dalende deel ter hoogte 
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abdominale deel van de aorta ter hoogte van de a. mesenterica superior. 
De vrouwen met TS hadden gedilateerde aortas met een grotere aortadiameter op 
alle nivo’s, muv nivo 4, het abdominale deel van de aorta. De TS vrouwen hadden ook 
aanwijzingen voor een verminderde aortawandfunctie, gemeten aan de hand van de 
aorta elasticiteit. De ernst van de afwijkingen lijken gerelateerd te zijn aan de GH 
dosis, waarbij een hogere dosis een positief effect heeft op de afwijkingen.
Hoofdstuk 9 bespreekt de resultaten van de diverse studies in relatie met de 
literatuur en bediscussieert de klinische implicaties.
Hoofdstuk 10 geeft een overzicht van alle onderzoeksresultaten voortkomend uit 
deze twee langlopende GH-studies, begonnen in 1991 (SGA studie) en 1989 (Turner 
studie). Vervolgens komt de vraagstelling aan bod: “Was het − en is het − het allemaal 
waard?”. Tevens worden de sterke kanten en de beperkingen van de studies besproken 
en worden er suggesties gegeven voor toekomstig onderzoek. 
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rdDankwoord
 Deze studie had niet tot dit resultaat kunnen leiden zonder de hulp van vele 
mensen. Zij hebben niet alleen aan een studie mee gewerkt, maar ook hebben zij mij 
geholpen, onderwezen, gesteund, gemotiveerd en gestimuleerd in mijn persoonlijke 
groeiproces. Hierbij wil ik de meesten van hen graag laten weten hoezeer ik hun 
bijdrage heb gewaardeerd. 
Allereerst de studiedeelnemers. Alle kinderen, inmiddels (bijna) volwassen, en 
hun ouders die jarenlang, nog voor ‘mijn tijd’, regelmatig en zeer getrouw naar de 
poliafspraken kwamen in het ziekenhuis. Een aantal van jullie heb ik nooit gekend, 
een aantal van jullie heb ik één keer of regelmatig ontmoet. Dit boekje is de vierde in 
een rij met resultaten door jullie inzet verkregen. Mede dankzij jullie bijdrage is de 
medische wetenschap weer een stukje vooruit gegaan. Daar mogen jullie echt trots 
op zijn. Ik wens jullie het allerbeste met studie, werk en priveleven.
Mijn (co-)promotoren, Prof. Dr. S.L.S. Drop, Prof. Dr. A.C.S. Hokken-Koelega en Dr. 
S.M.P.F. de Muinck Keizer-Schrama, beste Sten, Anita en Sabine, hartelijk dank voor 
de kans die jullie me gegeven hebben onderzoek te doen binnen de endocrinologie. Ik 
heb jullie enthousiasme, tijd, steun en inbreng erg op prijs gesteld en veel geleerd in 
de afgelopen jaren. Ieder heeft op zijn/haar eigen manier een bijdrage geleverd aan 
dit boekje en aan mijn ontwikkeling. Hartelijke dank hiervoor.
Beste Wouter de Waal, Arne van Teunenbroek (in memorium), Theo Sas en Yvonne 
van Pareren, de dokters van de studies. Zonder jullie werk had ik natuurlijk niet 
kunnen ‘oogsten’. Yvonne, bedankt voor alle databasen die je aan mij hebt gestuurd. 
Theo, bedankt voor je snelle antwoorden op vragen die over jaren geleden gaan.
Beste Ingrid van Slobbe en Janneke van Nieuwkasteele, de studie ‘know-alls’, 
oftewel de onderzoeksverpleegkundigen. Hartelijk dank voor al jullie zorgen, hulp en 
ondersteuning bij het goed laten verlopen van de studies. Zonder jullie was het een 
puinhoop geweest. Ook buiten de studies en polibezoeken stonden jullie altijd klaar 
om te helpen, om maar iets te noemen: vriezers, invoeren, uitzoeken, plannen etc 
etc, hulp waar het maar kan. Beatrix Elink-Schuurman, dank je wel voor je hulp en 
het overnemen van de studie tijdens Ingrid haar wereldreis.
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rd Leden van de kleine commissie Prof. Dr. W.A. Helbing, Prof. Dr. F.H. de Jong en 
Prof. Dr. A.A. Kaptein wil ik hartelijk danken voor het snel beoordelen van mijn 
manuscript.
Prof. Dr. N.S. MacKlon, Dr. J. van Doorn en Dr. A. Juul, wil ik naast de leden van 
de kleine commissie en mijn (co)-promotoren hartelijk danken voor de toezegging 18 
oktober 2006 lid te zullen zijn van de promotiecommissie.
Dear Dr. A. Juul, thank you for measuring free IGF-I in part of our samples, and 
thank you for your willingness to participate in the Committee. 
Beste Dr. Paul Mulder en Prof. dr. Theo Stijnen, hartelijk dank voor het meedenken, 
helpen en bediscussiëren van de statistiek. Het lijkt zo logisch als jullie tekst en 
uitleg geven over waarom en hoe een bepaalde test toegepast moet worden. Jullie 
vriendelijkheid en bereidheid te helpen, heb ik ook plezierig gevonden. Bedankt. 
Ook Maria de Ridder wil ik graag bedanken voor het snel beantwoorden van mijn 
statistische vragen.
Dr. H. Raat en Dr. N.C.M. Theunissen, beste Hein en Nicolet, hartelijk dank voor 
jullie inbreng aan de kwaliteit van leven artikelen. Het was prettig en leerzaam 
met jullie te mogen samenwerken. Jullie inbreng heeft de kwaliteit van mijn leven 
ten tijde van het schrijven van de betreffende artikelen verbeterd. Nogmaals dank 
daarvoor.
Beste Prof. Dr. W.A. Helbing, bedankt voor de hulp en ondersteuning van de 
cardiologische kant van de Turnerstudie. Samen met Jochem van den Berg is er veel 
tijd en energie gestoken in het uitwerken van alle MRI- en echodata. Het resultaat 
mag er zijn, hartelijk dank daarvoor.
Dr. J. van Doorn,  beste Jaap, hartelijk dank voor de kans die je me hebt geboden 
een deel van mijn onderzoek uit te voeren binnen het ‘endo-lab’ in Utrecht. Ook 
ben ik je zeer dankbaar voor je hulp, ondersteuning, discussies, adviezen en tijd 
die je aan mij hebt gegeven bij de artikelen over het vrije IGF-I. Het bleek allemaal 
ingewikkelder te zijn dan dat ik in eerste instantie verwachtte. Op een gegeven 
moment stond ik op een punt dat ik dacht: “Hoe kun je in godsnaam hieruit conclusies 
trekken. Wat betekent zo’n lab-waarde eigenlijk?”. Jij wist toch orde in die chaos te 
scheppen en het resultaat is reeds (deels) gepubliceerd. Ik heb meer geleerd dan 
alleen maar een IRMA uit te voeren in een koelcel bij 5ºC. Hartelijk dank hiervoor.
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rdBeste Inge Maitimu, bedankt voor het altijd weer snel plannen van de IGF-testen. 
Beste mensen uit het ‘endo-lab’ in Utrecht. Hartelijk dank voor het uitvoeren van de 
IGF-testen. Ook wil ik jullie hartelijk jullie danken voor jullie medelevenheid tijdens 
mijn lab-periode, wanneer ik weer na een uur uit de koelcel verscheen met koude 
vingers en voeten. En jullie bereidwillendheid de ‘afzuiger’ voor radioactiviteit voor 
2 uur aan mij af te staan. Jullie interesse en vriendelijkheid heb ik gewaardeerd, 
evenals de radio (radio 2) en de discussies over het nieuws.
Dr. W.H. Hackeng, bedankt voor het bepalen van alle insulinebepalingen van 
de studies. Altijd een vriendelijk woordje. Ik heb toch nog meer gedaan dan voor 
receptioniste van mijn collega’s te functioneren.
Prof. dr. F.H de Jong en Prof. dr. T.J. Visser, bedankt voor het overleg en uitleg 
betreffende uitslagen van de Turnerstudie. Tevens wil ik de medewerkers van uw lab 
bedanken voor het uitvoeren van de testen.
Prof. dr. S. Van Buuren, beste Stef, jij was gelijk enthousiast toen ik je vertelde 
waarvoor ik kwam. Bedankt voor je bijdrage en het maken van mooie figuren.
Dr. M. Lequin, beste Maarten, bedankt voor het mogelijk maken van de echo’s bij 
de meisjes met het syndroom van Turner. Dames van de radiologie, bedankt voor het 
inplannen, wat niet altijd even makkelijk was.
Jochem van den Berg, samen hebben we alle Turnerpatienten gescand, dwz ik 
haalde de koffie, terwijl jij de MRI-scans uitvoerde. Ik vond het prettig met je samen 
te werken en te discussiëren over de resultaten. Succes met je opleiding.
Roel en Charlotte, 2 studenten die zich vol enthousiasme hebben gestort op een 
deel van mijn studie. Hartelijk dank voor jullie inbreng. Ik hoop dat jullie iets geleerd 
hebben. Ik wel van jullie, het was plezierig met jullie samen te werken. Succes in 
jullie verdere carrière.
De vele mensen van Novo Nordisk A/S Denemarken en Novo Nordisk Farma BV 
Nederland dank ik hartelijk voor de samenwerking en de financiele ondersteuning van 
de studies en dit proefschrift. In het bijzonder wil ik bedanken Suzanne Timmermans, 
Helene Philipo en Melan Balvers-Bakker voor hun samenwerking betreffende de 
studies.
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rd David Alexander, thank you for helping me to improve this thesis and its content. 
Although I am married to an English speaking person, good quality English is also 
difficult for an ‘Aussie’.
Ook ben ik dank verschuldigd aan de leden van de Adviesgroep Groeihormoon en 
met name naar de kinderarts-endocrinologen die jarenlang meegewerkt hebben aan 
de 2 studies. Hartelijk dank voor het mogelijk maken van deze multi-center studies, 
waarvan ik het staartje heb mogen uitvoeren.
Mijn collega endo-ers, hartelijk dank voor alle gezelligheid, kopjes koffie en thee, 
BBQ’s, feestjes, uitjes, luisterend oor, en discussies. Mijn kamergenoten door de jaren 
heen, Marije, Ingrid, Janneke, Marieke, Robert, Floor, Lydia en Inge, maar ook Venje, 
Ruben, Nicolette, Wietske, Emile, Sandra, Christel, Esther, Marian, de ‘bewoners’ van 
de kamers Sk0154 en Sk0156, en niet te vergeten Dini, Karen, Daniëlle en Dederieke 
ook bedankt voor jullie gezelligheid, kopjes thee en koffie, en interesse.
Collega’s van de kindergeneeskunde uit het St. Lucas Andreas ziekenhuis en het 
VUMC, bedankt voor jullie interesse en begrip. Een nieuw leerproces is aangebroken. 
Dear friends from Australia en uit Nederland, my thesis is finished. The guest room, 
which turned into my ‘thesis-office’ for the past 12 months, is available again....
Lieve Marije en Marieke, mijn paranimfen. In februari ’06 Marieke, nu ik, en in 
2007 Marije.... Wat heb ik een leuke tijd gehad met jullie tijdens het promotietraject 
en daarbuiten. Hartelijk dank dat jullie naast me staan bij de promotie, voor al jullie 
steun rondom de promotie, tijdens de 4 jaar studie en daarna. Collega’s, paranimfen 
en vriendinnen, laten we zo houden.
Meiden van 7, Lieve Minke, Nienke, Karin, Leonie, Maaike en Florette. Zonder de 
‘etentjes met 7’ was het echt noooooit gelukt. Hoewel ik niet in Rwanda, Londen 
of Sydney woon of heb gewoond, ben ik toch vaak afwezig geweest het afgelopen 
jaar. Dit gaat eindelijk weer veranderen.... “I am back”. Bedankt voor jullie steun 
en begrip. Jullie zijn stuk voor stuk lieve vriendinnen. Ik vind het echt super om te 
zien hoe iedereen zijn eigen weg heeft gevonden binnen de geneeskunde, en dat we, 
ondanks onze drukke banen, zwangerschappen, gezinsleven, en sociale leven, toch 
altijd tijd voor elkaar vinden. Laten we dit nog jaren blijven volhouden.
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rdLieve Corien en Linda, tjeemig wat hebben jullie ons laten verassen op 12 juni 
2005. Zoveel voor mij gedaan, niet alleen betreffende de bruiloft. Er komt meer 
tijd vrij voor etentjes en drankjes (of worden het wandelingetjes in het park bij de 
speeltuin?), ook al was ik niet ver weg, ik heb jullie wel gemist. Bedankt dat jullie 
mijn vriendin willen zijn. (PS Jullie verdelen het wel ‘netjes’, Linda rondom mijn 
bruiloft en Corien rondom mijn promotie..., wel handig dat jullie me voor zijn, kan ik 
mooi ‘afkijken’)
Dear Margaret, Jim, Pat, Rebecca, Carolin, Jason, Jack, Amanda, Marty and 
Margie, and of course nieces and nephews, my family ‘down under’. Thank you so 
much for your support and interest. I wrote it all in English, so you know a little what 
I have been busy with since I met you. I hope to see you all again soon. Margaret, 
looking forward to welcome you back in Amstelveen in January 2007.
Lieve Ilse, Jos, Gaby en Mats, erg bedankt voor al jullie steun, adviezen, etenjes 
en plezier. Ik hoop dat we nog jaren samen kunnen genieten van wintersport, bakkies 
cappu, BBQ’s, Efteling en nog meer. Fijn dat jullie lekker dichtbij wonen.
Lieve mama en papa, altijd gestimuleerd, nooit gepusht. Altijd klaar gestaan 
met hulp in welke vorm dan ook. Ik heb veel geleerd de afgelopen 4 jaar, en mijn 
doctorstitel ermee verdiend, maar jullie weten niet half hoeveel ik van jullie geleerd 
heb. Dat is nog veel meer waard. Dank jullie wel voor jullie oneindige steun en 
liefde. 
Lieve lieve Michael, beide hard werken en studeren. Jij met je MBA en nederlands, 
ik met mijn opleiding en boekje. Het is klaar! Samen hebben we het allemaal gedaan. 
Ikke nu, jij in februari. En ons volgende feestje is dan alweer begonnen. Zo maken we 
elkaar sterk en gaan we samen het leven door. Het is één groot feest met jou! Ik ben 
erg trots en gelukkig met jouw getrouwd te zijn. Ik hou vreselijk veel van jou......
En nu genieten
Lieve lieve Michael, working and studying hard. You with your MBA and Dutch 
lessons, and me with my trainingship and this thesis. It is finished! Together we did it 
all. Me right now, and you in February. And than our next festivity has already started, 
‘alive and kicking’. We make each other strong and go through life together. We are 
very lucky. Life is one big party with you! I am proud and very happy to be your wife. 
I love you a lot lot......Let’s enjoy
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Curriculum Vitae of Ellen Manon Noëlle Bannink
Ellen Manon Noëlle Bannink was born on 25th December 1972 in Uden, in the south 
of the Netherlands and moved to Neede, in the east of the Netherlands, at the age 
of 4 years. After finishing high school (VWO) in 1991 (RSG Lochem), she began to 
study Human Movement Science at the Vrije University (VU) in Amsterdam. After 
successfully passing the first 2 years of Human Movement Science, Ellen was able 
to start her medical study in 1993, also at the VU. During Ellen’s medical studies, 
she spent 4 months of 1997 at the Garvan Institute in Sydney, Australia where she 
participated in a research project on serum growth hormone binding proteins, under 
supervision of Prof. Dr. K.Y. Ho in Sydney and Prof. Dr. E.A. van der Veen in Amsterdam. 
When returning from Australia, she continued her training and began her internship 
at the VU Medical Centre. When Ellen successfully completed her training in 1999, 
she returned to the southern hemisphere for a five month travel adventure through 
Australia and Indonesia. Upon returning home to the Netherlands, Ellen worked for 
3 months as a school-physician for local public health care services and then took up 
as a pediatric resident at Hospital Eemland, Amersfoort from 2000 to 2001. In August 
2001, Ellen began her research project as presented in this thesis at the Department 
of Pediatrics, Subdivision of Endocrinology, Erasmus MC − Sophia Children’s Hospital 
in Rotterdam, under the supervision of Dr. S.M.P.F. de Muinck Keizer-Schrama, Prof. 
Dr. A.C.S.Hokken-Koelega, and Prof. Dr. S.L.S. Drop. In October 2005, she started 
her clinical pediatric trainingship at the VU Medical Centre (Head: Prof. Dr. W.P.F. 
Fetter) and was posted to the St. Lucas Andreas Hospital (Head: Dr. B.H.M. Wolf) 
in Amsterdam. Ellen lives in Amstelveen with her Australian husband Michael Kerlin. 
They are expecting their first child in December 2006.
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